

**Framework Contract SANCO/2012/02/011 Lot 1: Public Health
– Contract N° SANCO/2012/02/011 Lot 1- Provision of
Evaluation, Impact Assessment and Related Services to the
Commission in the Areas of Public Health, Consumer Protection
and Food Chain**

**Specific Contract: The second independent
evaluation of the ECDC in accordance with its
Founding Regulation (European Parliament and
Council Regulation (EC) no 851/2004**

**FINAL REPORT
Volume 2 – Annexes**

submitted by

Economisti Associati srl (Lead Firm)

**Coffey International Development Ltd. trading as The Evaluation Partnership
(Partner)**

Libero Istituto Universitario Carlo Cattaneo – CREMS (Partner)

CEMKA-EVAL (Partner)

IBF International Consulting (Partner)

October 8th, 2014

TABLE OF CONTENTS

	Page
Annex A – List of key-informants interviewed at MS and international levels	1
Annex B – Checklist used for interviews with key-informants	7
Annex C – Survey questionnaire	22
Annex D – Bibliometric analysis of selected publications	61
Annex E – Updated bibliography	109
Annex F – Survey results dataset (provided as separated Excel file)	

ANNEX B – CHECKLISTS FOR IN-DEPTH INTERVIEWS

Checklist for Management Board Members

- 1) To what extent is the current programming mechanism adequate in respect to its transparency, flexibility, realism and responsiveness to your Country's needs as stakeholders? To what extent are resources allocated appropriately to the different areas of activity? What are the areas of ECDC activity, if any, you deem comparatively overweighed or underweighed?
- 2) To what extent does your Country feel the need to recur to your own scientific advice/other sources when ECDC is available? Why? Does this depend on limited awareness of ECDC products or language barriers? Can guidelines for providing scientific advice be adapted to the national policy context? What is then the added value of the ECDC work for your Country? Is the ECDC overstepping on risk management aspects still an issue? Any relevant examples?
- 3) What is your overall assessment of ECDC management of activities and procedures? Are there still issues with the coordination between the functional units and the disease programs? To what extent does ECDC staff have the right skills to manage its mission? What kind of skills, if any, are lacking among them? What is your level of satisfaction with the ECDC current outsourcing practices? What are the main pros and cons?
- 4) Incidentally, have sufficient steps been taken to make Sweden an easier and better place to work and live for staff of the ECDC?
- 5) To what extent do you feel adequately informed about the Centre activities by the current planning, monitoring and reporting system? Do you feel there are performance indicators in place that can be easily monitored and evaluated against the objectives of the ECDC Strategy? If not, what's missing in particular?
- 6) Overall, how do you rate your level of satisfaction with the role you play in ECDC governance? Are you adequately supported by ECDC in fulfilling your mandate? Has your mandate overlapped with other governance bodies (e.g. AF) and resulted in conflicting messages How would you rate your cooperation and coordination with the other governance bodies?
- 7) How is ECDC cooperation overall with all other relevant stakeholders at the national and international level Are the responsibilities and the tasks of national and international collaborating partners clearly defined? What could be done to further improve national cooperation? (e.g. preparing joint work plans?). To what extent ECDC activities can be further streamlined and made complementary to those of other international agencies?
- 8) Should the ECDC in the future build on its current activities or should it expand its mandate? In particular, to what extent do you feel the need to expand/strengthen the ECDC mandate in the following areas: 1) assistance to MS in preparedness and response; 2) evaluation of treatment effectiveness for public health purposes; 3) health monitoring and indicators outside of communicable diseases.

Further points you would like to raise.

Checklist for Advisory Forum Members

- 1) To what extent is the current programming mechanism adequate in respect to its transparency, flexibility, realism and responsiveness to stakeholders' needs? To what extent are resources allocated appropriately to the different areas of activity? What are the areas of ECDC activity, if any, you deem comparatively overweighed or underweighed? To what extent are current procedures to prioritize scientific work adequate?
- 2) To what extent has ECDC managed to deepen activities to build/maintain its sound scientific reputation and provide important services to you as stakeholders? does your Country feel the need to recur to your own scientific advice/other sources when ECDC is available? Can guidelines for providing scientific advice be adapted to the national policy context? What is then the added value of the ECDC work for your Country? Is the ECDC overstepping on risk management aspects still an issue? Any relevant examples?
- 3) How do you rate the overall quality (timeliness, independence of judgment, completeness, etc.) and usefulness of ECDC scientific advice reports / guidance documents in general?
- 4) What is your overall assessment of the way the delivery of scientific advice is managed? Does ECDC staff have the right skills to manage the process? What skills, if any, are lacking among them? What is your level of satisfaction with the ECDC current outsourcing practices in this field? What are the main pros and cons? To what extent is duplication of work at the European level being considered? Is there realistic room for improvement? How?
- 5) How effective is the ECDC at getting its communication products out and reaching the right public? Are you adequately informed of the ECDC dissemination plan for the year / are you able to plan your own communications in-line with ECDC outputs? To what extent were you aware / have you used technical communication products from the ECDC in the past (e.g. the influenza risk communication toolkit or of the general communication toolkit on gastrointestinal diseases)? Does the ECDC website meet your expectations?
- 6) To what extent do you feel adequately informed about the Centre activities by the current planning, monitoring and reporting system? Do you feel there are performance indicators in place that can be easily monitored and evaluated against the objectives of the ECDC Strategy? If not, what is missing in particular?
- 7) Overall, how do you rate your level of satisfaction with the role you play in ECDC governance? Are you adequately supported by ECDC in fulfilling your mandate? Has your mandate overlapped with other governance bodies (e.g. NCB) and resulted in conflicting messages? How would you rate your cooperation and coordination with the other governance bodies?
- 8) How is cooperation overall with all other relevant stakeholders at the national and international level? Are the responsibilities and the tasks of national and international collaborating partners clearly defined? What could be done to further improve national cooperation? (e.g. preparing joint work plans). To what extent ECDC activities can be further streamlined and made complementary to those of other international agencies?
- 9) Should the ECDC build on its current activities or should it expand its mandate? In particular, to what extent do you feel the need to expand/strengthen the ECDC mandate in the following areas: 1) assistance to MS in preparedness and response; 2) evaluation of treatment effectiveness; 3) health monitoring and indicators outside of CD.

Further points you would like to raise.

Checklist for National Coordinators – Coordinating Competent Body Directors

- 1) To what extent is the current programming mechanism adequate in respect to its transparency, flexibility and realism and responsiveness to stakeholders' needs? To what extent are resources allocated appropriately to the different areas of activity? What are the areas of ECDC activity, if any, you deem comparatively overweighed or underweighed? To what extent are current procedures to prioritize scientific work adequate?
- 2) To what extent has ECDC managed to build/deepen in this period its scientific reputation in your Country and provide you as stakeholders with trustful services? Does your MS feel the need to recur to your own scientific advice/other sources when ECDC is available? Can guidelines and scientific be adapted to the national policy context? What is then the added value of the ECDC work for your Country? To what extent is this added value justified by what you contribute as a Country in terms of your own resources?
- 3) How do you rate the overall quality (timeliness, independence of judgment, completeness, etc.) and usefulness of ECDC scientific advice reports / guidance documents in general?
- 4) In particular, what is your overall assessment of the way the delivery of scientific advice is managed? Does ECDC staff have the right skills to manage the process? What skills, if any, are lacking among them? What is your level of satisfaction with the ECDC current outsourcing practices? What are the main pros and cons? To what extent is duplication of work at the European level being considered?
- 5) To what extent are you satisfied with ECDC support in responding to threats with respect to usefulness, quality and management of preparedness and crisis management activities? Overall, is the quality/quantity of activities (e.g. exercises) and guidance docs for country preparedness and crisis management produced by ECDC in line with your expectations? Were there direct impacts on your national capacity to respond to threats?
- 6) More generally speaking, what is your level of satisfaction with your current cooperation with ECDC? In particular, what is your level of satisfaction with your communication arrangements with ECDC? Do you experience difficulties in finding the right counterparts? a) in ordinary conditions b) during public health emergencies (e.g. H1N1, salmonella outbreaks). Do you feel adequately informed about the Centre's activities? And what about the current division of labour with the ECDC? Is the ECDC involvement in risk management aspects in your view still an issue? What could be done, if anything, to further improve national cooperation? (E.g. preparing joint work plans?).
- 7) How do you assess the level of cooperation between the ECDC and other International organisations/European agencies in (i) ordinary conditions and (ii) during public health emergencies (H1N1, salmonella outbreaks)?
- 8) Has ECDC ever contributed to your communication campaigns? How? Do you collaborate with the ECDC on messages to the media and public? If so, are roles and procedures clear? What could be done to further improve the coordination on risk communication with the ECDC?
- 9) Overall, how do you rate your level of satisfaction with the role you play as CCB in ECDC governance? To what extent does your mandate overlap with other bodies (e.g. advisory forum) and eventually result in conflicting messages? How do you assess your cooperation and coordination with the other governance bodies? Do you think that your responsibilities as national coordinating body are clearly defined?
- 10) Should the ECDC in the future build on its current activities or should it expand its mandate? In particular, to what extent do you feel the need to expand/strengthen the ECDC mandate in the following areas: 1) assistance to MS in preparedness and response; 2) evaluation of treatment effectiveness; 3) health monitoring and indicators outside of CD?

Further points you would like to raise.

Checklist for Communication Experts

- 1) To what extent do the contents of the ECDC communication strategy reflect your priorities? ii) What are the areas, if any, you deem overweighed or underweighted?
- 2) To what extent does ECDC manage to tailor its public health communication products to different target groups? To what extent have these audiences been identified properly? What are the main critical areas, if any? Do you think that the ECDC should do more to tailor its technical reports to your Country needs? Are there any good practice examples of other similar organizations?
- 3) To what extent do you turn to the ECDC as a source for your RC activities? Have you recurred to other sources in the same area? What was the added value of the ECDC in this case? Overall, how do you rate the ECDC contribution to strengthening your programmes? The ECDC set itself the goal of being the prime referent for supporting risk communication in the EU. To what extent do you think it has met this goal? To what is the added value received from the ECDC in the field of RC worth the effort in terms of what you contribute as a MS to the Centre?
- 4) How effective is the ECDC at getting its communication products out? To what extent do you think that the products reach the right people? How systematic does the approach to dissemination appear to be? Are you adequately informed of the ECDC dissemination plan for the year / are you able to plan your own communications in-line with ECDC outputs? To what extent were you aware / have you used technical communication products from the ECDC in the past? For instance, have you ever made use of the influenza risk communication toolkit or of the general communication toolkit on gastrointestinal diseases? If so, how useful have these been? Does the ECDC website meet your expectations? What if anything could be improved? What about relations with the press and media?
- 5) What is your overall assessment of the way the communication activities are managed? Do ECDC staff have the right skills to manage these programmes? What skills, if any, are missing among them? What is your level of satisfaction with the ECDC current outsourcing practices in the field of communication? What are the main pros and cons?
- 6) Has ECDC ever contributed to your campaigns? If so which ones? In what ECDC contribution consisted of?
- 7) How do you collaborate with the ECDC on messages to the media and public? Are roles and procedures clear? How are you satisfied with the benefits of working together? Is it possible to generate economies of scale / resource / reach by working together? Is there anything that could be done to improve the way that you coordinate messages with the ECDC?
- 8) To what extent are you satisfied of your communication arrangements with ECDC? Do you experience difficulties in finding the right counterparts? a) in ordinary conditions b) during public health emergencies (H1N1, salmonella outbreaks) Are you adequately informed about the Centre's activities? a) in ordinary conditions b) during public health emergencies (H1N1, salmonella outbreaks) What should be done to further improve it?

Further points you would like to raise.

Checklist for Capacity Building experts

- 1) If you compare your actual DDIC¹ capacity with 2008, how has it evolved? What evidence can be used to substantiate this claim? Overall, how do you rate the contribution of ECDC to enhancing DDIC capacity in your country? How can this be increased?
- 2) Are the priorities identified for EQA coherent with your country lab 'needs? Are there other similar schemes already in place? What is the level of complementarity/ coordination? How do you rate the overall burden for EQA? How does it compare with the added value of the exercise? Is the EQA delivery and implementation model appropriate? What are the pros and cons of outsourcing EQA? Does ECDC have the right skills to manage EQA? If not, what's lacking? What are the reasons for not participating to EQA? For a sample of EQA: Are you aware of these EQA reports? Were they useful to take redressing measures at MS level? (ix) How do you rate the quality of this specific EQA exercise? And of the report? How did the lab capacity change following the EQA?
- 3) Overall, how do you rate the contribution of ESCAIDE to enhancing capacity in your country? How can this be increased? Do you have evidence of 'change' induced by knowledge, skills, best practices, networking acquired through ESCAIDE?
- 4) How do you rate the overall utility of ECDC training programmes (EPIET or EUPHEM as applied)? How do you rate their quality? Is that changed overtime? Are topics of training programmes coherent with your country training needs? Which areas were too much/not enough covered? To what extent is ECDC Capacity Building work complementary / synergic w/ other similar schemes? What is the added value of the programmes as compared to other national training schemes? And the degree of complementarity/ synergy with other schemes? How do you rate the functioning of the training schemes? How can this be improved? What are the main pros and cons of current outsourcing practices? What other training tools/ outputs would be needed?
- 5) To what extent ECDC Capacity Building support has improved the way health measures for the control of disease outbreaks are defined in your country? Can you provide evidence for it? If not, why? Has there been a follow-up to ECDC Capacity Building initiative in your country? Can you provide evidence of it? If not, why? If (i) and/or (ii) are positive: what is the extent of benefits stemming from the implementation of ECDC support? All in all, are you satisfied with the level of Capacity Building support received? At a strategic level, how can ECDC Capacity Building work be optimized?

Further points you would like to raise.

¹ diagnosis, detection, identification, characterisation

Checklist for Preparedness and Response experts

- 1) To what extent RRA in the field of influenza and salmonella and following updates were relevant for risk management purposes? In particular how do you rate (RRA)'s, timeliness, relevance, quality, clarity? Could you provide documentary evidence of risk management action that was informed by these RRA?
- 2) How do you rate EPIS FWD as regards its:
 - user-friendliness
 - quality of support
 - functionalities
 - integration with EWRS
- 3) What is the added value of EPIS as compared to other 'official' and 'unofficial' systems? Is the 'burden' of EPIS justified / acceptable? Considering [e.g. specific event], how do you rate :
 - the timeliness of notification
 - the quality of the information
 - the feedback provided to the urgent inquiry
- 4) To what extent TTT provides a useful support to EI activities? How can it be improved? Do you regularly review CDTR? How do you rate quality and usefulness of CDTR for your EI activities? How do you rate the efficiency of the various steps of ECDC's EI processes, namely:
 - screening activities
 - filtering of signals
 - validation of events
 - analysis of events
 - EWRS notification

Are there adequate procedures in place to ensure a smooth notification process?
- 5) To what extent are you satisfied with ECDC simulation exercise with respect to usefulness and quality and management? Overall, is the quality/quantity of exercises organised by ECDC in line with your expectations? To what extent are you satisfied with ECDC [guidance doc / tools] with respect to usefulness, quality and clarity? Overall, is the quality/quantity of guidance docs / tools for country preparedness and crisis management produced by ECDC in line with your expectations? Can you provide evidence of change in national capacity related to ECDC support (e.g. infrastructure, staff, and adoption of procedures)? To what extent are you satisfied with the level of support provided by ECDC to MS as concerns (i) preparedness and (ii) crisis management and response, with respect to:
 - quality
 - timeliness
 - usefulness
- 6) Following the (RRA) have you adopted risk communication messages for either professionals or general public that were substantially informed by the content of the (RRA)? How do you rate the overall coherence of messages issued by MS authorities following the (RRA)-related event? More generally, to what extent do ECDC RRAs and analogous outputs inform your risk communication activity? What possible improvement (if any) would be needed?
- 7) Has ECDC played a leading role during the pandemic crisis? Why? To what extent ECDC was able to coordinate its activities with the various national and international bodies? How do you rate ECDC monitoring activities of the pandemic? How do you rate the outputs produced (assessment, communication) in that particular occasion? Did ECDC follow up timely to requests? Was ECDC involvement in support of response actions appropriate? Overall, how do you rate the quality of ECDC

support provided to risk managers? In your opinion, which lesson should ECDC learn from that experience?

- 8) How do you rate overall effectiveness of support received for investigation of outbreak? Was the support provided timely? Was the scope of assistance adequate to your need? How do you rate the quality of the expertise provided by ECDC? What was the result of ECDC support? What would have happened in the absence of ECDC?

Further points you would like to raise.

Checklist for EWRS Experts

- 1) To what extent RRA in the field of influenza and salmonella and following updates were relevant for risk management purposes? In particular how do you rate (RRA)'s, timeliness, relevance, quality, clarity? Could you provide documentary evidence of risk management action that was informed by these RRA?
- 2) How does the current version of EWRS compare with the previous one? How do you rate EWRS, with respect to:
 - user-friendliness
 - functionalities
 - quality of support
 - degree of integration with EPIS

Is the EWRS sufficiently integrated with other EU alert systems? More generally speaking what is your overall assessment of the way the early warning platforms and information systems are managed? Does ECDC staff have the right skills to manage these platforms and systems? What skills, if any, are lacking among them? What is your level of satisfaction with the ECDC current outsourcing practices in this field? What are the main pros and cons of these practices from the viewpoint of your organisation? Which aspects of EWRS (if any) would need to be further improved?

- 3) How do you rate EPIS FWD as regards its:
 - user-friendliness;
 - quality of support;
 - functionalities;
 - integration with EWRS
- 4) What is the added-value of EPIS as compared to other 'official' and 'unofficial' systems? Is the 'burden' of EPIS justified / acceptable? Considering [e.g. specific event], how do you rate:
 - the timeliness of notification
 - the quality of the information
 - the feedback provided to the urgent inquiry
- 5) To what extent TTT provides a useful support to EI activities? How can it be improved? Do you regularly review CDTR? How do you rate quality and usefulness of CDTR for your EI activities? How do you rate the efficiency of the various steps of ECDC's EI processes, namely:
 - screening activities
 - filtering of signals
 - validation of events
 - analysis of events
 - EWRS notification

Are there adequate procedures in place to ensure a smooth notification process?

- 6) Following the (RRA) have you adopted risk communication messages for either professionals or general public that were substantially informed by the content of the (RRA)? How do you rate the overall coherence of messages issued by MS authorities following the (RRA)-related event? More generally, to what extent do ECDC RRAs and analogous outputs inform your risk communication activity? What possible improvement (if any) would be needed
- 7) Has ECDC played a leading role during the pandemic crisis? To what extent ECDC was able to coordinate its activities with the various national and international bodies? How do you rate ECDC monitoring

activities and the outputs produced (assessment, communication) during the pandemic? Did ECDC follow up timely to requests and provide support to risk managers adequately? In your opinion, which lesson should ECDC learn from that experience?

- 8) How do you rate overall effectiveness of support received for investigation of outbreak? Was the support provided timely? Was the scope of assistance adequate to your need? How do you rate the quality of the expertise provided by ECDC? What was the result of ECDC support? What would have happened in the absence of ECDC?

Further points you would like to raise.

Checklist for Microbiology Experts

- 1) To what extent have the subjects chosen in the Microbiology strategy and work plan (2012-2016) reflected your priorities? To what extent are resources allocated appropriately to the different areas of activity? What are the areas, if any, you deem overweighed or underweighed?
- 2) What is your appreciation of the ECDC work in the field of integration of molecular typing data into EU level surveillance?
- 3) In your Country, to what extent has participation into ECDC activities resulted in:
 - improved your overall capacity for laboratory diagnosis
 - improved the quality of your microbiological data
 - improved the comparability of your microbiological data
 - improved capacity to detect resistances
 - improved capacity to respond to outbreaks of unknown origin?
 - resulted in information better integrated in the epidemiological data?
- 4) Are the priorities identified for External Quality Assurance exercises coherent with your country laboratories' needs? Are there other similar schemes already in place? How do you rate the overall burden for EQA? How does it compare with the added value of the exercise? Is the EQA delivery and implementation model appropriate? What are the pros and cons of outsourcing EQA? Have you taken part to the specific EQAs? Typing exercises on salmonella (the fourth run in 2013 is out of scope)? How do you rate the quality of these specific EQA exercises? How has the lab capacity changed following the EQA? What are the reasons for not participating to EQA?
- 5) How do you rate the overall quality (timeliness, perceived independence, etc.) and usefulness of the ECDC risk assessments? Have recommendations or decisions been taken based on this advice? What, if any, possible improvement would be needed to further increase their level of use/usefulness?
- 6) To what extent has the quality of ECDC surveillance indicators improved in the last five years? To what extent has this improved the possible detection of health threats or significant trends? Can you mention relevant instances in your experience? How would you rate your level of interest in the data included in the TESSy platform and EPIS databases?
- 7) What is your level of satisfaction with the ECDC current outsourcing practices in this field? What are the main pros and cons of these practices from the viewpoint of your organization?

Further points you would like to raise.

Checklist for Surveillance experts

- 1) To what extent has the quality of ECDC surveillance indicators improved in the last five years? (score from 1 to 5) To what extent has this improved the possible detection of health threats or significant trends? Can you mention relevant instances in your experience?
- 2) How would you rate your level of interest in the data included in the TESSy platform and databases? What are the most and the least interesting ones and why? Is there any room for simplification?
- 3) What is your overall assessment of the way the surveillance platforms and databases are managed? Does ECDC staff have the right skills to manage these platforms and databases? What skills, if any, are missing among them? What is your level of satisfaction with the ECDC current outsourcing practices in this field? What are the main pros and cons of these practices from the viewpoint of your organization?
- 4) More specifically, how do you assess the overall user friendliness of the data uploading mechanism? And the overall user friendliness of data validation procedures? What about the overall quality and methodological appropriateness of data validation procedures? What is very roughly the total person time you devote annually to data conversion, uploading and validation activities? How has it increased over time? What are the main problem areas if any?
- 5) What were the consequences of DSN integration into the ECDC into the following factors (improved +2 / worsened -2)
 - standardisation of data
 - microbiological quality of data
 - communication within network
 - flexibility of activities
 - identification of priorities for support
 - implementation costs
 - integration between epidemiologists and microbiologists (when applicable)
- 6) What is then your overall assessment of the results of the integration? To what extent is the added value received from the ECDC worth the effort in terms of what you contribute?
- 7) To what extent has cooperation between epidemiologists and microbiologists improved over the last five years? And if so, has this improved cooperation impacted on the network activities? For instance on steering priorities? Can you mention any relevant instance in your experience? More generally speaking, to what extent has your MS participation to ECDC activities in your area of expertise resulted in:
 - improved your overall capacity for laboratory diagnosis
 - improved the quality of your microbiological data
 - improved the comparability of your microbiological data
 - improved capacity to detect resistances
 - improved capacity to respond to outbreaks of unknown origin?
 - resulted in information integrated in the epidemiological data?

Further points you would like to raise.

Checklist for Salmonella Experts

- 1) To what extent have the subjects chosen for the FWD DP reflected your priorities? To what extent are resources allocated appropriately to the different areas of activity? What are the areas, if any, you deem overweighed or underweighed?
- 2) How do you rate the overall quality (timeliness, perceived independence, etc.) and usefulness of the ECDC risk assessments in the field of salmonella? Have you concretely used the 1) ECDC Risk assessment: multi-country outbreak of Salmonella Agora infections and 2) the Joint ECDC EFSA rapid risk assessment of multi-country outbreak of Salmonella Stanley infections as a primary source to inform your risk management and your risk communication activities? Have recommendations or decisions been taken based on this advice? What, if any, possible improvement would be needed to further increase their level of use/usefulness? To what extent have ECDC RRA/RAs in the field of FWD contradicted other evidence you used as a basis for risk management and communication decisions and therefore resulted in conflicting/confusing messages?
- 3) To what extent has the quality of ECDC surveillance indicators improved in the last five years? To what extent has this improved the possible detection of health threats or significant trends? Can you mention relevant instances in your experience? How would you rate your level of interest in the data included in the TESSy platform and EPIS databases?
- 4) What is your overall assessment of the way the salmonella surveillance platforms and databases are managed? Does ECDC staff have the right skills to manage them? What skills, if any, are missing among them? What is your level of satisfaction with the ECDC current outsourcing practices in this field? What are the main pros and cons?
- 5) What is roughly the total person time you devote annually to ECDC activities? Has it increased over time? What is then your overall assessment of the results of the integration into ECDC? To what extent is the added value received from the ECDC worth the effort in terms of what you contribute?
- 6) Are the priorities identified for External Quality Assurance exercises coherent with your country laboratories' needs? Are there other similar schemes already in place? How do you rate the overall burden for EQA? How does it compare with the added value of the exercise? Is the EQA delivery and implementation model appropriate? What are the pros and cons of outsourcing EQA? Does ECDC have the right skills to manage EQA? If not, what is lacking? What are the reasons for not participating to EQA? Have you taken part to the specific EQAs? Typing exercises on salmonella (the fourth run in 2013 is out of scope)? How do you rate the quality of these specific EQA exercises? How has the lab capacity changed following the EQA? What are the reasons for not participating to EQA?
- 7) How do you rate the ECDC contribution to strengthening salmonella programmes? How do you rate the ECDC contribution to improving scientific understanding of the disease determinants? How do you rate the ECDC contribution to improving your capacity to prevent and control salmonella? How do you rate the ECDC support received to improve your preparedness against outbreaks?

Further points you would like to raise.

Checklist for Influenza Experts

- 1) To what extent have the subjects chosen for the influenza DP reflected your priorities? To what extent are resources allocated appropriately to the different areas of activity? What are the areas, if any, you deem overweighed or underweighed?
- 2) To what extent have you used the few ECDC RA/RRA in the field of influenza (e.g. the “ECDC Forward Looking Risk Assessment of the Seasonal influenza” or the nine updates of the H1N1 risk assessment report as a primary source to inform your risk management and your risk communication activities? Have recommendations or decisions been taken based on this advice? What, if any, possible improvement would be needed to further increase their level of use/usefulness? To what extent have ECDC RRA/RAs contradicted other evidence you used your field of activity?
- 3) Have you used these ECDC outputs in particular?
 - The report on the follow up survey on seasonal influenza vaccination (2010-2011)
 - The consensus document on the minimum core data for vaccination coverage and a common set of indicators
 - The report on public health use of influenza antivirals during pandemics
 - The ECDC scientific advice on seasonal influenza vaccination of children and pregnant women
 - The Report on the behavioral aspects and the role of health communication in mitigating the impact of seasonal influenza
 - The risk communication toolkit on how to improve vaccination coverage.If not why? What was the related impact/follow up? Have you recurred to other sources in the same areas? Why? What was the added value of the ECDC in this case?
- 4) How do you rate the overall quality (timeliness, independence, completeness, etc.) and usefulness of the RA/RRA reports above in particular and of the ECDC scientific reports/guidance documents in general?
- 5) What is your overall assessment on the ECDC management of influenza-related activities so far? To what extent does ECDC staff have the right skills to manage its mission? What skills, if any, are missing? What is your level of satisfaction with the ECDC current outsourcing practices in your area? What are the main pros and cons?
- 6) What is roughly the total person time you devote annually to ECDC activities? Has it increased over time? To what extent is the added value received from the ECDC worth the effort in terms of what you contributed?
- 7) Has ECDC played a leading role during the pandemic crisis? To what extent ECDC was able to coordinate its activities with the various national and international bodies? How do you rate ECDC monitoring activities and the outputs produced (assessment, communication) during the pandemic? Did ECDC follow up timely to requests and provide support to risk managers adequately? In your opinion, which lesson should ECDC learn from that experience?
- 8) How do you rate the ECDC contribution to strengthening influenza vaccination programmes? And the ECDC contribution to improving scientific understanding of the disease determinants? How do you rate the ECDC contribution to improving your capacity to prevent and control influenza? How do you rate the ECDC support received to improve your preparedness against outbreaks?
- 9) Are the priorities identified for External Quality Assurance exercises coherent with your country laboratories’ needs? Are there other similar schemes already in place? How do you rate the overall burden for EQA? How does it compare with the added value of the exercise? Is the EQA delivery and implementation model appropriate? What are the pros and cons of outsourcing EQA? Have you taken part to the specific EQAs? Typing exercises on salmonella (the fourth run in 2013 is out of scope)? How do you rate the quality of these specific EQA exercises? How has the lab capacity changed following the EQA? What are the reasons for not participating to EQA?

Further points you would like to raise.

Checklist for HIV/AIDS Experts

- 1) To what extent have the subjects chosen for the HIV DP reflected your priorities? To what extent are resources allocated appropriately to the different areas of activity? What are the areas, if any, you deem overweighed or underweighed?
- 2) To what extent have you used the ECDC Risk Assessment/Rapid Risk Assessment in the field of HIV (e.g. Risk assessment of HIV in Greece and the Joint ECDC and EMCDDA rapid risk assessment of HIV in injecting drug users) as a primary source to inform your risk management and your risk communication activities? Why? Have recommendations or decisions been taken based on this advice? What, if any, possible improvement would be needed to further increase their level of use/usefulness? To what extent have ECDC RRA/RAs contradicted other evidence you used in your field of activity
- 3) Have you used these ECDC outputs in particular?
 - Development of a framework for the monitoring of the recommendation and action plan on HIV/AIDS/;
 - Monitoring report on the implementation of the European Commission Communication and Action Plan for combating HIV/AIDS;
 - Report on evidence for the effectiveness of interventions to prevent infectious diseases among people who inject drugs;
 - Standardized protocol for behavioral surveillance- Development of a web-based toolkit and self-assessment tool.If not, why? What was the related impact / follow up? Have you recurred to other sources in the same areas? Why? What was the added value of the ECDC in this case?
- 4) How do you rate the overall quality (timeliness, independence of judgment, completeness, etc.) and usefulness of the RA/RRA reports above in particular and of the ECDC scientific reports / guidance documents in general?
- 5) What is your overall assessment on the ECDC management of HIV-related activities so far? To what extent does ECDC staff have the right skills to manage its mission? What skills, if any, are missing? What is your level of satisfaction with the ECDC current outsourcing practices in your area? What are the main pros and cons of these practices from your viewpoint?
- 6) What is roughly the total person time you devote annually to ECDC activities? Has it increased over time? To what extent is the added value received from the ECDC worth the effort in terms of what you contributed?
- 7) How do you rate the ECDC contribution to strengthening HIV programmes? Has ECDC given an important contribution to improving scientific understanding of the disease determinants? If so in which respects? How do you rate the ECDC contribution to improving your capacity to prevent and control HIV?

Further points you would like to raise.

Checklist for International Agencies' representatives on Partnership Issues

- 1) To what extent are you satisfied of your current cooperation with ECDC? What are the most relevant instances of cooperation between your organization and the ECDC in the field of HIV/AIDS, Influenza and Salmonella? What are the related strong and the weak areas? What should be done to further improve cooperation for these diseases?
- 2) To what extent does cooperation with ECDC: 1) provide information not otherwise available? 2) enhance the quality of the information? 3) allow you to make savings on your activities? 4) streamline networking (including laboratory networks)? To what extent is the added value received from the ECDC worth the effort in terms of what you contributed? Are there specific areas where this effort is not justified by added value?
- 3) To what extent are you satisfied with your current division of labour with ECDC a) in ordinary conditions and b) during public health emergencies? What are the main problem areas? a) in ordinary conditions b) during public health emergencies (H1N1, etc.) What should be done to further improve it? What are the main lessons to be learnt from the recent pandemics in terms of WHO – ECDC partnership?
- 4) To what extent are you satisfied with your communication / management arrangements with ECDC? Do you experience difficulties in finding the right counterparts? Have you ever experienced lack of information sharing with ECDC a) in ordinary conditions b) during public health emergencies? What about procedures? Are they sufficiently clear?
- 5) Do you feel adequately informed about the Centre's activities? What should be done to further improve it?
- 6) Has ECDC ever contributed to your communication campaigns on the three diseases under consideration? In what ECDC contribution consisted of? Is there any good practice in your organization that could be shared with ECDC?
- 7) Looking at the future, what are in your view the complementarities, or otherwise, of the ECDC's current mission, tasks and activities with WHO Europe that could be further streamlined?

Further points you would like to raise.

ANNEX C – QUESTIONNAIRE FOR THE STAKEHOLDER SURVEY

C.1 Complete Questionnaire

Section 1 - Preliminary questions

On respondent's background	For ALL																	
P.B.1	<p>What is your <u>main</u> professional background and current position in the field of disease prevention and control? Please select all that applies</p> <table border="1" data-bbox="347 674 866 992"> <tr><td>i. Epidemiologist</td><td></td></tr> <tr><td>ii. Microbiologist</td><td></td></tr> <tr><td>iii. Clinician</td><td></td></tr> <tr><td>iv. Public health expert</td><td></td></tr> <tr><td>v. Researcher</td><td></td></tr> <tr><td>vi. Risk manager / involved in decision-making process</td><td></td></tr> <tr><td>vii. Communication expert / Advisor</td><td></td></tr> <tr><td>viii. Other, specify</td><td>_____</td></tr> </table>	i. Epidemiologist		ii. Microbiologist		iii. Clinician		iv. Public health expert		v. Researcher		vi. Risk manager / involved in decision-making process		vii. Communication expert / Advisor		viii. Other, specify	_____	Multiple answer
i. Epidemiologist																		
ii. Microbiologist																		
iii. Clinician																		
iv. Public health expert																		
v. Researcher																		
vi. Risk manager / involved in decision-making process																		
vii. Communication expert / Advisor																		
viii. Other, specify	_____																	
P.B.2	<p>If P.B.1.vi.=X (only risk managers)</p> <p>Which of the following best reflects where you work?</p> <table border="1" data-bbox="347 1144 895 1361"> <tr><td>i. Central Government</td><td></td></tr> <tr><td>ii. Regional / decentralised government (for federal countries)</td><td></td></tr> <tr><td>iii. Autonomous agency / institute</td><td></td></tr> <tr><td>iv. Other, specify</td><td>_____</td></tr> </table>	i. Central Government		ii. Regional / decentralised government (for federal countries)		iii. Autonomous agency / institute		iv. Other, specify	_____	One answer								
i. Central Government																		
ii. Regional / decentralised government (for federal countries)																		
iii. Autonomous agency / institute																		
iv. Other, specify	_____																	
P.B.3	<p>Do you have any professional responsibility and/or scientific interest in any of the following infectious diseases? Please indicate the <u>main</u> one</p> <table border="1" data-bbox="347 1458 858 1585"> <tr><td>i. Influenza</td><td></td></tr> <tr><td>ii. HIV/AIDS</td><td></td></tr> <tr><td>iii. Salmonella</td><td></td></tr> <tr><td>iv. None of the above</td><td></td></tr> </table>	i. Influenza		ii. HIV/AIDS		iii. Salmonella		iv. None of the above		One answer								
i. Influenza																		
ii. HIV/AIDS																		
iii. Salmonella																		
iv. None of the above																		
On the experience with ECDC	For ALL																	
P.E.1	<p>Did you ever / do you currently hold any role in the ECDC - Member States governance / collaboration system? Please select all that applies</p> <table border="1" data-bbox="347 1816 858 2027"> <tr><td>i. Management Board member/alternate</td><td></td></tr> <tr><td>ii. Advisory Forum member/alternate</td><td></td></tr> <tr><td>iii. National Coordinator / Director of the Coordinating Competent Body</td><td></td></tr> </table>	i. Management Board member/alternate		ii. Advisory Forum member/alternate		iii. National Coordinator / Director of the Coordinating Competent Body		Multiple answer										
i. Management Board member/alternate																		
ii. Advisory Forum member/alternate																		
iii. National Coordinator / Director of the Coordinating Competent Body																		

	iv. Expert within a national Competent Body		
	v. National Focal Point (including alternate)		
	vi. Operating Contact Point		
	vii. Former ECDC staff		
	viii. None of the above		
P.E.2	IF P.E.1.viii=X (no roles with ECDC) To what extent are you familiar with ECDC's role and activities? <ul style="list-style-type: none"> • Significantly • Moderately • Marginally • Not at all 		IF (4) skip to end
P.E.3	Overall, since how many years do you follow / interact with ECDC in the framework of your professional activity? Please, indicate approximately the number of years _____		Open

Section 2 - Overall assessment

Mandate, operating environment, added-value	For All																																															
O.M.1	Has ECDC added value to national and other international bodies working in disease prevention and control? Please rate from 1=very low to 5=very high the perceived added-value of ECDC activities		One answer																																													
		<table border="1"> <thead> <tr> <th></th> <th>Rating (From 1=very low to 5=very high)</th> <th>Don't know</th> </tr> </thead> <tbody> <tr> <td>i. Epidemic intelligence / early threat detection</td> <td></td> <td></td> </tr> <tr> <td>ii. Coordination of threat investigation / characterisation</td> <td></td> <td></td> </tr> <tr> <td>iii. Support to country's preparedness</td> <td></td> <td></td> </tr> <tr> <td>iv. Support to risk management</td> <td></td> <td></td> </tr> <tr> <td>v. Support to risk communication</td> <td></td> <td></td> </tr> <tr> <td>vi. Support to response in the event of severe emergencies</td> <td></td> <td></td> </tr> <tr> <td>vii. Training and capacity building</td> <td></td> <td></td> </tr> <tr> <td>viii. Preparation of communication toolkits / support to information campaigns</td> <td></td> <td></td> </tr> <tr> <td>ix. Laboratory support</td> <td></td> <td></td> </tr> <tr> <td>x. Facilitation of collaboration between epidemiologist and microbiologist</td> <td></td> <td></td> </tr> <tr> <td>xi. Integration and harmonisation of surveillance data</td> <td></td> <td></td> </tr> <tr> <td>xii. Support to networking and collaboration between different countries' experts and bodies</td> <td></td> <td></td> </tr> <tr> <td>xiii. Provision of evidence-based scientific advice and guidance</td> <td></td> <td></td> </tr> <tr> <td>xiv. <u>Overall</u> added-value of ECDC</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1=very low to 5=very high)	Don't know	i. Epidemic intelligence / early threat detection			ii. Coordination of threat investigation / characterisation			iii. Support to country's preparedness			iv. Support to risk management			v. Support to risk communication			vi. Support to response in the event of severe emergencies			vii. Training and capacity building			viii. Preparation of communication toolkits / support to information campaigns			ix. Laboratory support			x. Facilitation of collaboration between epidemiologist and microbiologist			xi. Integration and harmonisation of surveillance data			xii. Support to networking and collaboration between different countries' experts and bodies			xiii. Provision of evidence-based scientific advice and guidance			xiv. <u>Overall</u> added-value of ECDC			
	Rating (From 1=very low to 5=very high)	Don't know																																														
i. Epidemic intelligence / early threat detection																																																
ii. Coordination of threat investigation / characterisation																																																
iii. Support to country's preparedness																																																
iv. Support to risk management																																																
v. Support to risk communication																																																
vi. Support to response in the event of severe emergencies																																																
vii. Training and capacity building																																																
viii. Preparation of communication toolkits / support to information campaigns																																																
ix. Laboratory support																																																
x. Facilitation of collaboration between epidemiologist and microbiologist																																																
xi. Integration and harmonisation of surveillance data																																																
xii. Support to networking and collaboration between different countries' experts and bodies																																																
xiii. Provision of evidence-based scientific advice and guidance																																																
xiv. <u>Overall</u> added-value of ECDC																																																

O.M.2	As compared to 2008, the overall added-value of ECDC has...? <ul style="list-style-type: none"> • Significantly increased • Moderately increased • Not changed • Worsened • Don't know 	One answer																																																												
O.M.3	To what extent are you satisfied with the existing collaboration between your organisation and ECDC? <ul style="list-style-type: none"> • Significantly • Moderately • Marginally • Not at all • Don't know / Not applicable 	One answer																																																												
O.M.5	Based on your experience, how would you qualify the existing cooperation between ECDC and its other counterparts at national, European and global levels? <table border="1" data-bbox="343 757 1321 1659"> <thead> <tr> <th></th> <th>Synergetic (optimal level of active collaboration)</th> <th>Complementary (limited collaboration, but limited overlap either)</th> <th>Competitive (some duplication of activities and tasks)</th> <th>Antagonistic (some contentious interactions / interferences)</th> <th>Don't know</th> </tr> </thead> <tbody> <tr> <td>i. National Competent Bodies</td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>ii. European Commission</td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>iii. Health Security Committee</td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>iv. EFSA</td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>v. EMA</td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>vi. EMCDDA</td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>vii. WHO-EURO</td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>viii. WHO - Geneva</td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>ix. Other similar agencies in third countries (e.g. CDC - USA)</td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table>		Synergetic (optimal level of active collaboration)	Complementary (limited collaboration, but limited overlap either)	Competitive (some duplication of activities and tasks)	Antagonistic (some contentious interactions / interferences)	Don't know	i. National Competent Bodies						ii. European Commission						iii. Health Security Committee						iv. EFSA						v. EMA						vi. EMCDDA						vii. WHO-EURO						viii. WHO - Geneva						ix. Other similar agencies in third countries (e.g. CDC - USA)						One answer
	Synergetic (optimal level of active collaboration)	Complementary (limited collaboration, but limited overlap either)	Competitive (some duplication of activities and tasks)	Antagonistic (some contentious interactions / interferences)	Don't know																																																									
i. National Competent Bodies																																																														
ii. European Commission																																																														
iii. Health Security Committee																																																														
iv. EFSA																																																														
v. EMA																																																														
vi. EMCDDA																																																														
vii. WHO-EURO																																																														
viii. WHO - Geneva																																																														
ix. Other similar agencies in third countries (e.g. CDC - USA)																																																														
O.M.6	In your opinion, is ECDC interpreting and executing its mandate in a way that is consistent with your expectations? <ul style="list-style-type: none"> • Yes, definitely • Yes, partly • Not at all • Don't know 	One answer																																																												
O.M.7	IF O.M.6=(2) or (3) In your opinion, which aspects of the mandate in particular have not been sufficiently fulfilled so far?	Open																																																												

	Please, specify_____	
O.M.8	<p>Are the mission and tasks of ECDC as currently designed, still in-line with the current needs and challenges of Member States and the EU as a whole?</p> <ul style="list-style-type: none"> • Yes, definitely • Yes, partly • Not at all • Don't know 	One answer
O.M.9	<p>IF O.M.8=(2) or (3)</p> <p>Do you have any suggestion as to how ECDC mission and tasks could be modified in order to better respond to Member States and EU expectations?</p> <p>Please, describe_____</p>	

ECDC management and structure	IF P.E.1.i=Yes OR P.E.1.ii=Yes OR P.E.1.iii=Yes OR P.E.1.v=Yes																
O.S.1	<p>How do you judge the way ECDC selects its work priorities and the extent these respond to concrete needs in your country? Please rate from 1=poor to 5=excellent the following aspects related to the selection of work priorities</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 70%;"></th> <th style="width: 15%; text-align: center;">Rating (From 1=poor to 5=excellent)</th> <th style="width: 15%; text-align: center;">Don't know</th> </tr> </thead> <tbody> <tr> <td>i. Overall coherence of ECDC priorities with our needs</td> <td></td> <td></td> </tr> <tr> <td>ii. Clarity and transparency of criteria adopted by ECDC to select work priorities</td> <td></td> <td></td> </tr> <tr> <td>iii. Extent to which ECDC actually executes the planned work priorities (i.e. absence of discrepancy between planned and actual work)</td> <td></td> <td></td> </tr> <tr> <td>iv. Perceived consistency of resource allocations with plans (i.e. balance in the distribution of staff and financial resources)</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1=poor to 5=excellent)	Don't know	i. Overall coherence of ECDC priorities with our needs			ii. Clarity and transparency of criteria adopted by ECDC to select work priorities			iii. Extent to which ECDC actually executes the planned work priorities (i.e. absence of discrepancy between planned and actual work)			iv. Perceived consistency of resource allocations with plans (i.e. balance in the distribution of staff and financial resources)			One answer
	Rating (From 1=poor to 5=excellent)	Don't know															
i. Overall coherence of ECDC priorities with our needs																	
ii. Clarity and transparency of criteria adopted by ECDC to select work priorities																	
iii. Extent to which ECDC actually executes the planned work priorities (i.e. absence of discrepancy between planned and actual work)																	
iv. Perceived consistency of resource allocations with plans (i.e. balance in the distribution of staff and financial resources)																	
O.S.2	<p>Based on your experience, to what extent are the current ECDC management system and processes efficient and appropriate? Please rate from 1=very low to 5=very high your overall satisfaction with the following aspects of ECDC management</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 70%;"></th> <th style="width: 15%; text-align: center;">Rating (From 1=very low to 5=very high)</th> <th style="width: 15%; text-align: center;">Don't know</th> </tr> </thead> <tbody> <tr> <td>i. Internal coordination between disease-related units and functional units of ECDC</td> <td></td> <td></td> </tr> <tr> <td>ii. Clarity in the definition of roles and competences of staff</td> <td></td> <td></td> </tr> <tr> <td>iii. Speed in following up stakeholders' enquiries</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1=very low to 5=very high)	Don't know	i. Internal coordination between disease-related units and functional units of ECDC			ii. Clarity in the definition of roles and competences of staff			iii. Speed in following up stakeholders' enquiries			One answer			
	Rating (From 1=very low to 5=very high)	Don't know															
i. Internal coordination between disease-related units and functional units of ECDC																	
ii. Clarity in the definition of roles and competences of staff																	
iii. Speed in following up stakeholders' enquiries																	

	iv. Appropriateness of monitoring activities, performance indicators and reporting v. Transparency of management decisions vi. Adequacy of procedures to ensure independence and absence of conflicts of interest vii. Overall (perceived) cost-efficiency of the organisational 'machine'				
O.S.3	In your opinion, in which specific areas – if any – skills and expertise of ECDC staff may be strengthened? Please select all that applies				One answer
	i. Scientific knowledge / expertise on the subject matter ii. Project management capabilities iii. Understanding of Member States' systems and processes iv. Understanding of the EU-level and global policymaking framework v. Other, specify _____				
O.S.5	How do you assess the ECDC's current outsourcing practices? Please express your agreement / disagreement with the following statements.				One answer
		Rating (From 1= strong disagreement to 5= strong agreement)	Don't know		
	i. Outsourcing maximizes the quality of output because it facilitates recruitment of the best expertise available				
	ii. The volume of activities outsourced is excessive, some core competences should be kept in-house				
	iii. Outsourced activities and their results are reported with sufficient clarity and detail				
	iv. Current outsourcing practices appear overly burdensome for the ECDC in terms of administrative management and financial costs				
	v. The rationale behind outsourcing of activities is always clear and transparent				
	vi. There should be more geographical balance in outsourcing				
	vii. ECDC should expand the range of institutes to which projects and activities are outsourced				
Governance	IF P.E.1.i = (x) OR P.E.1.ii = (x) OR P.E.1.iii = (x) (For MB or AF or NC /CCBDir)				
O.G.1	IF P.E.1.i= (x) (MB) What is your overall assessment of the functioning of the ECDC Management Board (MB)? Please rate from 1=poor to 5=excellent the following aspects				One answer

	<table border="1"> <thead> <tr> <th></th> <th>Rating (From 1=poor to 5=excellent)</th> <th>Don't know</th> </tr> </thead> <tbody> <tr> <td>i. Overall coherence of MB activities with the mandate as laid down in the ECDC Founding Regulation</td> <td></td> <td></td> </tr> <tr> <td>ii. Extent of actual involvement and active participation of all countries represented in the MB</td> <td></td> <td></td> </tr> <tr> <td>iii. Language regime of MB meetings</td> <td></td> <td></td> </tr> <tr> <td>iv. Time and logistical aspects of MB meetings</td> <td></td> <td></td> </tr> <tr> <td>v. Quality and extent of discussion on ECDC work priorities</td> <td></td> <td></td> </tr> <tr> <td>vi. Quality and extent of discussion on ECDC management and structure</td> <td></td> <td></td> </tr> <tr> <td>vii. Quality and extent of discussion on budgetary allocations</td> <td></td> <td></td> </tr> <tr> <td>viii. Complementarity and synergy with the Advisory Forum</td> <td></td> <td></td> </tr> <tr> <td>ix. Dialogue and interactions with ECDC's senior management</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1=poor to 5=excellent)	Don't know	i. Overall coherence of MB activities with the mandate as laid down in the ECDC Founding Regulation			ii. Extent of actual involvement and active participation of all countries represented in the MB			iii. Language regime of MB meetings			iv. Time and logistical aspects of MB meetings			v. Quality and extent of discussion on ECDC work priorities			vi. Quality and extent of discussion on ECDC management and structure			vii. Quality and extent of discussion on budgetary allocations			viii. Complementarity and synergy with the Advisory Forum			ix. Dialogue and interactions with ECDC's senior management			
	Rating (From 1=poor to 5=excellent)	Don't know																														
i. Overall coherence of MB activities with the mandate as laid down in the ECDC Founding Regulation																																
ii. Extent of actual involvement and active participation of all countries represented in the MB																																
iii. Language regime of MB meetings																																
iv. Time and logistical aspects of MB meetings																																
v. Quality and extent of discussion on ECDC work priorities																																
vi. Quality and extent of discussion on ECDC management and structure																																
vii. Quality and extent of discussion on budgetary allocations																																
viii. Complementarity and synergy with the Advisory Forum																																
ix. Dialogue and interactions with ECDC's senior management																																
O.G.2	<p>IF P.E.1.i= (x) (MB)</p> <p>Do you have any suggestions as to how the current organisational arrangements and working methods of the Management Board could be improved?</p> <p>Please, describe _____</p>	Open																														
O.G.3	<p>IF P.E.1.ii= (x) (AF)</p> <p>What is your overall assessment of the functioning of the ECDC Advisory Forum (AF)? Please rate from 1=poor to 5=excellent the following aspects</p> <table border="1"> <thead> <tr> <th></th> <th>Rating (From 1=poor to 5=excellent)</th> <th>Don't know</th> </tr> </thead> <tbody> <tr> <td>i. Overall coherence of AF activities with the mandate as laid down in the ECDC Founding Regulation</td> <td></td> <td></td> </tr> <tr> <td>ii. Extent and comprehensiveness of scientific expertise available in the AF</td> <td></td> <td></td> </tr> <tr> <td>iii. Language regime of AF meetings</td> <td></td> <td></td> </tr> <tr> <td>iv. Time and logistical aspects of AF meetings</td> <td></td> <td></td> </tr> <tr> <td>v. Extent of actual room for discussion of ECDC scientific work priorities and outputs</td> <td></td> <td></td> </tr> <tr> <td>vi. Effectiveness of AF for networking purposes</td> <td></td> <td></td> </tr> <tr> <td>vii. Complementarity and synergy with the Management Board</td> <td></td> <td></td> </tr> <tr> <td>viii. Dialogue and interactions with ECDC's senior management</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1=poor to 5=excellent)	Don't know	i. Overall coherence of AF activities with the mandate as laid down in the ECDC Founding Regulation			ii. Extent and comprehensiveness of scientific expertise available in the AF			iii. Language regime of AF meetings			iv. Time and logistical aspects of AF meetings			v. Extent of actual room for discussion of ECDC scientific work priorities and outputs			vi. Effectiveness of AF for networking purposes			vii. Complementarity and synergy with the Management Board			viii. Dialogue and interactions with ECDC's senior management			One answer			
	Rating (From 1=poor to 5=excellent)	Don't know																														
i. Overall coherence of AF activities with the mandate as laid down in the ECDC Founding Regulation																																
ii. Extent and comprehensiveness of scientific expertise available in the AF																																
iii. Language regime of AF meetings																																
iv. Time and logistical aspects of AF meetings																																
v. Extent of actual room for discussion of ECDC scientific work priorities and outputs																																
vi. Effectiveness of AF for networking purposes																																
vii. Complementarity and synergy with the Management Board																																
viii. Dialogue and interactions with ECDC's senior management																																
O.G.4	<p>IF P.E.1.ii= (x) (AF)</p>																															

	<p>Do you have any suggestions as to how the current organisational arrangements and working methods of the Advisory Forum could be improved?</p> <p>Please, describe _____</p>																						
O.G.5	<p>IF P.E.1.iii= (x) (NC/CCBDir)</p> <p>What is your overall assessment of the efficiency of the structure in place for the coordination between ECDC and national Competent Bodies? Please rate from 1=poor to 5=excellent the following aspects</p> <table border="1"> <thead> <tr> <th></th> <th>Rating (From 1=poor to 5=excellent)</th> <th>Don't know</th> </tr> </thead> <tbody> <tr> <td>i. Overall clarity of respective roles and responsibilities of National Coordinators and ECDC</td> <td></td> <td></td> </tr> <tr> <td>ii. Overall clarity of roles and responsibilities of National Focal Points</td> <td></td> <td></td> </tr> <tr> <td>iii. Overall clarity of roles and responsibilities of Operating Contact Points</td> <td></td> <td></td> </tr> <tr> <td>iv. Coherence of coordination structures with institutional and governance set-up in your country</td> <td></td> <td></td> </tr> <tr> <td>v. Overall efficiency of communication flow with ECDC staff</td> <td></td> <td></td> </tr> <tr> <td>vi. Complementarity and synergy between national competent bodies and the ECDC governance bodies i.e. the Management Board and the Advisory Forum</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1=poor to 5=excellent)	Don't know	i. Overall clarity of respective roles and responsibilities of National Coordinators and ECDC			ii. Overall clarity of roles and responsibilities of National Focal Points			iii. Overall clarity of roles and responsibilities of Operating Contact Points			iv. Coherence of coordination structures with institutional and governance set-up in your country			v. Overall efficiency of communication flow with ECDC staff			vi. Complementarity and synergy between national competent bodies and the ECDC governance bodies i.e. the Management Board and the Advisory Forum			One answer
	Rating (From 1=poor to 5=excellent)	Don't know																					
i. Overall clarity of respective roles and responsibilities of National Coordinators and ECDC																							
ii. Overall clarity of roles and responsibilities of National Focal Points																							
iii. Overall clarity of roles and responsibilities of Operating Contact Points																							
iv. Coherence of coordination structures with institutional and governance set-up in your country																							
v. Overall efficiency of communication flow with ECDC staff																							
vi. Complementarity and synergy between national competent bodies and the ECDC governance bodies i.e. the Management Board and the Advisory Forum																							
O.G.6	<p>IF P.E.1.iii= (x) (NC/CCBDir)</p> <p>Could you estimate the level of effort required to undertake the tasks allocated to the National Coordinator / Coordinating Competent Body in your country? Please provide a rough estimate of annual man/days spent on the following tasks</p> <table border="1"> <thead> <tr> <th></th> <th>Approx. total number of man/days per year</th> </tr> </thead> <tbody> <tr> <td>i. Dissemination of ECDC publications in my country</td> <td>_____</td> </tr> <tr> <td>ii. Coordination of the other competent bodies in my country</td> <td>_____</td> </tr> <tr> <td>iii. Respond to requests for information received by ECDC (request for data, questionnaires etc.)</td> <td>_____</td> </tr> <tr> <td>iv. Participation in meetings organised by ECDC</td> <td>_____</td> </tr> <tr> <td>v. Other main tasks. Please, specify _____</td> <td>_____</td> </tr> </tbody> </table>		Approx. total number of man/days per year	i. Dissemination of ECDC publications in my country	_____	ii. Coordination of the other competent bodies in my country	_____	iii. Respond to requests for information received by ECDC (request for data, questionnaires etc.)	_____	iv. Participation in meetings organised by ECDC	_____	v. Other main tasks. Please, specify _____	_____	One answer									
	Approx. total number of man/days per year																						
i. Dissemination of ECDC publications in my country	_____																						
ii. Coordination of the other competent bodies in my country	_____																						
iii. Respond to requests for information received by ECDC (request for data, questionnaires etc.)	_____																						
iv. Participation in meetings organised by ECDC	_____																						
v. Other main tasks. Please, specify _____	_____																						
O.G.7	<p>IF P.E.1.iii= (x) (NC/CCBDir)</p> <p>Have you ever formulated a request for support to ECDC related to scientific or technical assistance? If YES, please briefly describe</p> <ul style="list-style-type: none"> • YES, please describe _____ 	One answer																					

	<ul style="list-style-type: none"> • NO 	
O.G.8	<p>IF P.E.1.iii= (x) (NC/CCBDir)</p> <p>Do you have any suggestions as to how the current coordination structure with ECDC, and working methods could be streamlined and/or improved?</p> <p>Please, describe _____</p>	Open

Burden	IF P.E.1.viii = ()																			
O.B.1	<p>How do you rate the overall amount of workload for competent bodies and stakeholders that is implied by collaborating with ECDC? Please rate from 1=very low to 5=very high the workload for the following tasks</p> <table border="1"> <thead> <tr> <th></th> <th>Rating (from 1=very low to 5=very high)</th> <th>Don't know</th> </tr> </thead> <tbody> <tr> <td>i. Collection and submission of surveillance data</td> <td></td> <td></td> </tr> <tr> <td>ii. Responding to other enquiries / information requests</td> <td></td> <td></td> </tr> <tr> <td>iii. Participation in meetings</td> <td></td> <td></td> </tr> <tr> <td>iv. Review of documents</td> <td></td> <td></td> </tr> <tr> <td>v. Other, specify _____</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (from 1=very low to 5=very high)	Don't know	i. Collection and submission of surveillance data			ii. Responding to other enquiries / information requests			iii. Participation in meetings			iv. Review of documents			v. Other, specify _____			One answer
	Rating (from 1=very low to 5=very high)	Don't know																		
i. Collection and submission of surveillance data																				
ii. Responding to other enquiries / information requests																				
iii. Participation in meetings																				
iv. Review of documents																				
v. Other, specify _____																				
O.B.2	<p>Could you estimate approximately the total number of man/days that you work on tasks / activities related to ECDC in a year?</p> <p>_____ Number of man/days per year</p>	Open																		
O.B.3	<p>As compared to 2008, has this workload...?</p> <ul style="list-style-type: none"> • Significantly increased • Moderately increased • Not changed • Moderately decreased • Significantly decreased • Don't know 	One answer																		
O.B.4	<p>Overall how does the burden (workload) imposed by ECDC tasks compare with the added-value of ECDC work in your opinion?</p> <ul style="list-style-type: none"> • Benefits significantly outweigh burden • Benefits moderately outweigh burden • Benefits are approximately equal to burden • Burden moderately outweighs benefits • Burden significantly outweighs benefits • Don't know 	One answer																		
O.B.6	<p>How often do you participate to the meetings that ECDC invites you to attend?</p> <ul style="list-style-type: none"> • All the time • Most of time (more than 50% of times) • Sometimes (Less than 50% of times) • Don't know / not applicable 	One answer																		

Section 3 - Disease Programmes

Salmonella	<p>For NFP-FWD OR Net-salm OR Net-smol</p> <p>OR</p> <p>IF P.B.3.iii = (x) (self-declared salmonella experts)</p>	
-------------------	--	--

D.S.0	<p>To what extent are you familiar with the ECDC's Food- and Waterborne Diseases and Zoonoses (FWD) programme, which covers <i>inter alia</i> activities for prevention and control of salmonella?</p> <ul style="list-style-type: none"> • Significantly • Moderately • Marginally • Not at all 	<p>One answer</p> <p>IF (4) skip this module</p>																								
D.S.1	<p>What is your overall assessment of the abovementioned FWD programme, with specific reference to activities in the field of salmonella? Please rate from 1= poor to 5= excellent your appreciation of the following aspects</p> <table border="1" data-bbox="347 566 1109 1249"> <thead> <tr> <th></th> <th>Rating (From 1=poor to 5=excellent)</th> <th>Don't know</th> </tr> </thead> <tbody> <tr> <td>i. Relevance of the priorities selected for the FWD programme to my country's needs</td> <td></td> <td></td> </tr> <tr> <td>ii. Contribution of FWD programme to a better integration of risk assessment, management and communication in my country</td> <td></td> <td></td> </tr> <tr> <td>iii. Efficiency of FWD programme coordination by ECDC staff</td> <td></td> <td></td> </tr> <tr> <td>iv. Quality / reliability of the surveillance data collected on salmonella</td> <td></td> <td></td> </tr> <tr> <td>v. Usefulness of risk assessments related to salmonella outbreaks</td> <td></td> <td></td> </tr> <tr> <td>vi. Usefulness of ECDC work on molecular typing for salmonella</td> <td></td> <td></td> </tr> <tr> <td>vii. Preparedness of ECDC staff on the subject matter</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1=poor to 5=excellent)	Don't know	i. Relevance of the priorities selected for the FWD programme to my country's needs			ii. Contribution of FWD programme to a better integration of risk assessment, management and communication in my country			iii. Efficiency of FWD programme coordination by ECDC staff			iv. Quality / reliability of the surveillance data collected on salmonella			v. Usefulness of risk assessments related to salmonella outbreaks			vi. Usefulness of ECDC work on molecular typing for salmonella			vii. Preparedness of ECDC staff on the subject matter			<p>One answer</p>
	Rating (From 1=poor to 5=excellent)	Don't know																								
i. Relevance of the priorities selected for the FWD programme to my country's needs																										
ii. Contribution of FWD programme to a better integration of risk assessment, management and communication in my country																										
iii. Efficiency of FWD programme coordination by ECDC staff																										
iv. Quality / reliability of the surveillance data collected on salmonella																										
v. Usefulness of risk assessments related to salmonella outbreaks																										
vi. Usefulness of ECDC work on molecular typing for salmonella																										
vii. Preparedness of ECDC staff on the subject matter																										
D.S.2	<p>How do you rate the level of integration and synergy between ECDC's salmonella-related activities and the other relevant agencies, instruments and programmes? Please rate from 1= poor to 5= excellent</p> <table border="1" data-bbox="347 1373 1109 1780"> <thead> <tr> <th></th> <th>Rating (From 1=poor to 5=excellent)</th> <th>Don't know</th> </tr> </thead> <tbody> <tr> <td>i. The European Food Safety Authority (EFSA)</td> <td></td> <td></td> </tr> <tr> <td>ii. The WHO's Global Foodborne Infections Network (GFN)</td> <td></td> <td></td> </tr> <tr> <td>iii. The Rapid Alert System for Food and Feed - (RASFF)</td> <td></td> <td></td> </tr> <tr> <td>iv. The EU Reference Laboratories (EURLs)</td> <td></td> <td></td> </tr> <tr> <td>v. National-level agencies and bodies</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1=poor to 5=excellent)	Don't know	i. The European Food Safety Authority (EFSA)			ii. The WHO's Global Foodborne Infections Network (GFN)			iii. The Rapid Alert System for Food and Feed - (RASFF)			iv. The EU Reference Laboratories (EURLs)			v. National-level agencies and bodies			<p>One answer</p>						
	Rating (From 1=poor to 5=excellent)	Don't know																								
i. The European Food Safety Authority (EFSA)																										
ii. The WHO's Global Foodborne Infections Network (GFN)																										
iii. The Rapid Alert System for Food and Feed - (RASFF)																										
iv. The EU Reference Laboratories (EURLs)																										
v. National-level agencies and bodies																										
D.S.3	<p>Overall, have ECDC's activities helped to improve your country's capacity to prevent and control salmonella? Is there concrete evidence of this? Please briefly describe the possible added-value of ECDC's FWD programme for your country and – if available – provide weblinks to official documents published in your country, which have taken up the results of ECDC work</p> <div style="border: 1px solid black; height: 20px; width: 250px; margin-top: 10px;"></div>	<p>Open</p>																								

Influenza	For NFP-FLU OR Net-flu OR FLU-HSC OR IF P.B.3.i = (x) (self-declared influenza experts)																												
D.I.0	To what extent are you familiar with the ECDC's Influenza and other Respiratory Viruses (IRV) programme, which covers <i>inter alia</i> activities for prevention and control of influenza? <ul style="list-style-type: none"> • Significantly • Moderately • Marginally • Not at all 	One answer IF (4) skip this module																											
D.I.1	What is your overall assessment of the abovementioned Influenza programme (IRV)? Please rate from 1= poor to 5= excellent your appreciation of the following aspects <table border="1" data-bbox="347 689 1107 1402"> <thead> <tr> <th></th> <th>Rating (From 1=poor to 5=excellent)</th> <th>Don't know</th> </tr> </thead> <tbody> <tr> <td>i. Relevance of the priorities selected for the IRV programme with respect to my country needs</td> <td></td> <td></td> </tr> <tr> <td>ii. Contribution of IRV programme to a better integration of risk assessment, management and communication in my country</td> <td></td> <td></td> </tr> <tr> <td>iii. Efficiency of IRV programme coordination by ECDC staff</td> <td></td> <td></td> </tr> <tr> <td>iv. Quality / reliability of the surveillance data on influenza</td> <td></td> <td></td> </tr> <tr> <td>v. Usefulness of risk assessments on seasonal influenza</td> <td></td> <td></td> </tr> <tr> <td>vi. Usefulness of risk assessments on pandemic viruses / animal influenza</td> <td></td> <td></td> </tr> <tr> <td>vii. Usefulness of ECDC scientific advice on influenza vaccination</td> <td></td> <td></td> </tr> <tr> <td>viii. Preparedness of ECDC staff on the subject matter</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1=poor to 5=excellent)	Don't know	i. Relevance of the priorities selected for the IRV programme with respect to my country needs			ii. Contribution of IRV programme to a better integration of risk assessment, management and communication in my country			iii. Efficiency of IRV programme coordination by ECDC staff			iv. Quality / reliability of the surveillance data on influenza			v. Usefulness of risk assessments on seasonal influenza			vi. Usefulness of risk assessments on pandemic viruses / animal influenza			vii. Usefulness of ECDC scientific advice on influenza vaccination			viii. Preparedness of ECDC staff on the subject matter			One answer
	Rating (From 1=poor to 5=excellent)	Don't know																											
i. Relevance of the priorities selected for the IRV programme with respect to my country needs																													
ii. Contribution of IRV programme to a better integration of risk assessment, management and communication in my country																													
iii. Efficiency of IRV programme coordination by ECDC staff																													
iv. Quality / reliability of the surveillance data on influenza																													
v. Usefulness of risk assessments on seasonal influenza																													
vi. Usefulness of risk assessments on pandemic viruses / animal influenza																													
vii. Usefulness of ECDC scientific advice on influenza vaccination																													
viii. Preparedness of ECDC staff on the subject matter																													
D.I.2	How do you assess the support provided by ECDC during the influenza pandemic (2009)? Please rate from 1= poor to 5= excellent your appreciation of the following aspects <table border="1" data-bbox="347 1503 1107 1872"> <thead> <tr> <th></th> <th>Rating (From 1=poor to 5=excellent)</th> <th>Don't know</th> </tr> </thead> <tbody> <tr> <td>i. Timeliness of publication of risk assessments and subsequent updates</td> <td></td> <td></td> </tr> <tr> <td>ii. Degree of coordination with WHO</td> <td></td> <td></td> </tr> <tr> <td>iii. Degree of coordination with DG SANCO</td> <td></td> <td></td> </tr> <tr> <td>iv. Scientific quality of ECDC output</td> <td></td> <td></td> </tr> <tr> <td>v. Credibility / reliability of recommendations</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1=poor to 5=excellent)	Don't know	i. Timeliness of publication of risk assessments and subsequent updates			ii. Degree of coordination with WHO			iii. Degree of coordination with DG SANCO			iv. Scientific quality of ECDC output			v. Credibility / reliability of recommendations			One answer									
	Rating (From 1=poor to 5=excellent)	Don't know																											
i. Timeliness of publication of risk assessments and subsequent updates																													
ii. Degree of coordination with WHO																													
iii. Degree of coordination with DG SANCO																													
iv. Scientific quality of ECDC output																													
v. Credibility / reliability of recommendations																													
D.I.3	What is in your opinion the main lesson to be learned by ECDC from the pandemic experience? Please, describe _____	Open																											

HIV/AIDS	For NFP-HASH OR Net-HIV OR HIV-TT	
-----------------	--	--

	<p>OR</p> <p>IF P.B.3.ii = (x) (self-declared HIV/AIDS experts)</p>																									
D.H.0	<p>To what extent are you familiar with the ECDC’s HIV, Sexually Transmitted Infections and viral Hepatitis (HSH) programme, which covers inter alia activities for prevention and control of HIV/AIDS?</p> <ul style="list-style-type: none"> • Significantly • Moderately • Marginally • Not at all 	<p>One answer</p> <p>IF (4) skip this module</p>																								
D.H.1	<p>What is your overall assessment of the abovementioned HIV/ AIDS programme (HSH)? Please rate from 1= poor to 5= excellent your appreciation of the following aspects</p> <table border="1"> <thead> <tr> <th></th> <th>Rating (from 1= poor to 5= excellent)</th> <th>Don't know</th> </tr> </thead> <tbody> <tr> <td>i. Relevance of the priorities selected for the HSH programme with respect to my country needs</td> <td></td> <td></td> </tr> <tr> <td>ii. Contribution of HSH programme to a better integration of risk assessment, management and communication in my country</td> <td></td> <td></td> </tr> <tr> <td>iii. Efficiency of HSH programme coordination by ECDC staff</td> <td></td> <td></td> </tr> <tr> <td>iv. Quality / reliability of the surveillance data collected on HIV/AIDS</td> <td></td> <td></td> </tr> <tr> <td>v. Usefulness of risk assessments related to HIV/AIDS</td> <td></td> <td></td> </tr> <tr> <td>vi. Usefulness of ECDC’s behavioural surveillance work and outputs</td> <td></td> <td></td> </tr> <tr> <td>vii. Preparedness of ECDC staff on the subject matter</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (from 1= poor to 5= excellent)	Don't know	i. Relevance of the priorities selected for the HSH programme with respect to my country needs			ii. Contribution of HSH programme to a better integration of risk assessment, management and communication in my country			iii. Efficiency of HSH programme coordination by ECDC staff			iv. Quality / reliability of the surveillance data collected on HIV/AIDS			v. Usefulness of risk assessments related to HIV/AIDS			vi. Usefulness of ECDC’s behavioural surveillance work and outputs			vii. Preparedness of ECDC staff on the subject matter			<p>One answer</p>
	Rating (from 1= poor to 5= excellent)	Don't know																								
i. Relevance of the priorities selected for the HSH programme with respect to my country needs																										
ii. Contribution of HSH programme to a better integration of risk assessment, management and communication in my country																										
iii. Efficiency of HSH programme coordination by ECDC staff																										
iv. Quality / reliability of the surveillance data collected on HIV/AIDS																										
v. Usefulness of risk assessments related to HIV/AIDS																										
vi. Usefulness of ECDC’s behavioural surveillance work and outputs																										
vii. Preparedness of ECDC staff on the subject matter																										
D.H.2	<p>How do you rate the level of integration and synergy between ECDC’s HIV/AIDS-related activities and the other relevant agencies and bodies? Please rate from 1= poor to 5= excellent</p> <table border="1"> <thead> <tr> <th></th> <th>Rating (From 1=poor to 5=excellent)</th> <th>Don't know</th> </tr> </thead> <tbody> <tr> <td>i. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)</td> <td></td> <td></td> </tr> <tr> <td>ii. WHO-Euro</td> <td></td> <td></td> </tr> <tr> <td>iii. HIV Think Tank European Commission)</td> <td></td> <td></td> </tr> <tr> <td>v. National-level agencies and bodies</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1=poor to 5=excellent)	Don't know	i. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)			ii. WHO-Euro			iii. HIV Think Tank European Commission)			v. National-level agencies and bodies			<p>One answer</p>									
	Rating (From 1=poor to 5=excellent)	Don't know																								
i. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)																										
ii. WHO-Euro																										
iii. HIV Think Tank European Commission)																										
v. National-level agencies and bodies																										
D.H.3	<p>Overall, have ECDC’s activities helped to improve your country’s capacity for the prevention and control of HIV/AIDS? Is there concrete evidence of this? Please briefly describe the possible added-value of ECDC’s HSH programme for your country and – if available – provide weblinks to official documents published in your country, which have taken up the results of ECDC work</p>	<p>One answer</p>																								

	Please, describe _____	
--	------------------------	--

All DP	For NFP-HASH OR Net-HIV OR NFP-FLU OR Net-flu OR NFP-FWD OR Net-salm OR Net-smol	
D.D.1	Do you have any suggestions as to how to increase the added-value of ECDC disease programmes for the Member States? Please, describe _____	Open

Section 4 - Threat Detection, Preparedness and response

Rapid risk assessment - general	For ALL																																		
T.R.0	Are you aware of the ECDC's Rapid Risk Assessments (RRA)? <ul style="list-style-type: none"> • YES, I read them quite regularly • YES, I sometimes read them • YES, but I have never read them • NO, I was not aware of the RRAs 	One answer If (3) OR (4) skip to the next module																																	
T.R.1	Overall, what is your appreciation of the following features of ECDC's RRAs? Please rate from 1=poor to 5= excellent <table border="1" style="width: 100%; margin-top: 10px;"> <thead> <tr> <th></th> <th>Rating (From 1=poor to 5=excellent)</th> <th>Don't Know</th> </tr> </thead> <tbody> <tr> <td>i. Speed of release</td> <td></td> <td></td> </tr> <tr> <td>ii. Reliability of scientific assessment</td> <td></td> <td></td> </tr> <tr> <td>iii. Comprehensiveness of analysis</td> <td></td> <td></td> </tr> <tr> <td>iv. Clarity of the messages provided</td> <td></td> <td></td> </tr> <tr> <td>v. Perceived independence from political pressure</td> <td></td> <td></td> </tr> <tr> <td>vi. Perceived independence from corporate pressures</td> <td></td> <td></td> </tr> <tr> <td>vii. Usefulness for own, national-level scientific assessment purposes</td> <td></td> <td></td> </tr> <tr> <td>viii. Usefulness for decision-making on response measures to be taken</td> <td></td> <td></td> </tr> <tr> <td>ix. Usefulness for risk communication to specialist audiences</td> <td></td> <td></td> </tr> <tr> <td>x. Usefulness for risk communication to the media and the general public</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1=poor to 5=excellent)	Don't Know	i. Speed of release			ii. Reliability of scientific assessment			iii. Comprehensiveness of analysis			iv. Clarity of the messages provided			v. Perceived independence from political pressure			vi. Perceived independence from corporate pressures			vii. Usefulness for own, national-level scientific assessment purposes			viii. Usefulness for decision-making on response measures to be taken			ix. Usefulness for risk communication to specialist audiences			x. Usefulness for risk communication to the media and the general public			One answer
	Rating (From 1=poor to 5=excellent)	Don't Know																																	
i. Speed of release																																			
ii. Reliability of scientific assessment																																			
iii. Comprehensiveness of analysis																																			
iv. Clarity of the messages provided																																			
v. Perceived independence from political pressure																																			
vi. Perceived independence from corporate pressures																																			
vii. Usefulness for own, national-level scientific assessment purposes																																			
viii. Usefulness for decision-making on response measures to be taken																																			
ix. Usefulness for risk communication to specialist audiences																																			
x. Usefulness for risk communication to the media and the general public																																			
T.R.2	In your opinion, how has the usefulness / quality of RRAs evolved since 2008? <ul style="list-style-type: none"> • Significantly improved • Moderately improved • Not changed • Worsened • Don't know 	One answer																																	
T.R.4	Have you ever contributed to ECDC RRAs as an external expert (e.g. providing data and analysis)? <ul style="list-style-type: none"> • YES • NO 	One answer																																	

RRA – Salmonella	For NFP ThDet OR NFP P&R OR NFP-FWD OR Net-salm OR Net-smol OR HSCmem OR HSCcomm OR EWRS OR	
-------------------------	--	--

	<p>IF P.B.3.iii = (x) (self-declared salmonella experts)</p> <p>OR</p> <p>IF P.B.1.vi = (x) (risk manager)</p>	
T.S.1	<p>Are you familiar with the ECDC's Rapid Risk Assessment (RRA) on Salmonella Stanley 2012 (including updates)? If so, could you indicate the impact it had in your country?</p> <ul style="list-style-type: none"> • Major impact: it inspired the measures we adopted to tackle the outbreak • Moderate impact: we used it as background for our investigation and/or communication work • Limited impact • Don't know / I am not familiar with this RRA 	One answer
T.S.2	<p>IF T.S.1=(1) OR (2)</p> <p>Could you provide any evidence of such impact, by providing a short description and – if relevant – the weblink to any national-level document (strategy, guideline etc.) that was to some extent inspired by this ECDC Rapid Risk Assessment?</p> <p>Please, describe _____</p>	Open
T.S.3	<p>Are you familiar with the ECDC's Rapid Risk Assessment (RRA) on Salmonella Agona 2008 (including updates)? If so, could you indicate the impact it had in your country?</p> <ul style="list-style-type: none"> • Major impact: it inspired the measures we adopted to tackle the outbreak • Moderate impact: we used it as background for our investigation and/or communication work • Limited impact • Don't know / I am not familiar with this RRA 	One answer
T.S.4	<p>IF T.S.3=(1) OR (2)</p> <p>Could you provide any evidence of such impact, by providing a short description and – if relevant – the weblink to any national-level document (strategy, guideline etc.) that was to some extent inspired by this ECDC Rapid Risk Assessment?</p> <p>Please, describe _____</p>	Open

RRA - Influenza	<p>For NFP ThDet OR NFP P&R OR NFP-FLU OR Net-flu OR FLU HSC OR HSCmem OR HSCcomm OR EWRS</p> <p>OR</p> <p>IF P.B.3.i = (x) (self-declared influenza experts)</p> <p>OR</p> <p>IF P.B.1.vi = (x) (risk manager)</p>	
T.F.1	<p>Are you familiar with the ECDC's Rapid Risk Assessment (RRA) on Influenza A/H1N1 - pandemic 2009 (including the various updates)? If so, could you indicate the impact it had in your country?</p> <ul style="list-style-type: none"> • Major impact: it inspired the measures we adopted to tackle the outbreak • Moderate impact: we used it as background for our investigation and/or communication work • Limited impact • Don't know / I am not familiar with this RRA 	One answer
T.F.2	<p>IF T.F.1=(1) OR (2)</p> <p>Could you provide any evidence of such impact, by providing a short description and – if relevant – the weblink to any national-level document (strategy, guideline etc.) that was to some extent inspired by this ECDC Rapid Risk Assessment?</p>	Open

	Please, describe _____	
T.F.3	<p>Are you familiar with the ECDC’s Rapid Risk Assessment (RRA) on Influenza A/H5N1 - avian influenza in Egypt, 2011 (including the various updates)? If so, could you indicate the impact it had in your country?</p> <ul style="list-style-type: none"> • Major impact: it inspired the measures we adopted to tackle the outbreak • Moderate impact: we used it as background for our investigation and/or communication work • Limited impact • Don’t know / I am not familiar with this RRA 	One answer
T.F.4	<p>IF T.F.3=(1) OR (2)</p> <p>Could you provide any evidence of this impact, for example a weblink to any national-level document (strategy, guideline etc.) that was to some extent inspired by this ECDC Rapid Risk Assessment?</p> <p>Please, describe _____</p>	Open

RRA - HIV	<p>For NFP ThDet OR NFP P&R OR NFP-HASH OR Net-HIV OR HIV TT OR HSCmem OR HSCcomm OR EWRS</p> <p>OR</p> <p>IF P.B.3.ii = (x) (self-declared HIV experts)</p> <p>OR</p> <p>IF P.B.1.vi = (x) (risk manager)</p>	
T.H.1	<p>Are you familiar with the joint ECDC and EMCDDA rapid risk assessment: HIV in injecting drug users in the EU/EEA 2012 (following a reported increase of cases in Greece and Romania)? If so, could you indicate the impact it had in your country?</p> <ul style="list-style-type: none"> • Major impact: it inspired the measures we adopted to tackle the outbreak • Moderate impact: we used it as background for our investigation and/or communication work • Limited impact • Don’t know / I am not familiar with this RRA 	One answer
T.H.2	<p>IF T.H.1=(1) OR (2)</p> <p>Could you provide any evidence of this impact, for example a weblink to any national-level document (strategy, guideline etc.) that was to some extent inspired by this Rapid Risk Assessment?</p> <p>_____</p>	Open

EPIS	For EPIS									
T.E.1	<p>Do you have access to the following EPIS platforms? Please, select all that applies</p> <table border="1"> <tr> <td>i. AMR-HAI (Antimicrobial Resistance Healthcare Associated Infections)</td> <td></td> </tr> <tr> <td>ii. ELDSNet (Legionnaires' disease)</td> <td></td> </tr> <tr> <td>iii. FWD – as a reader (Food and Waterborne diseases)</td> <td></td> </tr> <tr> <td>iv. FWD – as a contributor (Food and Waterborne diseases)</td> <td></td> </tr> </table>	i. AMR-HAI (Antimicrobial Resistance Healthcare Associated Infections)		ii. ELDSNet (Legionnaires' disease)		iii. FWD – as a reader (Food and Waterborne diseases)		iv. FWD – as a contributor (Food and Waterborne diseases)		<p>Multiple answer</p> <p>If vii.=x) skip to the next module</p>
i. AMR-HAI (Antimicrobial Resistance Healthcare Associated Infections)										
ii. ELDSNet (Legionnaires' disease)										
iii. FWD – as a reader (Food and Waterborne diseases)										
iv. FWD – as a contributor (Food and Waterborne diseases)										

	<table border="1"> <tr> <td>v. STI (Sexually Transmitted Infections)</td> <td></td> </tr> <tr> <td>vi. VPD (Vaccine-Preventable Diseases)</td> <td></td> </tr> <tr> <td>vii. None</td> <td></td> </tr> </table>	v. STI (Sexually Transmitted Infections)		vi. VPD (Vaccine-Preventable Diseases)		vii. None														
v. STI (Sexually Transmitted Infections)																				
vi. VPD (Vaccine-Preventable Diseases)																				
vii. None																				
T.E.2	<p>How often do you access EPIS ?</p> <ul style="list-style-type: none"> • More times per day • On a daily basis • On a weekly basis • Seldom 	One answer																		
T.E.3	<p>IF T.E.1.iv=(X) (only FWD contributors)</p> <p>On average, how frequently do you follow up other countries' enquiries on the EPIS FWD platform? (in percentage) ____%</p>	Open																		
T.E.4	<p>IF T.E.1.v=(X) (only STI)</p> <p>Approximately, how often do you follow up on Sexually Transmitted Infections (STI) reports submitted by other countries? ____%</p>	Open																		
T.E.5	<p>Based on your direct experience, to what extent does the EPIS platform(s) make an effective contribution to your epidemic intelligence activities? Please rate from 1= poor to 5= excellent your appreciation of the following aspects</p> <table border="1"> <thead> <tr> <th></th> <th>Rating (From 1=poor to 5=excellent)</th> <th>Don't know</th> </tr> </thead> <tbody> <tr> <td>i. Relevance of the signals / alerts published on EPIS</td> <td></td> <td></td> </tr> <tr> <td>ii. Comprehensiveness of EPIS as compared to other international epidemic intelligence sources</td> <td></td> <td></td> </tr> <tr> <td>iii. Speed of threat detection through EPIS</td> <td></td> <td></td> </tr> <tr> <td>iv. Utility of EPIS as a tool to support joint (multi-country) investigation of threats</td> <td></td> <td></td> </tr> <tr> <td>v. Integration of EPIS with the EU Risk Management system and the EWRS platform, in particular</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1=poor to 5=excellent)	Don't know	i. Relevance of the signals / alerts published on EPIS			ii. Comprehensiveness of EPIS as compared to other international epidemic intelligence sources			iii. Speed of threat detection through EPIS			iv. Utility of EPIS as a tool to support joint (multi-country) investigation of threats			v. Integration of EPIS with the EU Risk Management system and the EWRS platform, in particular			One answer
	Rating (From 1=poor to 5=excellent)	Don't know																		
i. Relevance of the signals / alerts published on EPIS																				
ii. Comprehensiveness of EPIS as compared to other international epidemic intelligence sources																				
iii. Speed of threat detection through EPIS																				
iv. Utility of EPIS as a tool to support joint (multi-country) investigation of threats																				
v. Integration of EPIS with the EU Risk Management system and the EWRS platform, in particular																				
T.E.6	<p>Are you satisfied with the following management and operational aspects of EPIS? Please rate from 1= poor to 5= excellent your appreciation of the following aspects</p> <table border="1"> <thead> <tr> <th></th> <th>Rating (From 1=poor to 5=excellent)</th> <th>Don't know</th> </tr> </thead> <tbody> <tr> <td>i. Clarity and user-friendliness of the platform(s) design</td> <td></td> <td></td> </tr> <tr> <td>ii. Overall platform coordination by ECDC</td> <td></td> <td></td> </tr> <tr> <td>iii. Degree of responsiveness of partners to enquiries and reports</td> <td></td> <td></td> </tr> <tr> <td>iv. Extent and frequency of ECDC inputs (i.e. event notified by ECDC)</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1=poor to 5=excellent)	Don't know	i. Clarity and user-friendliness of the platform(s) design			ii. Overall platform coordination by ECDC			iii. Degree of responsiveness of partners to enquiries and reports			iv. Extent and frequency of ECDC inputs (i.e. event notified by ECDC)			One answer			
	Rating (From 1=poor to 5=excellent)	Don't know																		
i. Clarity and user-friendliness of the platform(s) design																				
ii. Overall platform coordination by ECDC																				
iii. Degree of responsiveness of partners to enquiries and reports																				
iv. Extent and frequency of ECDC inputs (i.e. event notified by ECDC)																				
T.E.7	<p>Could you indicate a concrete example where EPIS networking proved crucial for quickly detecting / assessing a threat that also affected your country? Please, briefly describe the event and the added-value of EPIS in that situation (please add weblink to relevant documents, if applicable)</p> <p>Please, describe _____</p>	Open																		

T.E.8	Do you utilise also other epidemic intelligence sources? <ul style="list-style-type: none"> • YES (Please, specify_____) • NO 	One answer
-------	--	------------

EWRS	For NFP ThDet OR NFP P&R OR HSCmem OR HSCcomm OR Netw 2119 OR EWRS OR FLU HSC OR HIV TT OR IF P.B.1.vi= (X) OR P.B.1.vii= (X) (risk managers and communicators)																						
T.W.0	Are you familiar with the EU Early Warning and Response System (EWRS)? <ul style="list-style-type: none"> • YES, I have direct access to it • YES, although I do not have direct access to it • NO, I am not familiar with EWRS 	One answer If (3) skip to the next module																					
T.W.1	Based on your direct experience, to what extent has the EWRS platform been effective in the management of public health threats in the EU? Please rate from 1=poor to 5=excellent the added-value of EWRS with respect to the specific aspects indicated below <table border="1"> <thead> <tr> <th></th> <th>Rating (From 1=poor to 5=excellent)</th> <th>Don't know</th> </tr> </thead> <tbody> <tr> <td>i. Early detection/identification of threats</td> <td></td> <td></td> </tr> <tr> <td>ii. In-depth investigation/assessment of threat</td> <td></td> <td></td> </tr> <tr> <td>iii. Definition of coordinated measures in response to 'mild' threats</td> <td></td> <td></td> </tr> <tr> <td>iv. Definition of coordinated response measures during 'severe' crisis</td> <td></td> <td></td> </tr> <tr> <td>v. Provision of useful information for risk communication</td> <td></td> <td></td> </tr> <tr> <td>vi. Improved preparedness of my country to outbreaks</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1=poor to 5=excellent)	Don't know	i. Early detection/identification of threats			ii. In-depth investigation/assessment of threat			iii. Definition of coordinated measures in response to 'mild' threats			iv. Definition of coordinated response measures during 'severe' crisis			v. Provision of useful information for risk communication			vi. Improved preparedness of my country to outbreaks			One answer
	Rating (From 1=poor to 5=excellent)	Don't know																					
i. Early detection/identification of threats																							
ii. In-depth investigation/assessment of threat																							
iii. Definition of coordinated measures in response to 'mild' threats																							
iv. Definition of coordinated response measures during 'severe' crisis																							
v. Provision of useful information for risk communication																							
vi. Improved preparedness of my country to outbreaks																							
T.W.2	Are you satisfied with how EWRS is currently designed and managed? Please rate from 1= poor to 5= excellent your appreciation of the following aspects. <table border="1"> <thead> <tr> <th></th> <th>Rating (From 1=poor to 5=excellent)</th> <th>Don't know</th> </tr> </thead> <tbody> <tr> <td>i. Design of the EWRS platform (clarity, user-friendliness etc.)</td> <td></td> <td></td> </tr> <tr> <td>ii. ECDC's management and support service</td> <td></td> <td></td> </tr> <tr> <td>iii. Integration with the EPIS system for epidemic intelligence</td> <td></td> <td></td> </tr> <tr> <td>iv. Integration with the European "Rapid Alert System for Food and Feed (RASFF)"</td> <td></td> <td></td> </tr> <tr> <td>v. Integration with WHO's IHR alert and response system</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1=poor to 5=excellent)	Don't know	i. Design of the EWRS platform (clarity, user-friendliness etc.)			ii. ECDC's management and support service			iii. Integration with the EPIS system for epidemic intelligence			iv. Integration with the European "Rapid Alert System for Food and Feed (RASFF)"			v. Integration with WHO's IHR alert and response system			One answer			
	Rating (From 1=poor to 5=excellent)	Don't know																					
i. Design of the EWRS platform (clarity, user-friendliness etc.)																							
ii. ECDC's management and support service																							
iii. Integration with the EPIS system for epidemic intelligence																							
iv. Integration with the European "Rapid Alert System for Food and Feed (RASFF)"																							
v. Integration with WHO's IHR alert and response system																							
T.W.3	As compared to the period before 2008, how has the usefulness of EWRS evolved in your opinion? <ul style="list-style-type: none"> • Significantly improved • Moderately improved • Not changed • Worsened • Don't know 	One answer																					
T.W.4	Are there any specific aspects concerning EWRS design and/or management that in your opinion could be improved in order to achieve better results?	Open question																					

	Please, describe _____	
T.W.5	In your country, are the roles of “EWRS contact point” and of WHO’s “National IHR focal point undertaken by the same person or by different persons? <ul style="list-style-type: none"> • Same person • Different persons • Don’t know 	One answer

Other investigation, detection, and preparedness matters	For NFP ThDet OR NFP P&R OR HSCmem OR HSCcomm OR EWRS OR IF P.B.1.vi= (X) OR P.B.1.vii= (X) (risk managers and communicators) OR P.E.1.iii=(x) (NC / CCB Dir)																			
T.I.1	Do you receive and read the ECDC daily Round Table report? <ul style="list-style-type: none"> • Yes, often • Yes, sometimes • No • Not sure 	One answer																		
T.I.2	IF T.I.1=(1) OR (2) To what extent is the Round Table report useful for your epidemic intelligence and threat monitoring activities? Please express your agreement / disagreement with the following statements. <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 70%;"></th> <th style="width: 15%; text-align: center;">Rating (From 1= strong disagreement to 5= strong agreement)</th> <th style="width: 15%; text-align: center;">Don't know</th> </tr> </thead> <tbody> <tr> <td>i. The Round Table reports help us identifying issues that we were not aware of yet</td> <td></td> <td></td> </tr> <tr> <td>ii. The Round Table report is practical, since it provides a quick update on current issues in a single, short bulletin</td> <td></td> <td></td> </tr> <tr> <td>iii. Since the information in the Round Table report is confidential, it is not very clear how it can be used</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1= strong disagreement to 5= strong agreement)	Don't know	i. The Round Table reports help us identifying issues that we were not aware of yet			ii. The Round Table report is practical, since it provides a quick update on current issues in a single, short bulletin			iii. Since the information in the Round Table report is confidential, it is not very clear how it can be used			One answer						
	Rating (From 1= strong disagreement to 5= strong agreement)	Don't know																		
i. The Round Table reports help us identifying issues that we were not aware of yet																				
ii. The Round Table report is practical, since it provides a quick update on current issues in a single, short bulletin																				
iii. Since the information in the Round Table report is confidential, it is not very clear how it can be used																				
T.I.3	Overall, to what extent are you satisfied with ECDC contribution to early detection of threat and response? Please rate from 1=poor to 5=high to what extent ECDC support in the following areas is in-line with your expectations <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 60%;"></th> <th style="width: 20%; text-align: center;">Rating (from 1=poor to 5=high)</th> <th style="width: 20%; text-align: center;">Don't know</th> </tr> </thead> <tbody> <tr> <td>i. Early detection, filtering and validation of threats</td> <td></td> <td></td> </tr> <tr> <td>ii. Investigation and assessment of threats</td> <td></td> <td></td> </tr> <tr> <td>iii. Dissemination of information on threats</td> <td></td> <td></td> </tr> <tr> <td>iv. Support to risk managers for response</td> <td></td> <td></td> </tr> <tr> <td>v. Overall, my country’s preparedness to manage threats</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (from 1=poor to 5=high)	Don't know	i. Early detection, filtering and validation of threats			ii. Investigation and assessment of threats			iii. Dissemination of information on threats			iv. Support to risk managers for response			v. Overall, my country’s preparedness to manage threats			One answer
	Rating (from 1=poor to 5=high)	Don't know																		
i. Early detection, filtering and validation of threats																				
ii. Investigation and assessment of threats																				
iii. Dissemination of information on threats																				
iv. Support to risk managers for response																				
v. Overall, my country’s preparedness to manage threats																				
T.I.4	IF T.I.5.vi = 4 or 5 (If there is contribution to country preparedness)	Multiple answer																		

	<p>Which specific improvements in your country were inspired / influenced by ECDC work in the field of preparedness and response? Please select all that applies</p> <table border="1"> <tr> <td>i. Increased the number of staff and/or resources dedicated to preparedness and response</td> <td></td> </tr> <tr> <td>ii. Adopted specific strategies and/or preparedness plan</td> <td></td> </tr> <tr> <td>iii. Improved the IT infrastructure dedicated to preparedness and response</td> <td></td> </tr> <tr> <td>iv. Adopted specific tools and procedures for crisis management suggested by ECDC</td> <td></td> </tr> <tr> <td>v. Enhanced crisis management training activities</td> <td></td> </tr> <tr> <td>v. Other, please specify _____</td> <td></td> </tr> </table>	i. Increased the number of staff and/or resources dedicated to preparedness and response		ii. Adopted specific strategies and/or preparedness plan		iii. Improved the IT infrastructure dedicated to preparedness and response		iv. Adopted specific tools and procedures for crisis management suggested by ECDC		v. Enhanced crisis management training activities		v. Other, please specify _____					
i. Increased the number of staff and/or resources dedicated to preparedness and response																	
ii. Adopted specific strategies and/or preparedness plan																	
iii. Improved the IT infrastructure dedicated to preparedness and response																	
iv. Adopted specific tools and procedures for crisis management suggested by ECDC																	
v. Enhanced crisis management training activities																	
v. Other, please specify _____																	
T.I.5	<p>Are you satisfied with the quantity and the quality of simulation exercises on public health emergencies that ECDC has performed so far? Please express your agreement / disagreement with the following statements.</p> <table border="1"> <thead> <tr> <th></th> <th>Rating (From 1= strong disagreement to 5= strong agreement)</th> <th>Don't know</th> </tr> </thead> <tbody> <tr> <td>i. ECDC should promote more simulation exercises</td> <td></td> <td></td> </tr> <tr> <td>ii. The themes of simulation exercises are generally in-line with our national priorities</td> <td></td> <td></td> </tr> <tr> <td>iii. The overall quality of exercise organisation and implementation is good</td> <td></td> <td></td> </tr> <tr> <td>iv. Desktop simulation exercises are preferable</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1= strong disagreement to 5= strong agreement)	Don't know	i. ECDC should promote more simulation exercises			ii. The themes of simulation exercises are generally in-line with our national priorities			iii. The overall quality of exercise organisation and implementation is good			iv. Desktop simulation exercises are preferable			One answer
	Rating (From 1= strong disagreement to 5= strong agreement)	Don't know															
i. ECDC should promote more simulation exercises																	
ii. The themes of simulation exercises are generally in-line with our national priorities																	
iii. The overall quality of exercise organisation and implementation is good																	
iv. Desktop simulation exercises are preferable																	
T.I.6	<p>Has your country ever received direct (on the field) assistance from ECDC to investigate a specific outbreak / issue? If YES, please specify.</p> <ul style="list-style-type: none"> • YES, specify _____ • NO 	One answer															
T.I.7	<p>IF T.I.6=(1)</p> <p>To what extent has the abovementioned direct assistance successfully addressed your needs? Please rate from 1=poor to 5=very high your appreciation of the following aspects.</p> <table border="1"> <thead> <tr> <th></th> <th>Rating (From 1=poor to 5=very high)</th> <th>Don't know</th> </tr> </thead> <tbody> <tr> <td>i. Scientific / technical quality of assistance received</td> <td></td> <td></td> </tr> <tr> <td>ii. Usefulness of assistance for strategic / policy purposes</td> <td></td> <td></td> </tr> <tr> <td>iii. Extent to which the assistance received had a positive impact in resolving the issue at stake</td> <td></td> <td></td> </tr> <tr> <td>iv. Rapidity of deployment of assistance</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1=poor to 5=very high)	Don't know	i. Scientific / technical quality of assistance received			ii. Usefulness of assistance for strategic / policy purposes			iii. Extent to which the assistance received had a positive impact in resolving the issue at stake			iv. Rapidity of deployment of assistance			One answer
	Rating (From 1=poor to 5=very high)	Don't know															
i. Scientific / technical quality of assistance received																	
ii. Usefulness of assistance for strategic / policy purposes																	
iii. Extent to which the assistance received had a positive impact in resolving the issue at stake																	
iv. Rapidity of deployment of assistance																	
T.I.8	<p>Do you have any suggestions on how ECDC can improve the usefulness and/or the efficiency of its support activities in the field of threat detection, country preparedness and response?</p> <p>Please, describe _____</p>	Open															

Section 5 – Surveillance and microbiology

Integration of networks	For ALL	
--------------------------------	----------------	--

S.N.1	<p>Were you personally involved in any European Disease Surveillance Networks (DSN) prior to their integration under ECDC? In particular, were you involved in any of the following networks? Please check all that applies</p> <table border="1" data-bbox="379 309 1013 562"> <tr> <td data-bbox="379 309 831 371">Enter-net (human gastrointestinal infections)</td> <td data-bbox="831 309 1013 371"></td> </tr> <tr> <td data-bbox="379 371 831 405">EuroHIV</td> <td data-bbox="831 371 1013 405"></td> </tr> <tr> <td data-bbox="379 405 831 468">European Influenza Surveillance Scheme (EISS)</td> <td data-bbox="831 405 1013 468"></td> </tr> <tr> <td data-bbox="379 468 831 530">Other, please specify all that applies (_____)</td> <td data-bbox="831 468 1013 530"></td> </tr> <tr> <td data-bbox="379 530 831 562">None</td> <td data-bbox="831 530 1013 562"></td> </tr> </table>	Enter-net (human gastrointestinal infections)		EuroHIV		European Influenza Surveillance Scheme (EISS)		Other, please specify all that applies (_____)		None		<p>Multiple answer</p> <p>If (5) skip to the next module</p>											
Enter-net (human gastrointestinal infections)																							
EuroHIV																							
European Influenza Surveillance Scheme (EISS)																							
Other, please specify all that applies (_____)																							
None																							
S.N.2	<p>How does the current network situation compare with the situation before DSN integration under ECDC? Please express your agreement / disagreement with the following statements.</p> <table border="1" data-bbox="379 685 1139 1462"> <thead> <tr> <th data-bbox="379 685 839 875"></th> <th data-bbox="839 685 1023 875">Rating (From 1= strong disagreement to 5= strong agreement)</th> <th data-bbox="1023 685 1139 875">Don't know</th> </tr> </thead> <tbody> <tr> <td data-bbox="379 875 839 965">i. Thanks to ECDC coordination network activities are more efficient now</td> <td data-bbox="839 875 1023 965"></td> <td data-bbox="1023 875 1139 965"></td> </tr> <tr> <td data-bbox="379 965 839 1055">ii. The network outputs are now more 'recognised' and therefore more likely to influence national policies</td> <td data-bbox="839 965 1023 1055"></td> <td data-bbox="1023 965 1139 1055"></td> </tr> <tr> <td data-bbox="379 1055 839 1144">iii. Synergies and coordination with other national and international entities have improved.</td> <td data-bbox="839 1055 1023 1144"></td> <td data-bbox="1023 1055 1139 1144"></td> </tr> <tr> <td data-bbox="379 1144 839 1234">iv. There are common operating methodologies in place, which ensure data of better quality</td> <td data-bbox="839 1144 1023 1234"></td> <td data-bbox="1023 1144 1139 1234"></td> </tr> <tr> <td data-bbox="379 1234 839 1323">v. Participating members are less proactive than before, since ECDC has taken over the coordination role</td> <td data-bbox="839 1234 1023 1323"></td> <td data-bbox="1023 1234 1139 1323"></td> </tr> <tr> <td data-bbox="379 1323 839 1462">vi. The scope of the network has enlarged and therefore members are more heterogeneous and less specialised than before</td> <td data-bbox="839 1323 1023 1462"></td> <td data-bbox="1023 1323 1139 1462"></td> </tr> </tbody> </table>		Rating (From 1= strong disagreement to 5= strong agreement)	Don't know	i. Thanks to ECDC coordination network activities are more efficient now			ii. The network outputs are now more 'recognised' and therefore more likely to influence national policies			iii. Synergies and coordination with other national and international entities have improved.			iv. There are common operating methodologies in place, which ensure data of better quality			v. Participating members are less proactive than before, since ECDC has taken over the coordination role			vi. The scope of the network has enlarged and therefore members are more heterogeneous and less specialised than before			One answer
	Rating (From 1= strong disagreement to 5= strong agreement)	Don't know																					
i. Thanks to ECDC coordination network activities are more efficient now																							
ii. The network outputs are now more 'recognised' and therefore more likely to influence national policies																							
iii. Synergies and coordination with other national and international entities have improved.																							
iv. There are common operating methodologies in place, which ensure data of better quality																							
v. Participating members are less proactive than before, since ECDC has taken over the coordination role																							
vi. The scope of the network has enlarged and therefore members are more heterogeneous and less specialised than before																							
S.N.3	<p>Based on your experience, have there been other positive or negative effects of network integration under a common platform?</p> <table border="1" data-bbox="379 1563 839 1624"> <tr> <td data-bbox="379 1563 839 1597">i. positive effects _____</td> </tr> <tr> <td data-bbox="379 1597 839 1624">ii. negative effects _____</td> </tr> </table>	i. positive effects _____	ii. negative effects _____	Open																			
i. positive effects _____																							
ii. negative effects _____																							

TESSy & datasets	For TESSy					
S.T.1	<p>Do you have access to the TESSy platform?</p> <ul style="list-style-type: none"> • YES • NO 		<p>One answer</p> <p>If (2) skip to the next module</p>			
S.T.2	<p>What is your assessment of TESSy design and functionalities? Please rate from 1=poor to 5=excellent the following aspects.</p> <table border="1" data-bbox="357 1973 1230 2031"> <tr> <td data-bbox="357 1973 938 2031"></td> <td data-bbox="938 1973 1102 2031">Rating</td> <td data-bbox="1102 1973 1230 2031">Don't know</td> </tr> </table>			Rating	Don't know	One answer
	Rating	Don't know				

		(From 1=poor to 5=excellent)																							
	i. User-friendliness for uploading data																								
	ii. User-friendliness for searching / downloading data																								
	iii. Assistance service provided by ECDC																								
	iv. Analytical and data classification tools																								
	v. Compliance / consistency of data requirements with national territorial divisions																								
S.T.3	<p>To what extent is your country able to regularly provide all the surveillance data required on TESSy? Please indicate approximately the percentage of data submitted on the total requested</p> <ul style="list-style-type: none"> • More than 90% • Between 60% and 89% • Between 40% and 59% • Less than 39% • Don't know 			One answer																					
S.T.4	<p>Based on your experience, what is the added-value of TESSy? Please rate from 1=very low to 5=very high the positive effects of TESSy in the following areas.</p> <table border="1"> <thead> <tr> <th></th> <th>Rating (From 1=very low to 5=very high)</th> <th>Don't know</th> </tr> </thead> <tbody> <tr> <td>i. Simplifying data reporting (everything is reported to one place)</td> <td></td> <td></td> </tr> <tr> <td>ii. Encouraging countries to improve their surveillance systems</td> <td></td> <td></td> </tr> <tr> <td>iii. Harmonising data definition on the best practice available</td> <td></td> <td></td> </tr> <tr> <td>iv. Allowing for benchmarking and cross-country comparisons</td> <td></td> <td></td> </tr> <tr> <td>v. Assessing overtime trends and detecting possible anomalies</td> <td></td> <td></td> </tr> <tr> <td>iv. Facilitating epidemiological analysis of rare diseases (by increasing the number of cases available)</td> <td></td> <td></td> </tr> </tbody> </table>				Rating (From 1=very low to 5=very high)	Don't know	i. Simplifying data reporting (everything is reported to one place)			ii. Encouraging countries to improve their surveillance systems			iii. Harmonising data definition on the best practice available			iv. Allowing for benchmarking and cross-country comparisons			v. Assessing overtime trends and detecting possible anomalies			iv. Facilitating epidemiological analysis of rare diseases (by increasing the number of cases available)			One answer
	Rating (From 1=very low to 5=very high)	Don't know																							
i. Simplifying data reporting (everything is reported to one place)																									
ii. Encouraging countries to improve their surveillance systems																									
iii. Harmonising data definition on the best practice available																									
iv. Allowing for benchmarking and cross-country comparisons																									
v. Assessing overtime trends and detecting possible anomalies																									
iv. Facilitating epidemiological analysis of rare diseases (by increasing the number of cases available)																									
S.T.5	<p>Based on your needs, is there any 'missing' dataset that in your opinion ECDC should add to TESSy datasets? Please, specify</p> <div style="border: 1px solid black; height: 20px; width: 200px; margin-top: 5px;"></div>			Open																					
S.T.6	<p>Overall, how do the benefits of TESSy compare to the burden it imposes on contributors?</p> <ul style="list-style-type: none"> • Benefits largely outweigh burden • Benefits moderately outweigh burden • Benefits are approximately equal to burden • Burden moderately outweighs benefits • Burden significantly outweighs benefits • Don't know 			One answer																					
S.T.7	<p>As compared to 2008, the reliability / comparability of data that are shared among participating countries through TESSy has...?</p> <ul style="list-style-type: none"> • Significantly improved • Moderately improved • Not changed • Worsened • Not sure 			One answer																					

Salmonella surveillance	For NFP Surv OR NFP-FWD OR Net-salm OR Net-smol OR IF P.B.3.iii = (x) (self-declared salmonella experts)																						
S.S.1	Are you familiar with the yearly “ <i>European Union Summary Report on Trends and Sources of Zoonoses, Zoonotic Agents and Food-borne Outbreaks</i> ” jointly published by ECDC and EFSA? <ul style="list-style-type: none"> • Yes, I read it systematically • Yes, I read it occasionally • Yes, but I rarely read it • No 	One answer IF (3) OR (4) skip to the next module																					
S.S.2	What is your overall appreciation of the abovementioned report? Please rate from 1=poor to 5=very high your appreciation of the following aspects <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 80%;"></th> <th style="width: 10%; text-align: center;">Rating (From 1=poor to 5=very high)</th> <th style="width: 10%; text-align: center;">Don't know</th> </tr> </thead> <tbody> <tr> <td>i. Relevance of the information provided for epidemiological purposes</td> <td></td> <td></td> </tr> <tr> <td>ii. Comprehensiveness and quality of data reported</td> <td></td> <td></td> </tr> <tr> <td>iii. Scientific strength of the analyses provided</td> <td></td> <td></td> </tr> <tr> <td>iv. Clarity of language</td> <td></td> <td></td> </tr> <tr> <td>v. Timeliness of publication</td> <td></td> <td></td> </tr> <tr> <td>vi. Usefulness for policy-making purposes</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1=poor to 5=very high)	Don't know	i. Relevance of the information provided for epidemiological purposes			ii. Comprehensiveness and quality of data reported			iii. Scientific strength of the analyses provided			iv. Clarity of language			v. Timeliness of publication			vi. Usefulness for policy-making purposes			One answer
	Rating (From 1=poor to 5=very high)	Don't know																					
i. Relevance of the information provided for epidemiological purposes																							
ii. Comprehensiveness and quality of data reported																							
iii. Scientific strength of the analyses provided																							
iv. Clarity of language																							
v. Timeliness of publication																							
vi. Usefulness for policy-making purposes																							

HIV/ AIDS surveillance	For NFP Surv OR NFP-HASH OR Net-HIV OR HIV-TT OR IF P.B.3.ii = (x) (self-declared HIV/AIDS experts)																						
S.H.1	Are you familiar with the ECDC’s annual reports: “ <i>HIV/AIDS Surveillance in Europe</i> ”? <ul style="list-style-type: none"> • Yes, I read it systematically • Yes, I read it occasionally • Yes, but I rarely read it • No 	One answer IF (3) OR (4) skip to the next module																					
S.H.2	What is your overall appreciation of the abovementioned reports? Please rate from 1=poor to 5=high your appreciation of the following aspects <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 80%;"></th> <th style="width: 10%; text-align: center;">Rating (From 1=poor to 5=high)</th> <th style="width: 10%; text-align: center;">Don't know</th> </tr> </thead> <tbody> <tr> <td>i. Relevance of the information provided for epidemiological purposes</td> <td></td> <td></td> </tr> <tr> <td>ii. Comprehensiveness and quality of data reported</td> <td></td> <td></td> </tr> <tr> <td>iii. Scientific strength of the analysis provided</td> <td></td> <td></td> </tr> <tr> <td>iv. Clarity of language</td> <td></td> <td></td> </tr> <tr> <td>v. Timeliness of publication</td> <td></td> <td></td> </tr> <tr> <td>vi. Usefulness for policy-making purposes</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1=poor to 5=high)	Don't know	i. Relevance of the information provided for epidemiological purposes			ii. Comprehensiveness and quality of data reported			iii. Scientific strength of the analysis provided			iv. Clarity of language			v. Timeliness of publication			vi. Usefulness for policy-making purposes			One answer
	Rating (From 1=poor to 5=high)	Don't know																					
i. Relevance of the information provided for epidemiological purposes																							
ii. Comprehensiveness and quality of data reported																							
iii. Scientific strength of the analysis provided																							
iv. Clarity of language																							
v. Timeliness of publication																							
vi. Usefulness for policy-making purposes																							

Influenza Surveillance	For NFP Surv OR NFP-FLU OR Net-flu OR FLU-HSC OR IF P.B.3.i = (x) (self-declared influenza experts)																			
S.F.1	Are you familiar with the ECDC's "Weekly Influenza Surveillance Overviews"? <ul style="list-style-type: none"> • Yes, I read it systematically • Yes, I read it occasionally • Yes, but I rarely read it • No 	One answer IF (3) OR (4) skip to the next module																		
S.F.2	What is your appreciation of these weekly overviews? Please rate from 1=poor to 5=high your appreciation of the following aspects <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 70%;"></th> <th style="width: 15%; text-align: center;">Rating (From 1=poor to 5=high)</th> <th style="width: 15%; text-align: center;">Don't know</th> </tr> </thead> <tbody> <tr> <td>i. Relevance of the information provided for epidemiological purposes</td> <td></td> <td></td> </tr> <tr> <td>ii. Comprehensiveness and quality of data reported</td> <td></td> <td></td> </tr> <tr> <td>iii. Scientific strength of the analysis provided</td> <td></td> <td></td> </tr> <tr> <td>iv. Clarity of language</td> <td></td> <td></td> </tr> <tr> <td>v. Usefulness for policy-making purposes</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1=poor to 5=high)	Don't know	i. Relevance of the information provided for epidemiological purposes			ii. Comprehensiveness and quality of data reported			iii. Scientific strength of the analysis provided			iv. Clarity of language			v. Usefulness for policy-making purposes			One answer
	Rating (From 1=poor to 5=high)	Don't know																		
i. Relevance of the information provided for epidemiological purposes																				
ii. Comprehensiveness and quality of data reported																				
iii. Scientific strength of the analysis provided																				
iv. Clarity of language																				
v. Usefulness for policy-making purposes																				
Surveillance outputs	For ALL																			
S.O.1	How frequently do you read the following ECDC surveillance reports and publications? To what extent are they useful for your work? Please rate from 1=very low to 5= very high the usefulness for your work of the following surveillance documents, reports and analyses regularly published by ECDC <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 70%;"></th> <th style="width: 15%; text-align: center;">Rating (1=very low to 5= very high)</th> <th style="width: 15%; text-align: center;">Don't know</th> </tr> </thead> <tbody> <tr> <td>i. The Annual Epidemiological Reports</td> <td></td> <td></td> </tr> <tr> <td>ii. The weekly Communicable Diseases Threat Report</td> <td></td> <td></td> </tr> <tr> <td>iii. The thematic Surveillance Reports (related to your area of work)</td> <td></td> <td></td> </tr> <tr> <td>iv. The Epidemiological Updates</td> <td></td> <td></td> </tr> <tr> <td>v. Eurosurveillance journal</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (1=very low to 5= very high)	Don't know	i. The Annual Epidemiological Reports			ii. The weekly Communicable Diseases Threat Report			iii. The thematic Surveillance Reports (related to your area of work)			iv. The Epidemiological Updates			v. Eurosurveillance journal			One answer
	Rating (1=very low to 5= very high)	Don't know																		
i. The Annual Epidemiological Reports																				
ii. The weekly Communicable Diseases Threat Report																				
iii. The thematic Surveillance Reports (related to your area of work)																				
iv. The Epidemiological Updates																				
v. Eurosurveillance journal																				
S.O.2	Do you have any suggestion as to how the ECDC surveillance outputs (publications, reports, TESSy datasets etc.) could be further improved in order to increase their value for Member States' stakeholders? Please, describe_____	Open																		
Integration of microbiology	For NFP Surv OR NFP-FWD OR NFP Mbio OR Net-salm OR Net-smol OR																			

	<p>IF PB1.ii= (x) (microbiologists)</p> <p>OR</p> <p>IF PE1.ii=(x) OR PE1.iii=(x) (Adv Forum members or NC / CCB Dir)</p>																						
S.M.1	<p>Are you familiar with the ECDC’s public health microbiology activities?</p> <ul style="list-style-type: none"> • Yes, significantly • Yes, moderately • Yes, but marginally • No 	<p>One answer</p> <p>IF (4) skip to the next module</p>																					
S.M.2	<p>Are you aware of the ECDC technical document “Surveillance of communicable diseases in Europe – a concept to integrate molecular typing data into EU-level surveillance” (2011)?</p> <ul style="list-style-type: none"> • YES, I have read it (entirely or partially) • YES, but I have not read it • NO 	One answer																					
S.M.3	<p>IF S.M.2=(1)</p> <p>What is your appreciation of the abovementioned technical document ? Please rate from 1=poor to 5=high your appreciation of the following aspects</p> <table border="1"> <thead> <tr> <th></th> <th>Rating (From 1=poor to 5=high)</th> <th>Don’t know</th> </tr> </thead> <tbody> <tr> <td>i. Relevance of the subject discussed</td> <td></td> <td></td> </tr> <tr> <td>ii. Overall credibility</td> <td></td> <td></td> </tr> <tr> <td>iii. Clarity of language</td> <td></td> <td></td> </tr> <tr> <td>iv. Usefulness for scientific progress</td> <td></td> <td></td> </tr> <tr> <td>v. Usefulness for policy-making purposes</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1=poor to 5=high)	Don’t know	i. Relevance of the subject discussed			ii. Overall credibility			iii. Clarity of language			iv. Usefulness for scientific progress			v. Usefulness for policy-making purposes			One answer			
	Rating (From 1=poor to 5=high)	Don’t know																					
i. Relevance of the subject discussed																							
ii. Overall credibility																							
iii. Clarity of language																							
iv. Usefulness for scientific progress																							
v. Usefulness for policy-making purposes																							
S.M.4	<p>Are you familiar with the External Quality Assessment (EQA) schemes promoted by ECDC?</p> <ul style="list-style-type: none"> • YES, and I have personally participated in it • YES, but I have not directly participated in it • NO 	One answer																					
S.M.5	<p>IF S.M.4=(1) OR (2)</p> <p>How do you assess the overall quality and usefulness of EQA schemes? Please rate from 1=poor to 5=excellent the following aspects</p> <table border="1"> <thead> <tr> <th></th> <th>Rating (From 1=poor to 5=excellent)</th> <th>Don’t know</th> </tr> </thead> <tbody> <tr> <td>i. Relevance of the themes selected</td> <td></td> <td></td> </tr> <tr> <td>ii. Appropriateness of the delivery model</td> <td></td> <td></td> </tr> <tr> <td>iii. Quality of the final report</td> <td></td> <td></td> </tr> <tr> <td>iv. Usefulness for improving laboratory capacities</td> <td></td> <td></td> </tr> <tr> <td>v. Complementarity / synergy with other schemes</td> <td></td> <td></td> </tr> <tr> <td>vi. Acceptability of the burden required</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1=poor to 5=excellent)	Don’t know	i. Relevance of the themes selected			ii. Appropriateness of the delivery model			iii. Quality of the final report			iv. Usefulness for improving laboratory capacities			v. Complementarity / synergy with other schemes			vi. Acceptability of the burden required			One answer
	Rating (From 1=poor to 5=excellent)	Don’t know																					
i. Relevance of the themes selected																							
ii. Appropriateness of the delivery model																							
iii. Quality of the final report																							
iv. Usefulness for improving laboratory capacities																							
v. Complementarity / synergy with other schemes																							
vi. Acceptability of the burden required																							
S.M.6	<p>IF S.M.4=(1)</p> <p>Have you taken part to at least one of the various EQA schemes for Salmonella typing run by ECDC in the past years?</p> <ul style="list-style-type: none"> • YES • NO 	One answer																					
S.M.7	IF S.M.8=(1)	One answer																					

	<p>What was the impact of participating in such schemes, if any? Please express your agreement / disagreement with the following statements.</p> <table border="1"> <thead> <tr> <th></th> <th>Rating (From 1= strong disagreement to 5= strong agreement)</th> <th>Don't know</th> </tr> </thead> <tbody> <tr> <td>i. EQA helped us to identify capacity gaps we were not aware before</td> <td></td> <td></td> </tr> <tr> <td>ii. We have adopted measures to strengthen our capacity in response to EQA results</td> <td></td> <td></td> </tr> <tr> <td>iii. Participating in EQA helped us for the laboratory's accreditation / certification purposes</td> <td></td> <td></td> </tr> <tr> <td>iv. We have set up and implemented a similar exercise at national level as a follow-up to ECDC EQA</td> <td></td> <td></td> </tr> <tr> <td>v. Other, specify_____</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1= strong disagreement to 5= strong agreement)	Don't know	i. EQA helped us to identify capacity gaps we were not aware before			ii. We have adopted measures to strengthen our capacity in response to EQA results			iii. Participating in EQA helped us for the laboratory's accreditation / certification purposes			iv. We have set up and implemented a similar exercise at national level as a follow-up to ECDC EQA			v. Other, specify_____			
	Rating (From 1= strong disagreement to 5= strong agreement)	Don't know																		
i. EQA helped us to identify capacity gaps we were not aware before																				
ii. We have adopted measures to strengthen our capacity in response to EQA results																				
iii. Participating in EQA helped us for the laboratory's accreditation / certification purposes																				
iv. We have set up and implemented a similar exercise at national level as a follow-up to ECDC EQA																				
v. Other, specify_____																				
S.M.8	<p>Overall, to what extent have ECDC public health microbiology activities resulted in an improved availability of microbiological data in your country? Please rate from 1=none to 5=significant the effect of ECDC activities as regards the following aspects</p> <table border="1"> <thead> <tr> <th></th> <th>Rating (From 1=none to 5=significant)</th> <th>Don't know</th> </tr> </thead> <tbody> <tr> <td>i. Impact on the quantity of microbiological surveillance data collected</td> <td></td> <td></td> </tr> <tr> <td>ii. Impact on the quality of microbiological surveillance data collected</td> <td></td> <td></td> </tr> <tr> <td>iii. Cross-country comparability of microbiological surveillance data collected</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1=none to 5=significant)	Don't know	i. Impact on the quantity of microbiological surveillance data collected			ii. Impact on the quality of microbiological surveillance data collected			iii. Cross-country comparability of microbiological surveillance data collected									
	Rating (From 1=none to 5=significant)	Don't know																		
i. Impact on the quantity of microbiological surveillance data collected																				
ii. Impact on the quality of microbiological surveillance data collected																				
iii. Cross-country comparability of microbiological surveillance data collected																				
S.M.9	<p>Can you mention any specific examples where the better integration of epidemiology and microbiology fostered by ECDC has enabled an earlier detection / better assessment of a threat?</p> <p>Please, describe_____</p>	Open																		
S.M.10	<p>Do you have any suggestion as to how ECDC could further support a better integration of microbiology and epidemiology ad Member States and EU levels?</p> <p>Please, describe_____</p>	Open																		

Section 6 – Public Health Training and Capacity Building

Capacity building - general	<p>For NFP Ph Train OR EP/EU</p> <p>OR</p> <p>IF PE1.i=(x) IF PE1.ii=(x) OR PE1.iii=(x) (MBoard or Adv Forum members or NC / CCB Dir)</p>							
C.G.1	<p>Based on your experience, to what extent have the public health training activities carried out by ECDC contributed to your country's capacity of prevention and control of communicable diseases? Please rate from 1=very low to 5=very high the perceived positive effects in the following areas</p> <table border="1"> <thead> <tr> <th></th> <th>Rating (From 1=very low</th> <th>Don't know</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1=very low	Don't know				One answer
	Rating (From 1=very low	Don't know						

		to 5=very high)		
	i. Early detection of threats			
	ii. Identification and characterisation of infectious agents			
	iii. Definition of preventive measures			
	iv. Definition of measures for outbreak control			
C.G.2	In particular, how do you judge the effectiveness of the different ECDC training and capacity building activities listed below? Please rate from 1=very low to 5=very high the effectiveness of the following activities and tools on your country capacity			
		Rating (From 1=very low to 5=very high)	Don't know / Not applicable	
	i. EPIET / EUPHEM programmes			
	ii. External Quality Assurance schemes for laboratories			
	iii. The ESCAIDE conference			
	iv. Specific toolkits and manuals (e.g. the Field Epidemiology manual)			
	v. Direct support received during a specific outbreak or event			
	vi. Trainings courses for public health professionals			
C.G.3	Is there tangible evidence of your country's improved capacity being enhanced by ECDC activities? Please select in the following list all that applies and - when applicable – provide reference to relevant documents, webpages and/or other sources of information			Multiple answer
	i. Adoption of action plans and/or other strategy documents (if available, please provide document's title and/or weblink)	_____		
	ii. Adoption of guidelines, methodological documents etc. (if available, please provide document's title and/or weblink)	_____		
	iii. Creation / strengthening of dedicated services at national level and/or within my organisations			
	iv. Reform of procedures at national level and/or within my organisations			
	v. Creation/strengthening of coordination among different domestic entities (e.g. set up of dedicated platform, appointment of a responsible person...)			
	vi. Increase in budgetary allocations for prevention and control of communicable diseases			
	vii. Implementation of initiatives (projects, trainings, quality assessments etc.) in continuity with previous ECDC actions			
	viii. Other improvements (please, specify)	_____		
	viii. None of the above			

EPIET / EUPHEM	For NFP Ph Train OR EP/EU					
C.E.1	Do you have a direct experience of the EPIET and the EUPHEM training programmes? If YES, in which capacity? Please select all that applies		Multiple answer			
		<table border="1"> <tr> <td></td> <td>a) EPIET</td> <td>b) EUPHEM</td> </tr> </table>		a) EPIET	b) EUPHEM	IF vi=(x) skip to
	a) EPIET	b) EUPHEM				

	<table border="1"> <tr><td>i. Yes, as a fellow – Member state track</td><td></td><td></td></tr> <tr><td>ii. Yes, as a fellow – EU track</td><td></td><td></td></tr> <tr><td>iii. Yes, as a supervisor</td><td></td><td></td></tr> <tr><td>iv. Yes, as a training expert</td><td></td><td></td></tr> <tr><td>v. Yes, in other capacity</td><td></td><td></td></tr> <tr><td>vi. No</td><td></td><td></td></tr> </table>	i. Yes, as a fellow – Member state track			ii. Yes, as a fellow – EU track			iii. Yes, as a supervisor			iv. Yes, as a training expert			v. Yes, in other capacity			vi. No				next module																	
i. Yes, as a fellow – Member state track																																						
ii. Yes, as a fellow – EU track																																						
iii. Yes, as a supervisor																																						
iv. Yes, as a training expert																																						
v. Yes, in other capacity																																						
vi. No																																						
C.E.2	<p>IF C.E.1.i.a =(x) OR IF C.E.1.i.b =(x) OR IF C.E.1.ii.a =(x) OR IF C.E.1.ii.b =(x) (only fellows i&ii)</p> <p>How do you judge your experience as a fellow of the ECDC training programme? Please, on the basis of your experience, indicate whether the following statements are true or false</p> <table border="1"> <thead> <tr> <th></th> <th>True</th> <th>False</th> <th>Don't know / Not applicable</th> </tr> </thead> <tbody> <tr><td>i. My professional skills have significantly increased</td><td></td><td></td><td></td></tr> <tr><td>ii. I am still in close contact with the professionals I met during the training</td><td></td><td></td><td></td></tr> <tr><td>iii. I have changed my employer as a result of the training</td><td></td><td></td><td></td></tr> <tr><td>iv. My employment position has improved after the training</td><td></td><td></td><td></td></tr> <tr><td>v. It would have been necessary to receive more supervision during the training</td><td></td><td></td><td></td></tr> <tr><td>vi. I currently use the knowledge / skills acquired during the training in my everyday work</td><td></td><td></td><td></td></tr> <tr><td>vii. Some methods and techniques I have learned during the training have been introduced and taken up by my current organisation</td><td></td><td></td><td></td></tr> <tr><td>viii. The quality of the training was in-line with my initial expectations or even better</td><td></td><td></td><td></td></tr> </tbody> </table>		True	False	Don't know / Not applicable	i. My professional skills have significantly increased				ii. I am still in close contact with the professionals I met during the training				iii. I have changed my employer as a result of the training				iv. My employment position has improved after the training				v. It would have been necessary to receive more supervision during the training				vi. I currently use the knowledge / skills acquired during the training in my everyday work				vii. Some methods and techniques I have learned during the training have been introduced and taken up by my current organisation				viii. The quality of the training was in-line with my initial expectations or even better				One answer
	True	False	Don't know / Not applicable																																			
i. My professional skills have significantly increased																																						
ii. I am still in close contact with the professionals I met during the training																																						
iii. I have changed my employer as a result of the training																																						
iv. My employment position has improved after the training																																						
v. It would have been necessary to receive more supervision during the training																																						
vi. I currently use the knowledge / skills acquired during the training in my everyday work																																						
vii. Some methods and techniques I have learned during the training have been introduced and taken up by my current organisation																																						
viii. The quality of the training was in-line with my initial expectations or even better																																						
C.E.3	<p>IF C.E.1.iii.a =(x) OR IF C.E.1.iii.b =(x) OR IF C.E.1.iv.a =(x) OR IF C.E.1.iv.b =(x) OR IF C.E.1.v.a =(x) OR IF C.E.1.v.b=(x) (supervisors, training experts etc.)</p> <p>What is in your experience the overall relevance and usefulness of ECDC training programmes? Please rate from 1=poor to 5= high the following aspects</p> <table border="1"> <thead> <tr> <th></th> <th>Rating (From 1=poor to 5=high)</th> <th>Don't know</th> </tr> </thead> <tbody> <tr><td>i. Complementarity (and non-duplication) with national schemes</td><td></td><td></td></tr> <tr><td>ii. Quality of scientific contents</td><td></td><td></td></tr> <tr><td>iii. Utility to increase threat detection, investigation and monitoring capacity in your organisation</td><td></td><td></td></tr> <tr><td>iv. Utility to increase preparedness and response capacity in your organisation</td><td></td><td></td></tr> <tr><td>v. Utility for expanding / consolidating collaboration networks</td><td></td><td></td></tr> <tr><td>vi. Efficiency of the organizational and administrative aspects</td><td></td><td></td></tr> </tbody> </table>		Rating (From 1=poor to 5=high)	Don't know	i. Complementarity (and non-duplication) with national schemes			ii. Quality of scientific contents			iii. Utility to increase threat detection, investigation and monitoring capacity in your organisation			iv. Utility to increase preparedness and response capacity in your organisation			v. Utility for expanding / consolidating collaboration networks			vi. Efficiency of the organizational and administrative aspects																		
	Rating (From 1=poor to 5=high)	Don't know																																				
i. Complementarity (and non-duplication) with national schemes																																						
ii. Quality of scientific contents																																						
iii. Utility to increase threat detection, investigation and monitoring capacity in your organisation																																						
iv. Utility to increase preparedness and response capacity in your organisation																																						
v. Utility for expanding / consolidating collaboration networks																																						
vi. Efficiency of the organizational and administrative aspects																																						

	vii. Overall benefits of the programme as compared to burden (e.g. supervision costs)			
C.E.4	Do you have any suggestion as to possible further improvement of ECDC training programme? Please select in the following list the possible recommendations you agree with and add your suggestions	Multiple answer		
	i. Seek better synergy with other national schemes in order to avoid overlapping			
	ii. Seek more geographical 'balance' in the implementation			
	iii. Refine fellow selection criteria so as to facilitate the access of young scientists with still limited experience			
	iv. Increase the offer (more fellowships per cohort)			
	v. Better prioritise mobility across MS			
	vi. Adopt further measures to prevent brain-drain (i.e. fellows moving to other countries or to ECDC)			
	vii. Other suggestions: _____			
	viii. None of the above			

FEM	IF PB1.i=(x) (For epidemiologists)																
C.F.1	Are you familiar with the Field Epidemiological Manual (FEM) Wiki? <ul style="list-style-type: none"> • Yes • No 	One answer IF (2) skip to the next module															
C.F.2	How often do you access FEM Wiki on average? <ul style="list-style-type: none"> • Frequently (weekly basis or more) • Moderately (on a monthly basis or so) • Sporadically 	One answer															
C.F.4	What is your overall judgment of FEM Wiki? Please rate from 1=poor to 5=excellent the following aspects.	One answer															
	<table border="1"> <thead> <tr> <th></th> <th>Rating (From 1=poor to 5=excellent)</th> <th>Don't know</th> </tr> </thead> <tbody> <tr> <td>i. Completeness / comprehensiveness</td> <td></td> <td></td> </tr> <tr> <td>ii. Quality / reliability of contents</td> <td></td> <td></td> </tr> <tr> <td>iii. Clarity and user-friendliness of structure and functionalities</td> <td></td> <td></td> </tr> <tr> <td>iv. Overall usefulness of the instrument</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1=poor to 5=excellent)	Don't know	i. Completeness / comprehensiveness			ii. Quality / reliability of contents			iii. Clarity and user-friendliness of structure and functionalities			iv. Overall usefulness of the instrument			
	Rating (From 1=poor to 5=excellent)	Don't know															
i. Completeness / comprehensiveness																	
ii. Quality / reliability of contents																	
iii. Clarity and user-friendliness of structure and functionalities																	
iv. Overall usefulness of the instrument																	

ESCAIDE Conference	For All											
C.C.1	Have you ever participated in the ESCAIDE conference? If YES, in which capacity? Please indicate all that applies	One answer IF (v)=(x) skip to the next module										
	<table border="1"> <tbody> <tr> <td>i. Yes, as a speaker</td> <td></td> </tr> <tr> <td>ii. Yes, as a poster presenter</td> <td></td> </tr> <tr> <td>iii. Yes, as a participant</td> <td></td> </tr> <tr> <td>iv. Yes, in other capacities</td> <td></td> </tr> <tr> <td>v. No</td> <td></td> </tr> </tbody> </table>	i. Yes, as a speaker		ii. Yes, as a poster presenter		iii. Yes, as a participant		iv. Yes, in other capacities		v. No		
i. Yes, as a speaker												
ii. Yes, as a poster presenter												
iii. Yes, as a participant												
iv. Yes, in other capacities												
v. No												
C.C.2	Based on your experience, how do you assess the following aspects of the ESCAIDE conference? Please rate from 1=poor to 5=excellent your degree of appreciation											
	<table border="1"> <thead> <tr> <th></th> <th>Rating (From 1=poor to 5=excellent)</th> <th>Don't know</th> </tr> </thead> <tbody> <tr> <td>i. Relevance of topics discussed</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1=poor to 5=excellent)	Don't know	i. Relevance of topics discussed							
	Rating (From 1=poor to 5=excellent)	Don't know										
i. Relevance of topics discussed												

	ii. Utility for scientific progress		
	iii. Utility to inform policy-making		
	iv. Utility for networking		
	v. Logistical arrangements		
	vi. Quality and reputation of speakers		
	vii. Added-value of ESCAIDE vis-à-vis other similar conferences		
	viii. Extent of outreach and participation across EU		
	ix. Extent of dissemination of results		
C.C.3	<p>Have you concretely used and/or implemented pieces of information and/or knowledge acquired through ESCAIDE in your work? If Yes, how? If No, why?</p> <ul style="list-style-type: none"> • YES – Please indicate how _____ • NO – Please indicate why _____ 		

Section 7 – Scientific Advice

Awareness and use of outputs	For ALL																													
A.A.1	<p>Are you familiar with any of the following scientific documents issued by ECDC? If YES, how do you rate them in terms of (i) relevance of the topic, (ii) technical / scientific quality; (iii) usefulness as a basis for risk management or policy decisions? Please provide ratings ranging from 1=very low to 5=very high to the following criteria</p> <table border="1"> <thead> <tr> <th></th> <th>A) Awareness of the document (Yes/No)</th> <th>B) Relevance of topic (from 1=very low to 5=very high)</th> <th>C) Scientific quality (from 1=very low to 5=very high)</th> <th>D) Usefulness for risk management / policy-making (from 1=very low to 5=very high)</th> </tr> </thead> <tbody> <tr> <td>i. Assessing the potential impacts of climate change on food- and waterborne diseases in Europe (2012)</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>ii. Evidence-based methodologies for public health (2011)</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>iii. Fostering collaboration in public health microbiology in the European Union (2010)</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>iv. Seasonal influenza vaccination of children and pregnant women (2012)</td> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table>					A) Awareness of the document (Yes/No)	B) Relevance of topic (from 1=very low to 5=very high)	C) Scientific quality (from 1=very low to 5=very high)	D) Usefulness for risk management / policy-making (from 1=very low to 5=very high)	i. Assessing the potential impacts of climate change on food- and waterborne diseases in Europe (2012)					ii. Evidence-based methodologies for public health (2011)					iii. Fostering collaboration in public health microbiology in the European Union (2010)					iv. Seasonal influenza vaccination of children and pregnant women (2012)					<p>One answer</p> <p>IF xi=YES skip to A.A.3</p>
	A) Awareness of the document (Yes/No)	B) Relevance of topic (from 1=very low to 5=very high)	C) Scientific quality (from 1=very low to 5=very high)	D) Usefulness for risk management / policy-making (from 1=very low to 5=very high)																										
i. Assessing the potential impacts of climate change on food- and waterborne diseases in Europe (2012)																														
ii. Evidence-based methodologies for public health (2011)																														
iii. Fostering collaboration in public health microbiology in the European Union (2010)																														
iv. Seasonal influenza vaccination of children and pregnant women (2012)																														

	v. Narcolepsy in association with pandemic influenza vaccination – a multi-country European epidemiological investigation (2012)						
	vi. The 2009 A(H1N1) pandemic in Europe, a review of the experience (2010)						
	vii. Joint ECDC/EMCDDA Guidance: Prevention and control of infectious diseases among people who inject drugs (2011)						
	viii. HIV testing: increasing uptake and effectiveness in the European Union (2010)						
	ix. Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals (2012)						
	x. Current and future burden of communicable diseases in the European Union and EEA/EFTA countries – Methodology protocol (2011)						
	xi. None of the above						
A.A.2	<p>Could you mention concrete examples where ECDC scientific advice documents (e.g. guidance documents, technical report, risk assessment etc.) have had a concrete impact on policy decisions in your country? If Yes, is there tangible evidence of it? (if available please provide the weblink to relevant national documents or other source – also in national language)</p> <input type="text"/>						Open
A.A.3	Overall, how do you rate the dissemination and impact of ECDC scientific work on scientific journals?						One answer

	<ul style="list-style-type: none"> • Very good • Rather good • Neither good nor bad • Rather poor • Very poor • Not sure 																						
Added-value and management	<p>For NFP ScAdv</p> <p>OR</p> <p>IF P.E.ii=(x) (AF members)</p>																						
A.M.0	<p>Is it clear enough for you, what are the responsibilities and competences of ECDC in the field of ‘scientific advice’ provision?</p> <ul style="list-style-type: none"> • Yes, definitely • Yes, partially • Only marginally • Not at all • Don’t know 	One answer																					
A.M.1	<p>Please rate from 1=poor to 5=excellent the added-value of ECDC scientific advice as compared to the existing other national and international agencies</p> <table border="1"> <thead> <tr> <th></th> <th>Rating (From 1=poor to 5=excellent)</th> <th>Don’t know</th> </tr> </thead> <tbody> <tr> <td>i. ECDC adds value as compared to scientific advice produced by own domestic agencies</td> <td></td> <td></td> </tr> <tr> <td>ii. ECDC adds value as compared to scientific advice produced by other countries’ national agencies (e.g. CDC - USA)?</td> <td></td> <td></td> </tr> <tr> <td>iii. ECDC adds value as compared to scientific advice produced by WHO</td> <td></td> <td></td> </tr> <tr> <td>iv. ECDC adds value as compared to scientific advice produced by other EU-level agencies and/or programmes</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1=poor to 5=excellent)	Don’t know	i. ECDC adds value as compared to scientific advice produced by own domestic agencies			ii. ECDC adds value as compared to scientific advice produced by other countries’ national agencies (e.g. CDC - USA)?			iii. ECDC adds value as compared to scientific advice produced by WHO			iv. ECDC adds value as compared to scientific advice produced by other EU-level agencies and/or programmes			One answer						
	Rating (From 1=poor to 5=excellent)	Don’t know																					
i. ECDC adds value as compared to scientific advice produced by own domestic agencies																							
ii. ECDC adds value as compared to scientific advice produced by other countries’ national agencies (e.g. CDC - USA)?																							
iii. ECDC adds value as compared to scientific advice produced by WHO																							
iv. ECDC adds value as compared to scientific advice produced by other EU-level agencies and/or programmes																							
A.M.2	<p>All in all, what is your assessment of ECDC scientific advice output? Please rate the following aspects from 1=poor to 5=excellent</p> <table border="1"> <thead> <tr> <th></th> <th>Rating (From 1=poor to 5=excellent)</th> <th>Don’t know</th> </tr> </thead> <tbody> <tr> <td>i. Overall scientific credibility</td> <td></td> <td></td> </tr> <tr> <td>ii. Responsiveness to policy needs</td> <td></td> <td></td> </tr> <tr> <td>iii. Timeliness with respect to needs</td> <td></td> <td></td> </tr> <tr> <td>iv. Clarity, readability</td> <td></td> <td></td> </tr> <tr> <td>v. Quality and depth of analysis</td> <td></td> <td></td> </tr> <tr> <td>vi. Perceived independence of judgment</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1=poor to 5=excellent)	Don’t know	i. Overall scientific credibility			ii. Responsiveness to policy needs			iii. Timeliness with respect to needs			iv. Clarity, readability			v. Quality and depth of analysis			vi. Perceived independence of judgment			One answer
	Rating (From 1=poor to 5=excellent)	Don’t know																					
i. Overall scientific credibility																							
ii. Responsiveness to policy needs																							
iii. Timeliness with respect to needs																							
iv. Clarity, readability																							
v. Quality and depth of analysis																							
vi. Perceived independence of judgment																							
A.M.3	<p>Based on your experience how has the overall usefulness of ECDC scientific advice evolved since 2008?</p> <ul style="list-style-type: none"> • Significantly increased • Moderately increased • Not changed • Worsened • Don’t know 	One answer																					

A.M.4	<p>Are you satisfied with the process and mechanisms in place for the selection of scientific questions, the production of outputs and their final dissemination? If NO, why?</p> <table border="1" data-bbox="376 282 1281 965"> <thead> <tr> <th data-bbox="376 282 759 405"></th> <th data-bbox="759 282 924 405">Yes, very satisfied</th> <th data-bbox="924 282 1046 405">Yes, rather satisfied</th> <th data-bbox="1046 282 1185 405">Not satisfied (please, explain)</th> <th data-bbox="1185 282 1281 405">Don't know</th> </tr> </thead> <tbody> <tr> <td data-bbox="376 405 759 528">i. Appropriateness of methods for discussion and selection of scientific questions to be addressed by ECDC</td> <td data-bbox="759 405 924 528"></td> <td data-bbox="924 405 1046 528"></td> <td data-bbox="1046 405 1185 528">_____</td> <td data-bbox="1185 405 1281 528"></td> </tr> <tr> <td data-bbox="376 528 759 591">ii. Appropriateness of outsourcing processes</td> <td data-bbox="759 528 924 591"></td> <td data-bbox="924 528 1046 591"></td> <td data-bbox="1046 528 1185 591">_____</td> <td data-bbox="1185 528 1281 591"></td> </tr> <tr> <td data-bbox="376 591 759 685">iii. Provision of guidance from ECDC on how to implement the advice in a national context</td> <td data-bbox="759 591 924 685"></td> <td data-bbox="924 591 1046 685"></td> <td data-bbox="1046 591 1185 685">_____</td> <td data-bbox="1185 591 1281 685"></td> </tr> <tr> <td data-bbox="376 685 759 837">iv. Coordination between National Focal Points for Scientific Advice, and the other horizontal and vertical focal points</td> <td data-bbox="759 685 924 837"></td> <td data-bbox="924 685 1046 837"></td> <td data-bbox="1046 685 1185 837">_____</td> <td data-bbox="1185 685 1281 837"></td> </tr> <tr> <td data-bbox="376 837 759 900">iv. Methods and tools for dissemination of outputs</td> <td data-bbox="759 837 924 900"></td> <td data-bbox="924 837 1046 900"></td> <td data-bbox="1046 837 1185 900">_____</td> <td data-bbox="1185 837 1281 900"></td> </tr> <tr> <td data-bbox="376 900 759 965">v. Extent of dissemination outreach</td> <td data-bbox="759 900 924 965"></td> <td data-bbox="924 900 1046 965"></td> <td data-bbox="1046 900 1185 965">_____</td> <td data-bbox="1185 900 1281 965"></td> </tr> </tbody> </table>		Yes, very satisfied	Yes, rather satisfied	Not satisfied (please, explain)	Don't know	i. Appropriateness of methods for discussion and selection of scientific questions to be addressed by ECDC			_____		ii. Appropriateness of outsourcing processes			_____		iii. Provision of guidance from ECDC on how to implement the advice in a national context			_____		iv. Coordination between National Focal Points for Scientific Advice, and the other horizontal and vertical focal points			_____		iv. Methods and tools for dissemination of outputs			_____		v. Extent of dissemination outreach			_____		
	Yes, very satisfied	Yes, rather satisfied	Not satisfied (please, explain)	Don't know																																	
i. Appropriateness of methods for discussion and selection of scientific questions to be addressed by ECDC			_____																																		
ii. Appropriateness of outsourcing processes			_____																																		
iii. Provision of guidance from ECDC on how to implement the advice in a national context			_____																																		
iv. Coordination between National Focal Points for Scientific Advice, and the other horizontal and vertical focal points			_____																																		
iv. Methods and tools for dissemination of outputs			_____																																		
v. Extent of dissemination outreach			_____																																		
A.M.5	<p>In your opinion, to what extent has ECDC managed to become a Centre of scientific excellence and technical leadership? Please rate from 1=not at all to 5=to a high extent ECDC achievements in the following areas</p> <table border="1" data-bbox="376 1088 1139 1583"> <thead> <tr> <th data-bbox="376 1088 836 1240"></th> <th data-bbox="836 1088 1019 1240">Rating (from 1=not at all to 5=to a high extent)</th> <th data-bbox="1019 1088 1139 1240">Don't know</th> </tr> </thead> <tbody> <tr> <td data-bbox="376 1240 836 1303">i. Promoting, initiating and coordinating major scientific studies</td> <td data-bbox="836 1240 1019 1303"></td> <td data-bbox="1019 1240 1139 1303"></td> </tr> <tr> <td data-bbox="376 1303 836 1397">ii. Producing credible and useful guidance, risk assessments, and other scientific and technical reports</td> <td data-bbox="836 1303 1019 1397"></td> <td data-bbox="1019 1303 1139 1397"></td> </tr> <tr> <td data-bbox="376 1397 836 1460">iii. Being a prime repository for scientific advice on infectious diseases</td> <td data-bbox="836 1397 1019 1460"></td> <td data-bbox="1019 1397 1139 1460"></td> </tr> <tr> <td data-bbox="376 1460 836 1523">iv. Being a public health research catalyst (e.g. with DG Research)</td> <td data-bbox="836 1460 1019 1523"></td> <td data-bbox="1019 1460 1139 1523"></td> </tr> <tr> <td data-bbox="376 1523 836 1583">v. Becoming a major provider of microbiological laboratory support</td> <td data-bbox="836 1523 1019 1583"></td> <td data-bbox="1019 1523 1139 1583"></td> </tr> </tbody> </table>		Rating (from 1=not at all to 5=to a high extent)	Don't know	i. Promoting, initiating and coordinating major scientific studies			ii. Producing credible and useful guidance, risk assessments, and other scientific and technical reports			iii. Being a prime repository for scientific advice on infectious diseases			iv. Being a public health research catalyst (e.g. with DG Research)			v. Becoming a major provider of microbiological laboratory support			One answer																	
	Rating (from 1=not at all to 5=to a high extent)	Don't know																																			
i. Promoting, initiating and coordinating major scientific studies																																					
ii. Producing credible and useful guidance, risk assessments, and other scientific and technical reports																																					
iii. Being a prime repository for scientific advice on infectious diseases																																					
iv. Being a public health research catalyst (e.g. with DG Research)																																					
v. Becoming a major provider of microbiological laboratory support																																					

Section 8 - Communication activities

External communication strategy	<p>For NFP comm</p> <p>OR</p> <p>IF P.B.1.vii=(x) (communication experts)</p> <p>OR</p> <p>IF P.E.1.i=(x)OR P.E.1.ii=(x) OR P.E.1.iii=(x) (MB or AF or NC / CCB Dir)</p>	
K.S.0	How do you rate stakeholders' level of awareness and understanding of ECDC work in your country? Please rate from 1=very low to 5=very high	One answer

		Rating (From 1=very low to 5=very high)	Don't know		
	i. policy-makers at national level				
	ii. policy-makers at regional level				
	iii. public health experts				
	iv. scientific community				
	v. media and journalists				
	vi. lay public				
K.S.1	To what extent does the ECDC overall Health Communication Strategy 2010-2013 and its implementation address your expectations and information needs? Please rate from 1=very low to 5=very high your appreciation of the following aspects of ECDC external communication activities				One answer
		Rating (From 1=very low to 5=very high)	Don't know		
	i. Overall amount of communication activities				
	ii. Relevance of communication activities to my country's priorities and needs				
	iii. Overall appropriateness of communication products and tools				
	iv. Appropriateness of target group coverage				
	v. Effectiveness and outreach of dissemination activities				
K.S.2	As compared to 2008, how have ECDC communication activities evolved?				One answer
	<ul style="list-style-type: none"> • Significantly improved • Moderately improved • No or marginal change • Worsened • Not sure 				
K.S.3	Overall, are you satisfied with the degree to which ECDC communication activities are tailored to the following target groups?				One answer
		ECDC should do more	ECDC is doing right	ECDC should do less	Don't know
	i. Policy-makers / risk managers				
	ii. Public health professionals / disease experts				
	iii. Journalists and media				
	iv. Public health communicators				
	v. Other communication stakeholders (NGOs, industry etc.)				
	vi. General public				
K.S.4.	Do you have any specific suggestions or indications as how ECDC may improve the relevance or efficiency of its communication activities for the abovementioned target groups? Please, describe _____				

Website	For All																			
K.W.1	How often do you visit the ECDC website? <ul style="list-style-type: none"> • Daily • Weekly • Monthly • Quarterly • Very rarely / never 	One answer IF (5) skip to the next module																		
K.W.2	Which kind of information do you typically look up on ECDC website? Please select all that applies <table border="1"> <tr> <td>i. Up-to-date information and data on potential threats or disease outbreak evolution</td> <td></td> </tr> <tr> <td>ii. Scientific publications (articles, reports, literature reviews, etc.)</td> <td></td> </tr> <tr> <td>iii. Information on ECDC activities and projects</td> <td></td> </tr> <tr> <td>iv. Press releases and other communication materials for media and/or the general public</td> <td></td> </tr> <tr> <td>v. Other, please specify _____</td> <td></td> </tr> </table>	i. Up-to-date information and data on potential threats or disease outbreak evolution		ii. Scientific publications (articles, reports, literature reviews, etc.)		iii. Information on ECDC activities and projects		iv. Press releases and other communication materials for media and/or the general public		v. Other, please specify _____		Multiple answer								
i. Up-to-date information and data on potential threats or disease outbreak evolution																				
ii. Scientific publications (articles, reports, literature reviews, etc.)																				
iii. Information on ECDC activities and projects																				
iv. Press releases and other communication materials for media and/or the general public																				
v. Other, please specify _____																				
K.W.3	To what extent does ECDC website respond to your needs and expectations? Please rate from 1=poor to 5=excellent the following aspects <table border="1"> <thead> <tr> <th></th> <th>Rating (From 1=poor to 5=excellent)</th> <th>Don't know</th> </tr> </thead> <tbody> <tr> <td>i. Clarity of language</td> <td></td> <td></td> </tr> <tr> <td>ii. Ease in finding the information sought</td> <td></td> <td></td> </tr> <tr> <td>iii. Frequency of updates</td> <td></td> <td></td> </tr> <tr> <td>iv. Quality and reliability of contents</td> <td></td> <td></td> </tr> <tr> <td>v. Added-value of information provided</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1=poor to 5=excellent)	Don't know	i. Clarity of language			ii. Ease in finding the information sought			iii. Frequency of updates			iv. Quality and reliability of contents			v. Added-value of information provided			One answer
	Rating (From 1=poor to 5=excellent)	Don't know																		
i. Clarity of language																				
ii. Ease in finding the information sought																				
iii. Frequency of updates																				
iv. Quality and reliability of contents																				
v. Added-value of information provided																				
Communication tools	For NFP comm OR IF P.B.1.vii=(x) (communication experts) OR IF P.E.1.i=(x)OR P.E.1.ii=(x) OR P.E.1.iii=(x) (MB or AF or NC / CCB Dir)																			
K.C.1	Are you aware of public information campaigns supported by ECDC in the past few years (such as disease-dedicated days)? If Yes, in which capacity? <ul style="list-style-type: none"> • Yes, my organisation / institution actively took part in the implementation of some campaigns in my country • Yes, but only as an external 'audience' • No 	One answer																		
K.C.2	IF K.C.1=(1) Are you happy with the efficiency of ECDC - Member State partnerships for the implementation of information campaigns? <ul style="list-style-type: none"> • Yes, it is very satisfactory • Yes, it is moderately satisfactory • No, it is not satisfactory. • Don't know 	One answer																		
K.C.3	IF K.C.2 =(3)	Open																		

	<p>If the way of working with the ECDC on joint information campaigns is not satisfactory, do you have any suggestions for improvements?</p> <p>Please, describe _____</p>													
K.C.4	<p>IF K.C.1=(1) OR (2)</p> <p>Based on your experience, could you name examples of ECDC information campaigns that were either well-received or not-so-well-received in your country?</p> <table border="1"> <tr> <td>i. example of well-received campaign</td> <td>_____</td> </tr> <tr> <td>ii. example of not-so-well-received campaign</td> <td>_____</td> </tr> </table>	i. example of well-received campaign	_____	ii. example of not-so-well-received campaign	_____	Open								
i. example of well-received campaign	_____													
ii. example of not-so-well-received campaign	_____													
K.C.5	<p>Are you aware of the following ECDC communication toolkits? If YES, did they respond to a communication need that existed in your country? If YES, were the toolkits used for communication activities at country level?</p> <table border="1"> <thead> <tr> <th></th> <th>A) Awareness of the toolkit (Yes/No)</th> <th>B) Relevance of the toolkit to national needs (Yes/No)</th> <th>C) Use of the toolkit in national communication campaign (Yes/No)</th> </tr> </thead> <tbody> <tr> <td>i. Communication toolkit for gastrointestinal diseases prevention for health and educational authorities, targeting children, teachers, parents and the school community</td> <td></td> <td></td> <td></td> </tr> <tr> <td>ii. Seasonal influenza communication toolkit targeting healthcare workers and people in risk groups</td> <td></td> <td></td> <td></td> </tr> </tbody> </table>		A) Awareness of the toolkit (Yes/No)	B) Relevance of the toolkit to national needs (Yes/No)	C) Use of the toolkit in national communication campaign (Yes/No)	i. Communication toolkit for gastrointestinal diseases prevention for health and educational authorities, targeting children, teachers, parents and the school community				ii. Seasonal influenza communication toolkit targeting healthcare workers and people in risk groups				One answer
	A) Awareness of the toolkit (Yes/No)	B) Relevance of the toolkit to national needs (Yes/No)	C) Use of the toolkit in national communication campaign (Yes/No)											
i. Communication toolkit for gastrointestinal diseases prevention for health and educational authorities, targeting children, teachers, parents and the school community														
ii. Seasonal influenza communication toolkit targeting healthcare workers and people in risk groups														
K.C.6	<p>IF K.C.5.i.c=(x) OR K.C.5.ii.c=(x) OR K.C.5.iii.c=(x) (were used)</p> <p>Could you provide evidence to national campaigns or other documents showing how the above ECDC toolkit was used in your country? (if available please provide the weblink to relevant national documents or other source – also in national language)</p> <p>_____</p>	Open												
K.C.7	<p>Overall, how do you assess the design and the impact of ECDC health communication activities? Please express your agreement / disagreement with the following statements.</p> <table border="1"> <thead> <tr> <th></th> <th>Rating (From 1= strong disagreement to 5= strong agreement)</th> <th>Don't know</th> </tr> </thead> <tbody> <tr> <td>i. ECDC health communication activities address crucial concerns for public health in my country</td> <td></td> <td></td> </tr> <tr> <td>ii. The information and communication tools prepared by ECDC can be easily implemented in my national context</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1= strong disagreement to 5= strong agreement)	Don't know	i. ECDC health communication activities address crucial concerns for public health in my country			ii. The information and communication tools prepared by ECDC can be easily implemented in my national context			One answer			
	Rating (From 1= strong disagreement to 5= strong agreement)	Don't know												
i. ECDC health communication activities address crucial concerns for public health in my country														
ii. The information and communication tools prepared by ECDC can be easily implemented in my national context														

	iii The amount of resources ECDC devotes to information and communication activities is excessive			
	iv. ECDC activities have contributed to improving health communication capacity and skills in my country			
K.C.8	IF K.C.7.v = (4) OR (5) (there has been contribution) Could you provide a concrete example of the positive impact of ECDC activities on your country's health communication capacities? Please, describe _____			

Risk communication	For NFP Comm OR NFP P&R OR HSCcomm OR EWRS OR IF P.B.1.vi=(x) OR P.B.1.vii=(x) (risk manager or communication experts) OR IF P.E.1.i=(x)OR P.E.1.ii=(x) OR P.E.1.iii=(x) (MB or AF or NC / CCB Dir)																								
K.R.1	To what extent do your professional responsibilities involve managing risk communication related to communicable diseases in your country? <ul style="list-style-type: none"> • Significantly • Moderately • Marginally • Not at all 			One answer IF (4) skip to the next module																					
K.R.2	Overall, what are the sources of information / advice that you rely on for your risk communication activities? Please rate from 1=poor to 5=very high the extent to which you turn to the following sources to inform decision-making on risk communication	<table border="1"> <thead> <tr> <th></th> <th>Rating (From 1=poor to 5=very high)</th> <th>Don't know</th> </tr> </thead> <tbody> <tr> <td>i. Domestic, country-level sources</td> <td></td> <td></td> </tr> <tr> <td>ii. ECDC</td> <td></td> <td></td> </tr> <tr> <td>iii. The European Commission / DG SANCO</td> <td></td> <td></td> </tr> <tr> <td>iv. The Health Security Committee</td> <td></td> <td></td> </tr> <tr> <td>v. WHO</td> <td></td> <td></td> </tr> <tr> <td>vi. Other countries' agencies (please specify the <u>main</u> one: _____)</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1=poor to 5=very high)	Don't know	i. Domestic, country-level sources			ii. ECDC			iii. The European Commission / DG SANCO			iv. The Health Security Committee			v. WHO			vi. Other countries' agencies (please specify the <u>main</u> one: _____)				One answer
	Rating (From 1=poor to 5=very high)	Don't know																							
i. Domestic, country-level sources																									
ii. ECDC																									
iii. The European Commission / DG SANCO																									
iv. The Health Security Committee																									
v. WHO																									
vi. Other countries' agencies (please specify the <u>main</u> one: _____)																									
K.R.3	How do you assess the relevance and utility of ECDC's outputs for risk communication purposes in your country? Please express your agreement / disagreement with the following statements.	<table border="1"> <thead> <tr> <th></th> <th>Rating (From 1= strong disagreement to 5= strong agreement)</th> <th>Don't know</th> </tr> </thead> <tbody> <tr> <td>i. Our risk communication messages are typically coherent with ECDC's conclusions / suggestions</td> <td></td> <td></td> </tr> <tr> <td>ii. ECDC outputs overlap with outputs from those with national / EU risk management responsibility</td> <td></td> <td></td> </tr> </tbody> </table>		Rating (From 1= strong disagreement to 5= strong agreement)	Don't know	i. Our risk communication messages are typically coherent with ECDC's conclusions / suggestions			ii. ECDC outputs overlap with outputs from those with national / EU risk management responsibility				One answer												
	Rating (From 1= strong disagreement to 5= strong agreement)	Don't know																							
i. Our risk communication messages are typically coherent with ECDC's conclusions / suggestions																									
ii. ECDC outputs overlap with outputs from those with national / EU risk management responsibility																									

	iii. We want more ECDC help in the field of risk communication to the media and general public iv. We want more ECDC help in the field of risk communication to public health experts and institutional stakeholders v. ECDC tools and capacity building activities have concretely helped us to improve our risk communication abilities vi. ECDC support is proving conducive to increased coherence / harmonisation of risk communication messages across different EU countries																				
K.R.4	Have you read the ECDC “ <i>literature review on effective risk communication for the prevention and control of communicable diseases in Europe</i> ”? If YES, did you find it useful for your risk communication needs? <ul style="list-style-type: none"> • Yes, very useful • Yes, rather useful • Yes, but not really useful • No, I have not read it 				One answer																
K.R.5	The ECDC could add more value in the field of risk communication by...? Please select the recommendations that you deem as particularly important (multiple answers are possible)	<table border="1"> <tr> <td>i. ...trying to increase awareness of its role by national media in my country</td> <td></td> </tr> <tr> <td>ii. ...putting more focus on training risk communicators</td> <td></td> </tr> <tr> <td>iii. ...providing more practical examples of new technologies/approaches to risk communication</td> <td></td> </tr> <tr> <td>iv. ...facilitating more discussion on what works and what doesn't in risk communication</td> <td></td> </tr> <tr> <td>v. ... increasing the use of real-life case studies to show how to communicate risk</td> <td></td> </tr> <tr> <td>vi... providing more examples of how to monitor and evaluate risk communication</td> <td></td> </tr> <tr> <td>vii. Other, please specify _____</td> <td></td> </tr> <tr> <td>viii. None of the above</td> <td></td> </tr> </table>	i. ...trying to increase awareness of its role by national media in my country		ii. ...putting more focus on training risk communicators		iii. ...providing more practical examples of new technologies/approaches to risk communication		iv. ...facilitating more discussion on what works and what doesn't in risk communication		v. ... increasing the use of real-life case studies to show how to communicate risk		vi... providing more examples of how to monitor and evaluate risk communication		vii. Other, please specify _____		viii. None of the above				Multiple answer
i. ...trying to increase awareness of its role by national media in my country																					
ii. ...putting more focus on training risk communicators																					
iii. ...providing more practical examples of new technologies/approaches to risk communication																					
iv. ...facilitating more discussion on what works and what doesn't in risk communication																					
v. ... increasing the use of real-life case studies to show how to communicate risk																					
vi... providing more examples of how to monitor and evaluate risk communication																					
vii. Other, please specify _____																					
viii. None of the above																					

Section 9 - Final questions

Final Questions	For ALL	
F.Q.1	Would you possibly be available for a follow-up brief phone call to further elaborate on some of the answers provided? If Yes, please provide your contact details <ul style="list-style-type: none"> • YES (Email and/or Phone number _____) • NO 	One answer
F.Q.2	Please, help us in making this exercise successful ! Are there other stakeholders in your country that in your opinion should receive this questionnaire? If so, please indicate their names and emails in the box below and we will include them in the survey. _____	Open

C.2 Filters specifications for modules

The table below illustrates which modules apply to respondents with specific profile characteristics. Some characteristics are defined in advance (based on CRM) and led to so-called 'ex-ante filters'; others are based on respondents' actual answers to the preliminary questions, and determine the so-called 'ex-post filters'.

Modules	PB	PE	OM	OS	OG	OB	DS	DI	DH	DD	TR	TS	TF	TH	TE	TW	TI	SN	ST	SS	SH	SF	SO	SM	CG	CE	CF	CC	AA	AM	KS	KW	KC	KR	FQ	
Target	Respondent Background	On ECDC experience	Mandate, operation, value	Management and structure	Governance	Burden	DP Salmonella	DP Influenza	DP HIV/AIDS	All DP	Rapid risk assessment - general	RRA-Salmonella	RRA-Flu	RRA-HIV	EPIS	EWRS	Other P&R matters	Integration of networks	TESSy & datasets	Salmonella surveillance	HIV Surveillance	Influenza Surveillance	Outputs	microbiology integration	Capacity building - general	EPIET / EUPHEM	FEM Wiki	ESCAIDE conference	Awareness and use	Added-value and management	External communication	Website	Other Comm. Tools	Risk communication	Final questions	
NFP ScAdv	1	1	1	1							1	1	1	1				1					1						1	1	1		1			1
NFP PH train	1	1	1	1							1							1					1		1	1							1			1
NFP Surv	1	1	1	1							1							1		1			1	1						1	1			1		1
NFP ThDet	1	1	1	1							1	1		1		1	1	1					1							1	1			1		1
NFP P&R	1	1	1	1							1	1		1		1	1	1					1							1	1			1		1
NFP Mbio	1	1	1	1							1							1					1	1						1	1			1		1
NFP Comm	1	1	1	1							1							1					1							1	1		1	1	1	1
NFP-FLU	1	1	1	1				1			1	1						1					1							1	1			1		1
NFP-FWD	1	1	1	1			1				1	1						1		1			1	1					1	1			1		1	
NFP-HASH	1	1	1	1					1		1	1			1			1					1							1	1			1		1
HSCmem	1	1	1								1	1	1	1		1	1	1					1						1	1			1		1	
HSCcomm	1	1	1								1	1	1	1		1	1	1					1						1	1			1		1	
Net-flu	1	1	1					1			1	1		1				1					1						1	1			1		1	
Net-HIV	1	1	1						1		1	1		1				1					1						1	1			1		1	
Net-salm	1	1	1				1				1	1	1					1		1			1	1					1	1			1		1	
Net-smol	1	1	1				1				1	1	1					1		1			1	1					1	1			1		1	
Net Oth	1	1	1								1							1					1	1					1	1			1		1	
Netw 2119	1	1	1								1					1		1					1						1	1			1		1	
EWRS	1	1	1								1	1	1	1		1	1	1					1						1	1			1		1	
FLU HSC	1	1	1					1			1		1					1					1						1	1			1		1	
HIV TT	1	1	1						1		1			1		1		1					1						1	1			1		1	
EPIS	1	1	1								1					1		1					1						1	1			1		1	
TESSY	1	1	1								1							1	1				1						1	1			1		1	
EP/EU	1	1	1								1							1					1			1	1		1	1			1		1	
Guest	1	1	1								1							1					1						1	1			1		1	
Epidem	1	1	1								1							1					1				1	1		1	1		1		1	
Microbiol	1	1	1								1							1					1	1					1	1			1		1	
RiskMan	1	1	1								1	1	1	1		1	1	1					1					1	1			1		1		
CommEx	1	1	1								1					1	1	1					1						1	1		1	1	1	1	
Flu	1	1	1					1			1		1					1					1						1	1			1		1	
HIV	1	1	1						1		1			1				1					1						1	1			1		1	

PB1 i
PB1 ii
PB1 vi
PB1 vii
PB3 i
PB3 ii

PB3 iii	Salmo	1	1	1				1							1		1			1			1	1			1			1			1	
PE1 i	Mboard	1	1	1	1	1									1					1			1				-1	1	1		1	1	1	1
PE1 ii	Aforum	1	1	1	1	1									1					1			1	1	1		-1	1	1	1	1	1	1	
PE1 iii	NC/CCB	1	1	1	1	1									1	1											-1	1	1		1	1	1	1
PE1 viii	Outside	1	1	1	-1										1														1	1		1	1	

EX ANTE Filters	Description	EX POST Filters	Description
NFP ScAdv	NFP for Scientific Advice	Epidem	Epidemiologists
NFP PH train	NFP for Public Health Training	Microbiol	Microbiologists
NFP Surv	NFP for Surveillance	RiskMan	Risk Managers
NFP ThDet	NFP for Threat Detection, EWRS	CommEx	Communication Experts
NFP P&R	NFP for Preparedness and Response	Flu	Influenza Experts
NFP Mbio	NFP for Microbiology	HIV	HIV experts
NFP Comm	NFP for Communication	Salmo	Salmonella experts
NFP-FLU	NFP For Influenza	Mboard	Management Board members (current or past)
NFP-FWD	NFP For Food- and Waterborne Diseases	Aforum	Advisory forum member members (current or past)
NFP-HASH	NFP for HASH	NC/CCB	National Coordinators/Coordinating Competent Body Directors
HSCmem	Health Security Committee Member	Outside	No role / appointment in the ECDC system
HSCcomm	Health Security Committee Communicators		
Net-flu	Member of the Influenza network		
Net-HIV	Member of the HIV network	1	Applicable if selected
Net-salm	Member of the FWD network	-1	NOT applicable if selected
Net-smol	Member of the FWD network (Salmonellosis Molecular Surveillance)		
Net Oth	Member of other networks		
Netw 2119	Member of the European Commission Network Committee 2119		
EWRS	Member of the EWRS		
FLU HSC	Member of the Influenza Health Security Committee		
HIV TT	Member of the HIV Think Tank		
EPIS	Epis User		
TESSY	TESSy User		
EP/EU	EPIET/EUPHEM fellows/supervisors		
Guest	(For respondents non-previously profiled)		

ANNEX D – BIBLIOMETRIC ANALYSIS

This Annex includes the detailed results of a bibliometric research, conducted on a sample of 20 ECDC selected publications or related articles, published on *Eurosurveillance* during the period under evaluation (2008-2012).

The following data have been obtained by means of a software programme, Publish or Perish 4, which retrieves and analyzes academic citations by performing an advanced research on Google Scholar. This software is generally intended to measure the research impact of individual academics, specific publications or scientific journals through the analysis of row citations and the calculation of several citation metrics.

In order to show the scientific impact of the following publications, two indicators have been selected, and namely:

- the total number of papers quoting the referred publication;
- the H-index;

The first indicator represents the total number of papers returned by Google Scholar, which contain a quotation of the abovementioned publication.

The second indicator, the H-index, provides a weighted average of the individual H-indexes referred to the authors citing the abovementioned publication. To be clearer, by definition an academic has an index h if “ h of his/her N_p papers have at least h citations each, and the other (N_p-h) papers have no more than h citations each”².

² Hirsch, J.E. An index to quantify an individual's scientific research output. [arXiv:physics/0508025](https://arxiv.org/abs/physics/0508025) v5 29 Sep 2005

1. EFSA (European Food Safety Authority) and ECDC (European Centre for Disease Prevention and Control), 2014. The European Union Summary Report on Trends and Sources of Zoonoses, Zoonotic Agents and Food-borne Outbreaks in 2012. EFSA Journal 2014;12(2):3547, 312pp. doi:10.2903/j.efsa.2014.3547

Total nr. of papers: 17

H-index: 2

Cites	Authors	Title	Year	Source	Publisher
3	M Hugas, PA Beloel	Controlling Salmonella along the food chain in the European Union-progress over the last ten years	2014	Euro surveillance: bulletin Europeen sur ...	eurosurveillance.eu
2	GL Nichols, Y Andersson, E Lindgren, I Devaux...	European Monitoring Systems and Data for Assessing Environmental and Climate Impacts on Human Infectious Diseases	2014	International journal of ...	mdpi.com
0	B Devleeschauwer, N Praet, N Speybroeck...	The low global burden of trichinellosis: evidence and implications	2014	International journal for ...	Elsevier
0	M Wierup, T Kristoffersen	Prevention of Salmonella contamination of finished soybean meal used for animal feed by a Norwegian production plant despite frequent Salmonella contamination of ...	2014	Acta Veterinaria Scandinavica	actavetscand.com
0	E Barbau-Piednoir, S Bertrand...	Genome sequence of the Salmonella enterica subsp. enterica serovar Namur strain 05-2929, lacking the Salmonella atypical fimbrial operon	2014	Genome ...	Am Soc Microbiol
0	F Pérez-Rodríguez, P González-García...	Impact of the prevalence of different pathogens on the performance of sampling plans in lettuce products	2014	International journal of ...	Elsevier
0	E Doménech, AJ Belenguer, JA Amoros, MA Ferrus...	Prevalence and antimicrobial resistance of <i>L. monocytogenes</i> and <i>S. Salmonella</i> strains isolated in ready-to-eat foods in Eastern Spain	2014	Food Control	Elsevier
0	C Zweifel, M Capek, R Stephan	Microbiological contamination of cattle carcasses at different stages of slaughter in two abattoirs	2014	Meat science	Elsevier
0	S Buncic	Public Health Hazards: B. Control of Biological Meat-Borne Hazards	0	Meat Inspection and Control in the Slaughterhouse	Wiley Online Library
0	A Alonso-Hernando, C Alonso-Calleja, R Capita	Effect of various decontamination treatments against Gram-positive bacteria on chicken stored under differing conditions of temperature abuse	2014	Food Control	Elsevier
0	T Skjerdal, E Reitehaug, K Eckner	Development of performance objectives for <i>Listeria monocytogenes</i> contaminated salmon (<i>Salmo salar</i>) intended used as sushi and sashimi based on ...	2014	International journal of food ...	Elsevier
0	T Mateus, RL Maia, P Teixeira	Awareness of listeriosis among Portuguese pregnant women	2014	Food Control	Elsevier
0	E Barbau-Piednoir, J Mahillon, J Pillyser...	Evaluation of viability-qPCR detection system on viable and dead <i>S. Salmonella</i> serovar Enteritidis	2014	Journal of ...	Elsevier

0	A Al-Nehlawi, S Guri, B Guamis, J Saldo	Synergistic effect of carbon dioxide atmospheres and high hydrostatic pressure to reduce spoilage bacteria on poultry sausages	2014	LWT-Food Science and ...	Elsevier
0	FK Lücke, P Zangerl	Food safety challenges associated with traditional foods in German-speaking regions	2014	Food Control	Elsevier
0	S de las zoonosis en Europa	SITUACIÓN DE LAS ZOOZONOSIS EN EUROPA Y EN ESPAÑA. INFORME DE LA AUTORIDAD EUROPEA DE SEGURIDAD ALIMENTARIA (EFSA), 2014.	0	higieneambiental.com	n.d.
0	L Silveira, J Machado	SALMONELLA SPP. ASOCIADA A ROEDORES	2014	DOENÇAS ASSOCIADAS A ...	repositorio.insa.pt

2. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2010. Stockholm: European Centre for Disease Prevention and Control; 2011.

Total nr. of papers: 80

H-index: 9

Cites	Authors	Title	Year	Source	Publisher
47	DP Wilson	HIV treatment as prevention: natural experiments highlight limits of antiretroviral treatment as HIV prevention	2012	PLoS medicine	dx.plos.org
21	E Jolley, T Rhodes, L Platt, V Hope, A Latypov...	HIV among people who inject drugs in Central and Eastern Europe and Central Asia: a systematic review with implications for policy	2012	BMJ open	bmjopen.bmj.com
19	G Likatavicius, MJ Van de Laar	HIV infection and AIDS in the European Union and European Economic Area, 2010	2011	Euro Surveill	eurosurveillance.eu
18	A Pharris, L Wiessing, O Sfetcu, D Hedrich...	Human immunodeficiency virus in injecting drug users in Europe following a reported increase of cases in Greece and Romania, 2011	2011	Euro ...	eurosurveillance.eu
17	L Wiessing, G Likatavicius, D Hedrich, B Guarita...	Trends in HIV and hepatitis C virus infections among injecting drug users in Europe, 2005 to 2010	2011	Euro ...	eurosurveillance.org
16	AK Sullivan, D Raben, J Reekie, M Rayment, A Mcroft...	Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study)	2013	PLoS One	dx.plos.org
13	EA DiNunno, AM Oster, C Sionean...	Suppl 1: Piloting a System for Behavioral Surveillance Among Heterosexuals at Increased Risk of HIV in the United States	2012	The open AIDS ...	ncbi.nlm.nih.gov
12	BD Rice, J Elford, Z Yin, VC Delpech	A new method to assign country of HIV infection among heterosexuals born abroad and diagnosed with HIV	2012	AIDS	journals.lww.com
11	PF Harrison, A Hemmerling, J Romano...	Developing multipurpose reproductive health technologies: an integrated strategy	2013	AIDS research and ...	hindawi.com

7	L Platt, E Jolley, T Rhodes, V Hope, A Latypov...	Factors mediating HIV risk among female sex workers in Europe: a systematic review and ecological analysis	2013	BMJ open	bmjopen.bmj.com
7	G Likatavicius, M Van de Laar	HIV and AIDS in the European Union, 2011	2012	Euro Surveill	eurosurveillance.eu
7	P Weatherburn, AJ Schmidt, F Hickson, D Reid...	The European Men-who-have-sex-with-men internet survey (EMIS): design and methods	2013	Sexuality Research and ...	Springer
6	M de Mulder, G Yebra, A Navas, MI de José...	High drug resistance prevalence among vertically HIV-infected patients transferred from pediatric care to adult units in Spain	2012	PloS one	dx.plos.org
6	P Grenfell, R Baptista Leite, R Garfein...	Tuberculosis, injecting drug use and integrated HIV-TB care: a review of the literature	2013	Drug and alcohol ...	Elsevier
4	KJ O'Keefe, S Scheer, MJ Chen, AJ Hughes, S Pipkin	People fifty years or older now account for the majority of AIDS cases in San Francisco, California, 2010	2013	AIDS care	Taylor & Francis
4	JPE Sánchez, AM Sabuco, MO Amorós...	Comportamiento sexual bajo la influencia del alcohol en adolescentes Españoles	2013	Adicciones: Revista ...	dialnet.unirioja.es
3	MM Kall, RD Smith, VC Delpech	Late HIV diagnosis in Europe: A call for increased testing and awareness among general practitioners	2012	European Journal of ...	informahealthcare.com
3	J Hoyos, S Fernández-Balbuena...	Never tested for HIV in Latin-American migrants and Spaniards: prevalence and perceived barriers	2013	Journal of the ...	ncbi.nlm.nih.gov
3	D Alvarez-del Arco, S Monge...	HIV testing policies for migrants and ethnic minorities in EU/EFTA Member States	2013	... European Journal of ...	Oxford Univ Press
3	WHO ECDC	Regional Office for Europe	2010	HIV/AIDS surveillance in Europe	
3	J Takács, JA Kelly, T PTóth, L Mocsonaki...	Effects of Stigmatization on Gay Men Living with HIV/AIDS in a Central-Eastern European Context: A Qualitative Analysis from Hungary	2013	Sexuality Research and ...	Springer
3	S Monge, B Alejos, F Dronda, J Del Romero...	Inequalities in HIV disease management and progression in migrants from Latin America and sub-Saharan Africa living in Spain	2013	HIV ...	Wiley Online Library
2	Z Mor, R Weinstein, I Grotto, Y Levin, D Chemtob	Thirty years of HIV in Israel: current epidemiology and future challenges	2013	BMJ open	bmjopen.bmj.com
2	V Svedhem-Johansson, P Pugliese...	Long-term gender-based outcomes for atazanavir/ritonavir (ATV/r)-containing regimens in treatment-experienced patients with HIV	2013	Current HIV ...	ncbi.nlm.nih.gov
2	C Agustí, L Fernández-López, J Mascort, R Carrillo...	Acceptability of rapid HIV diagnosis technology among primary healthcare practitioners in Spain	2013	AIDS care	Taylor & Francis
2	RR Patel, S Patel, E Clarke, AW Khan...	Guidance and practice on frequency of HIV and sexually transmitted infection testing in men who have sex with men—what is the European situation?	2014	... journal of STD & ...	std.sagepub.com

2	M Mulder, VA York, AA Wiznia, HA Michaud...	HIV-1 drug resistance prevalence, drug susceptibility and variant characterization in the Jacobi Medical Center paediatric cohort, Bronx, NY, USA	2014	HIV ...	Wiley Online Library
2	F Aragão, J Vera, IV Pinto	Cost-effectiveness of the third-agent class in treatment-naive human immunodeficiency virus-infected patients in Portugal	2012	PLOS one	dx.plos.org
1	DAMC van de Vijver, MCF Prosperi...	Transmission of HIV in sexual networks in sub-Saharan Africa and Europe	2013	The European Physical ...	Springer
1	JV Lazarus, JD Lundgren	E is for everything else, not least for expanding HIV testing in Europe	2012	Bulletin of the World Health ...	SciELO Public Health
1	L Camoni, V Regine, S Boros, MC Salfa...	AIDS patients with tuberculosis: characteristics and trend of cases reported to the National AIDS Registry in Italy—1993–2010	2013	... European Journal of ...	Oxford Univ Press
1	L Fiebig, C Kollan, B Hauer...	HIV-Prevalence in Tuberculosis Patients in Germany, 2002–2009: An Estimation Based on HIV and Tuberculosis Surveillance Data	2012	PloS one	dx.plos.org
1	I Bozicevic, S Handanagic, SZ Lepej...	The emerging and re-emerging human immunodeficiency virus epidemics in Europe	2013	Clinical Microbiology ...	Wiley Online Library
1	V Gómez, A Fernández, C Galeano, J Oliva...	Renal transplantation in HIV-infected patients: experience at a tertiary hospital in Spain and review of the literature	2013	Transplantation ...	Elsevier
1	S Ancker, B Rechel, M McKee, N Spicer	Kyrgyzstan: still a regional 'pioneer' in HIV/AIDS or living on its reputation?	2013	Central Asian Survey	Taylor & Francis
1	N Sherriff, L Gugglberger	A European Seal of Approval for 'gay' businesses: findings from an HIV-prevention pilot project	2014	Perspectives in public health	rsh.sagepub.com
1	P Grenfell, AC Carvalho, A Martins...	A rapid assessment of the accessibility and integration of HIV, TB and harm reduction services for people who inject drugs in Portugal	2012	Final Study Report. ...	antoniocasella.eu
1	JV Lazarus, M Hoekstra, D Raben, V Delpech...	The case for indicator condition-guided HIV screening	2013	HIV ...	Wiley Online Library
1	J Busza, M Douthwaite, R Bani, O Scutelniciuc...	Injecting behaviour and service use among young injectors in Albania, Moldova, Romania and Serbia	2013	International Journal of ...	Elsevier
1	D Gökengin	CİNSEL YOLLA BULAŞAN HASTALIKLARDA EPİDEMİYOLOJİK DURUM	0	ankemdernegi.org.tr	n.d.
1	C Cevallos García, J Verdejo Ortés...	Late Diagnosis of Human Immuno Deficiency Virus Infection in the Madrid Region (2007-2011)	2012	... Española de Salud ...	SciELO Public Health
0	A VAN DER VEKEN	HIV testing in Europe: opportunities in primary care.	0	lib.ugent.be	n.d.
0	S Session	AIDS/HIV in view of the XVIII International AIDS Conference (Vienna July 18)	2009		west-info.eu
0	HI Hall, J Halverson, DP Wilson, B Suligoj, M Diez...	Late Diagnosis and Entry to Care after Diagnosis of Human Immunodeficiency Virus Infection: A Country Comparison	2013	PloS one	dx.plos.org
0	J Deblonde, FF Hamers, S Callens, R Lucas, H Barros...	HIV testing practices as reported by HIV-infected patients in four European countries	2014	AIDS care	Taylor & Francis

0	B Valdes	Demographic Analysis of AIDS Mortality in Spain	2013	Population (English Edition)	cairn.info
0	JM Greig, J Anderson	Optimizing antiretroviral therapy for women living with HIV	2014	Current opinion in infectious diseases	journals.lww.com
0	N MAES	Study of the plasma levels of soluble CD14 in HIV infected patients	2012		uhdspace.uhasselt.be
0	A Karnite, G Brigis, A Uuskula	Years of potential life lost due to HIV infection and associated factors based on national HIV surveillance data in Latvia, 1991-2010	2013	Scandinavian journal of ...	informahealthcare.com
0	MJ van de Laar, A Pharris	Treatment as prevention: will it work?	2011	Euro surveillance: bulletin ...	eurosurveillance.org
0	A Morales, JP Espada, M Orgilés...	The short-term impact of peers as co-facilitators of an HIV prevention programme for adolescents: A cluster randomised controlled trial	2014	The European ...	informahealthcare.com
0	F Farahnaz	Enigma of HIV Control-Modelling a Global Surveillance Network for HIV Infection	2012		omicsonline.org
0	YK Hahn, EM Podhaizer, SP Farris, MF Miles...	Effects of chronic HIV-1 Tat exposure in the CNS: heightened vulnerability of males versus females to changes in cell numbers, synaptic integrity, and ...	2013	Brain Structure and ...	Springer
0	Z Mor, M Dan	The HIV epidemic among men who have sex with men—behaviour beats science	2012	EMBO reports	Wiley Online Library
0	D Strnisková, Z Nováková, M Kopecký	Case Study on tackling health inequalities at the Olomouc Region level	0	equitychannel.net	n.d.
0	YH Jin, A Potthoff, J Xu, WJ Yu, K Liu...	Evaluation of Mental Status HIV-Infected Patients: Implications for Treatment	2012	Current HIV ...	ingentaconnect.com
0	M Ciufo	Drawing Blood: Towards an EU Remedy for Blood Donation Rights	2013		HeinOnline
0	RH Dennin, M Lafrenz, G Gesk	HIV and Other Sexual Transmitted Infections—Challenges for Liberal Prevention Strategies	2014	World Journal of AIDS	file.scirp.org
0	R Reinties, M McKee	Chem 5 eve n	2013	Successes And Failures Of Health Policy ...	books.google.com
0	R Federation, S Marino	Full publication list	0	euro.who.int	n.d.
0	M Rahu, VV Vlassov, F Pega, T Andreeva, P Ay...	Population health and status of epidemiology: WHO European Region I	2013	International journal of ...	IEA
0	B Valdes	Analyse démographique de la mortalité par sida en Espagne	2013	Population	cairn.info
0	PDDC Wild, J Dellinger	HIV-Testung an der Allgemeinbevölkerung	2013	Wiener Medizinische Wochenschrift	Springer
0	JV Lazarus, JD Lundgren	Boletín de la Organización Mundial de la Salud	2012	Boletín de la Organización Mundial de la ...	apps.who.int
0	JV Lazarus, JD Lundgren	Bulletin de l'Organisation mondiale de la Santé	2012	Bulletin de l'Organisation mondiale de ...	wwwlive.who.int
0	N van der Knaap	Druggebruikers in Amsterdam: lopen ze nog risico op HIV?	0	seksoa.nl	n.d.
0	В Стародубов	Предисловие к выходу русскоязычной версии Бюллетеня Всемирной организации здравоохранения	2013	БЮЛЛЕТЕНЬ	who.int

0	M Goenee, H Kedde, C Picavet	Condoomgebruik en testgedrag in Nederland	0	seksuologie	mybody.nl
0	C Matz	Analyse du faible taux de découverte de séropositivité pour le VIH en Savoie et Haute-Savoie: profil des patients nouvellement diagnostiqués et des acteurs du ...	2013		dumas.ccsd.cnrs.fr
0	J Dellinger, C Wild	HASH (0xb4c24b8)	2012		eprints.hta.lbg.ac.at
0	F Bally, N Troillet	Infections sexuellement transmissibles en Suisse: un paysage en transformation	2012	Maladies infectieuses	rms.medhyg.ch
0	C Fernandes, F Esteves, O Matos, D Machado, I Couto...	AL5-A2	0	congressomedtrop.ihmt.unl.pt	
0	FKN Kalengayi	A world on the move	0	diva-portal.org	n.d.
0	FB Pilecco	Aborto provocado em mulheres vivendo com HIV/Aids	2014		lume.ufrgs.br
0	ADN DIAGNOSI, D DI INFEZIONE	dell'Istituto Superiore di Sanità dell'Istituto Superiore di Sanità	2009		iss.it
0	PL Hottz, M Schechter	A epidemiologia da infecção pelo HIV no Brasil e no mundo	2012	PERMANYER BRASIL	centrodegenomas.com.br
0	И НА, ТСИ СЕКСУАЛЬНОСТИ	СЛИШКОМ СТАРЫЕ ЧТОБЫ ЛЮБИТЬ?	0	СТАРЕНИЕ И СЕКСУАЛЬНОЕ ...	54.86.122.20
0	ТСИ СЕКСУАЛЬНОСТИ	СЛИШКОМ СТАРЫЕ ЧТОБЫ ЛЮБИТЬ?	0	СТАРЕНИЕ И СЕКСУАЛЬНОЕ ЗДОРОВЬЕ	eeca.unfpa.org
0	OPS AHO, OVI MU	Recomendaciones para mejorar y fortalecer los sistemas de vigilancia del VIH	0	mcr-comisca.org	n.d.

3. European Centre for Disease Prevention and Control. Annual Epidemiological Report 2011. Reporting on 2009 surveillance data and 2010 epidemic intelligence data. Stockholm: ECDC; 2011

Total nr. of papers: 103

H-index: 10

Cites	Authors	Title	Year	Source	Publisher
26	A Bechini, E Tiscione, S Boccalini, M Levi, P Bonanni	Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): a review of evidences and recommendations	2012	Vaccine	Elsevier
25	CA Ison, K Town, C Obi, S Chisholm, G Hughes...	Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England ...	2013	The Lancet infectious ...	Elsevier
23	JN Pendleton, SP Gorman, BF Gilmore	Clinical relevance of the ESKAPE pathogens	2013	n.d.	informahealthcare.com
22	Q Chang, YL Tzeng, DS Stephens	Meningococcal disease: changes in epidemiology and prevention	2012	Clinical epidemiology	ncbi.nlm.nih.gov

18	C Carvalho, H Thomas, K Balogun, R Tedder...	A possible outbreak of hepatitis A associated with semi-dried tomatoes, England, July-November 2011	2012	Euro ...	eurosurveillance.org
15	S Paz, D Malkinson, MS Green, G Tsioni, A Papa...	Permissive summer temperatures of the 2010 European West Nile fever upsurge	2013	PloS one	dx.plos.org
14	D Eibach, JS Casalegno, V Escuret, G Billaud...	Increased detection of Mycoplasma pneumoniae infection in children, Lyon, France, 2010 to 2011	2012	Euro ...	eurosurveillance.org
12	W Van der Hoek, BM Hogema, F Dijkstra, A Rietveld...	Relation between Q fever notifications and Coxiella burnetii infections during the 2009 outbreak in the Netherlands	2012	Euro Surveill	Citeseer
12	S Odolini, P Gautret, P Parola	Epidemiology of imported malaria in the mediterranean region	2012	Mediterranean journal of ...	ncbi.nlm.nih.gov
12	I Abbott, GM Cerqueira...	Carbapenem resistance in Acinetobacter baumannii: laboratory challenges, mechanistic insights and therapeutic strategies	2013	Expert review of ...	Expert Reviews Ltd London, UK
10	BA Lindstedt, M Torpdahl, G Vergnaud, S Le Hello...	Use of multilocus variable-number tandem repeat analysis (MLVA) in eight European countries, 2012	2013	n.d.	edoc.rki.de
8	J Artieda, M Basterrechea, L Arriola, M Yagüe...	Outbreak of cryptosporidiosis in a child day-care centre in Gipuzkoa, Spain, October to December 2011	2012	Euro ...	eurosurveillance.org
7	A Vila-Corcoles, O Ochoa-Gondar	Preventing Pneumococcal Disease in the Elderly	2013	Drugs & aging	Springer
6	J Fonager, S Barzinci, TK Fischer	Emergence of a new recombinant Sydney 2012 norovirus variant in Denmark, 26 December 2012 to 22 March 2013	2013	Euro Surveill	eurosurveillance.eu
5	H Zeller, L Marrama, B Sudre, W Bortel...	Mosquito-borne disease surveillance by the European Centre for Disease Prevention and Control	2013	Clinical Microbiology ...	Wiley Online Library
5	MM Fitzgibbon, N Gibbons, E Roycroft, S Jackson...	A snapshot of genetic lineages of Mycobacterium tuberculosis in Ireland over a two-year period, 2010 and 2011.	2013	n.d.	lenus.ie
5	L Mughini-Gras, C Graziani, F Biorci, A Pavan...	Surveillance of acute infectious gastroenteritis (1992–2009) and food-borne disease outbreaks (1996–2009) in Italy, with a focus on the Piedmont and ...	2012	Euro ...	eurosurveillance.eu
5	B Guzman-Herrador, L Vold, K Nygard	Surveillance of travel-associated gastrointestinal infections in Norway, 2009–2010: are they all actually imported?	2012	Europe	eurosurveillance.org
5	A Lenglet, Z Herrador, AP Magiorakos...	Surveillance status and recent data for Mycoplasma pneumoniae infections in the European Union and European Economic Area, January 2012.	2012	... : bulletin europÃ© en ...	eurosurveillance.eu
5	W Poepl, MJ Orola, H Herkner, M Muller...	High prevalence of antibodies against Leptospira spp. in male Austrian adults: a cross-sectional survey. April to June 2009	2013	Euro ...	eurosurveillance.org
4	M Klompas	What can we learn from international ventilator-associated pneumonia rates?*	2012	Critical care medicine	journals.lww.com

4	J Moran-Gilad, T Lazarovitch, M Mentasti, T Harrison...	Humidifier-associated paediatric Legionnaires' disease, Israel, February 2012	2012	Euro Surveill	Citeseer
4	A Rouz�, S Nseir	Continuous control of tracheal cuff pressure for the prevention of ventilator-associated pneumonia in critically ill patients: where is the evidence?	2013	Current opinion in critical care	journals.lww.com
3	S Schrell, A Ziemann, LGC Riesgo...	Local implementation of a syndromic influenza surveillance system using emergency department data in Santander, Spain	2013	Journal of Public ...	Faculty Public Health
3	A Bearth, ME Cousin, M Siegrist	Uninvited guests at the table—a consumer intervention for safe poultry preparation	2013	Journal of Food Safety	Wiley Online Library
3	J Cowden	Food-borne Clostridium botulinum intoxication from mass produced foodstuffs in Europe	2011	Euro Surveill	eurosurveillance.org
3	R Maini, F Naik, TG Harrison, M Mentasti...	Travel-associated Legionnaires' disease in residents from England and Wales travelling to Corfu, Greece, August to October 2011	2012	Euro ...	eurosurveillance.org
3	A Takla, O Wichmann, C Klinc, H Hautmann, T Rieck...	Mumps epidemiology in Germany 2007-11	2013	n.d.	edoc.rki.de
3	C Bernard, F Brossier, W Sougakoff...	A surge of MDR and XDR tuberculosis in France among patients born in the Former Soviet Union	2013	... europ�en sur les ...	eurosurveillance.eu
3	D Pace	Glycoconjugate vaccines	2013	Expert opinion on biological therapy	informahealthcare.com
3	RC Portero, MG Estepa	Enfermedad meningoc�cica en Espa�a. An�lisis de la temporada 2009-2010	2011	Bol Epidemiol Sem	revista.isciii.es
2	A Stefos, NK Gatselis, A Goudelas...	Cutaneous infection caused by Bacillus anthracis in Larissa, Thessaly, Central Greece, July 2012	2012	Zoonotic ...	eurosurveillance.eu
2	A Agodi, F Auxilia, M Barchitta, S Brusaferr�...	Trends, risk factors and outcomes of healthcare-associated infections within the Italian network SPIN-UTI	2013	Journal of Hospital ...	Elsevier
2	S Caini, A Hajdu, A Kurez...	Hospital-acquired infections due to multidrug-resistant organisms in Hungary, 2005-2010	2012	Euro surveillance: bulletin ...	eurosurveillance.eu
2	GH van Ramshorst, MC Vos, D den Hartog...	A Comparative Assessment of Surgeons' Tracking Methods for Surgical Site Infections	2013	Surgical ...	online.liebertpub.com
2	G Wewalka, D Schmid, TG Harrison...	Dual infections with different Legionella strains	2014	Clinical Microbiology ...	Wiley Online Library
2	A Schielke, RM Bettina, K Stark	Epidemiology of campylobacteriosis in Germany—insights from 10 years of surveillance	2014	BMC infectious diseases	biomedcentral.com
2	ID Pavlopoulou, KA Michail, E Samoli, G Tsiftis...	Immunization coverage and predictive factors for complete and age-appropriate vaccination among preschoolers in Athens, Greece: a cross-sectional study	2013	BMC public ...	biomedcentral.com
2	A Skoczynska, A Kuch, I Waiko, A Gołbiewska...	Inwazyjna choroba meningokokowa u chorych poniżej 20. roku życia w Polsce w latach 2009–2011	2012	pediatria polska	Elsevier

1	A Stefos, NK Gatselis, A Goudelas, M Mpakarosi...	Cutaneous infection caused by Bacillus anthracis in Larissa, Thessaly, Central Greece, July 2012 Travel-associated Legionnaires' disease in residents from ...	0	eurosurveillance.org	n.d.
1	D Blum-Menezes, I Deliberalli...	Listeriosis in the far South of Brazil: neglected infection?	2013	Revista da Sociedade ...	SciELO Brasil
1	K Mertens, I Morales, B Catry	Infections acquired in intensive care units: results of national surveillance in Belgium, 1997–2010	2013	Journal of Hospital Infection	Elsevier
1	AP Watt, M Brown, M Pathiraja...	The lack of routine surveillance of Parvovirus B19 infection in pregnancy prevents an accurate understanding of this regular cause of fetal loss and the risks posed by ...	2013	Journal of medical ...	Soc General Microbiol
1	M Liik, L Puksa, SM Lüüs, S Haldre...	Fulminant inflammatory neuropathy mimicking cerebral death	2012	BMJ case reports	casereports.bmj.com
1	A Skoczyńska, I Waško, A Kuch, M Kadłubowski...	A decade of invasive meningococcal disease surveillance in Poland	2013	PloS one	dx.plos.org
1	K Gravningen, GS Simonsen, AS Furberg...	Factors associated with Chlamydia trachomatis testing in a high school based screening and previously in clinical practice: a cross-sectional study in Norway	2013	BMC infectious ...	biomedcentral.com
1	VS Thors, RD Marlow, A Finn	Current developments and trends in childhood immunization	2013	Paediatrics and Child Health	Elsevier
1	H Laurichesse, U Zimmermann, F Galtier...	Immunogenicity and safety results from a randomized multicenter trial comparing a Tdap-IPV vaccine (REPEVAX®) and a tetanus monovalent vaccine in ...	2012	Human vaccines & ...	ncbi.nlm.nih.gov
1	B Lassen, T Jarvis, E Mägi	Gastrointestinal parasites of sheep on Estonian islands.	2013	Agraarteadus	agrt.emu.ee
1	F Dewavrin, F Zerimech, A Boyer, P Maboudou...	Accuracy of Alpha Amylase in Diagnosing Microaspiration in Intubated Critically-Ill Patients	2014	PloS one	dx.plos.org
1	AS Valenzuela, N Benomar, H Abriouel...	Biocide and copper tolerance in enterococci from different sources	2013	Journal of Food ...	ingentaconnect.com
1	M Hasegawa, E Iwabuchi, S Yamamoto...	Prevalence and characteristics of Listeria monocytogenes in bovine colostrum in Japan	2013	Journal of Food ...	ingentaconnect.com
1	V Vaillant, H De Valk, C Saura	Systèmes de surveillance des maladies d'origine alimentaire: sources, méthodes, apports, limites	2012	Santé animale-alimentation	sbssa.ac-montpellier.fr
1	R Cano Portero, M Garrido Estepa	Enfermedad meningocócica en España. Análisis de la temporada 2009-2010	2012	Boletín epidemiológico semanal	revistas.isciii.es
1	L Bäckström, E Larsson Bond	Omvårdnadsåtgärder som har betydelse för spridningen av antibiotikaresistenta bakterier i patientnära arbete	2013	n.d.	diva-portal.org
0	R Maini, F Naik, TG Harrison, M Mentasti, G Spala...	Cutaneous infection caused by Bacillus anthracis in Larissa, Thessaly, Central Greece, July 2012 Travel-associated Legionnaires' disease in residents from ...	0	eurosurveillance.org	n.d.

0	C Carvalho, HL Thomas, K Balogun, R Tedder...	Another possible food-borne outbreak of hepatitis A in the Netherlands indicated by two closely related molecular sequences, July to October 2011	0	eurosurveillance.org	n.d.
0	C Sullivan, J McNeish, A Mullings...	Surgical site infection surveillance: a Scottish perspective (2003–2010)	2012	Journal of Infection ...	bji.sagepub.com
0	IF Kretzer, A do Livramento, J da Cunha, S Gonçalves...	Hepatitis C worldwide and in Brazil: Silent Epidemic-Data on disease including incidence, transmission, prevention and treatment.	0	downloads.hindawi.com	n.d.
0	M Romanowska, I Stefańska...	Influenza and Influenza-Like Illnesses in Poland in the Epidemic Season 2010/2011 According to the SENTINEL Influenza Surveillance System	2013	Polish journal of ...	pjm.microbiology.pl
0	V Thors	Pertussis: more boosters needed?	2012	Prescriber	Wiley Online Library
0	L Mughini-Gras, C Graziani, F Biorci, A Pavan...	Wellness centres: an important but overlooked source of Legionnaires' disease. Eight years of source investigation in the Netherlands, 1 August 2002 to 1 ...	0	eurosurveillance.org	n.d.
0	T CHIȚĂ, D MUNTEAN, L BADIȚOIU, B TIMAR...	IDENTIFICATION OF THE ANTIBIOTIC RESISTANCE PHENOTYPES OF ESCHERICHIA COLI STRAINS ISOLATED IN THE URINE SPECIMENS OF DIABETIC ...	0	EDITORIAL ...	revista_fiziologia.umft.ro
0	W Rymer, B Szetela, A Szymczak	Acute infection with HIV-1 in a male patient with primary and secondary syphilis—Diagnostic problems	2012	HIV & AIDS Review	Elsevier
0	MM Fitzgibbon, N Gibbons, E Roycroft, S Jackson...	Use of Gamma-interferon assays in low-and medium-prevalence countries in Europe: a consensus statement of a Wolfheze Workshop organised by KNCV/ ...	0	eurosurveillance.org	n.d.
0	SE Majowicz, E Scallan, A Jones- Bitton...	Global Incidence of Human Shiga Toxin–Producing Escherichia coli Infections and Deaths: A Systematic Review and Knowledge Synthesis	2014	Foodborne ...	online.liebertpub.com
0	P Durando, SN Faust, M Fletcher...	Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults	2013	Clinical Microbiology ...	Wiley Online Library
0	W Poepl, MJ Orola, H Herkner, M Müller, S Tobudic...	Emergence of a new recombinant Sydney 2012 norovirus variant in Denmark, 26 December 2012 to 22 March 2013 High prevalence of antibodies against ...	0	eurosurveillance.org	n.d.
0	KG Snedeker, C Sikora	Q Fever in Alberta, Canada: 1998–2011	2014	Zoonoses and public health	Wiley Online Library
0	AA Zasada	Nontoxicogenic Highly Pathogenic Clone of Corynebacterium diphtheriae, Poland, 2004–2012	2013	Emerging infectious diseases	ncbi.nlm.nih.gov
0	B Tresó, M Takacs, A Dencs, M Dudas...	Molecular epidemiology of hepatitis C virus genotypes and subtypes among injecting drug users in Hungary.	2013	... Européen sur les ...	eurosurveillance.org
0	B Lassen, M Ståhl, HL Enemark	Cryptosporidiosis-an occupational risk and a disregarded disease in Estonia	2014	Acta Veterinaria Scandinavica	actavetscand.com
0	G Makrutzki, K Riehn, A Hamedy...	Detecting< i> Trichinella</i> infections using inverse microscopy and an improved larval counting technique	2013	Journal of ...	Cambridge Univ Press
0	P English	Vaccination against meningitis B: is it worth it?	2013	Drugs in context	ncbi.nlm.nih.gov
0	H Hosseinzadeh, A Dadich, C Bourne...	Clinician resources to improve evidence–based sexual healthcare: Does content and design matter?	2014	International Journal of ...	Inderscience

0	A Kouatchet, M Eveillard	Staphylococcus aureus résistant à la méticilline en réanimation	2012	Réanimation	Springer
0	G Gonçalves, E Gouveia, L Prasad	The response of a local health authority to reported cases of salmonellosis in a Portuguese municipality, 2007 to 2011	2014	BMC research notes	biomedcentral.com
0	H Enemark, M Ståhl, B Lassen	Cryptosporidiosis-an occupational risk and a disregarded zoonosis in Estonia	2014	Acta Veterinaria Scandinavica (Online)	orbit.dtu.dk
0	N Low, S Redmond, A Uusküla...	Screening for genital chlamydia infection	2013	The Cochrane ...	Wiley Online Library
0	W Feleszko, M Rusczyński, BM Zalewski	Non-specific immune stimulation in respiratory tract infections. Separating the wheat from the chaff	2014	Paediatric respiratory reviews	Elsevier
0	EA Maged	Q Fever: A Re-Emerging Disease?	2012	Journal of Veterinary Science & Technology	omicsonline.org
0	HM Crane, S Dhanireddy, HN Kim...	Hepatitis A vaccination among human immuno-deficiency virus (HIV)-infected adults: Current evidence and unanswered questions	2012	Journal of AIDS and ...	academicjournals.org
0	KL Pabilonia, KJ Cadmus, TM Lingus...	Environmental Salmonella in Agricultural Fair Poultry Exhibits in Colorado	2014	Zoonoses and public ...	Wiley Online Library
0	KM Gravningen	Genital Chlamydia trachomatis infections among adolescents in a high-incidence area in Norway: genotypes, prevalence, early sexual behaviour and testing patterns ...	2013	n.d.	munin.uit.no
0	A Martínez, N Torner, S Broner...	Norovirus: A Growing Cause of Gastroenteritis in Catalonia (Spain)?	2013	Journal of Food ...	ingentaconnect.com
0	ZD McCormic, MN Balihe, KA Havas	MSMR	2013	n.d.	phc.amedd.army.mil
0	A Rouzé, A Cottreau, S Nseir	CURRENT OPINION Chronic obstructive pulmonary disease and the risk for ventilator-associated pneumonia	2014	Curr Opin Crit Care	pdfs.journals.lww.com
0	MA Novo	Los casos	0	vacunas.org	n.d.
0	S Huhulescu	Nationale Referenzzentrale für Listeriose Jahresbericht 2013	0	bmg.gv.at	n.d.
0	C Stănescu, D Muntean, E Hogeia, M Licker...	IDENTIFICATION OF ANTIBIOTIC RESISTANCE PHENOTYPES IN ESCHERICHIA COLI ISOLATES FROM URINARY TRACT INFECTIONS	0	revistaigiena.umft.ro	n.d.
0	LM Gras	EPIDEMIOLOGIA DELLE GASTROENTERITI ACUTE A EZIOLOGIA INFETTIVA IN ITALIA: LE ESPERIENZE DELLE REGIONI LOMBARDIA E PIEMONTE, 1992- ...	0	ISTITUTO SUPERIORE DI SANITÀ	alleanzacontroilcancro.it
0	MC Paty	Expansion des arboviroses et gestion du risque transfusionnel: exemple des virus West Nile, de la dengue et du chikungunya	2013	Transfusion clinique et biologique	Elsevier
0	I Losada-López, M García-Gasalla, R Taberner...	Tuberculosis cutánea en una zona de Mallorca (2003-2011)	2012	Revista Clínica ...	Elsevier
0	S Huhulescu	Nationale Referenzzentrale für Listeriose	0	bmg.gv.at	n.d.
0	T Hald	EFSA Panel on Biological Hazards (BIOHAZ) and EFSA Panel on Contaminants in the Food Chain (CONTAM); Scientific Opinion on the minimum hygiene ...	2012	n.d.	orbit.dtu.dk

0	MJ Struelens, S Brisse, BA Lindstedt, M Torpdahl...	Vol. 18 Weekly issue 04 24 January 2013	0	Citeseer	n.d.
0	M Ejov	Автор: Henk van den Berg Raman Velayudhan	2013	n.d.	euro.who.int
0	S Høye	Delayed prescribing—a feasible strategy to lower antibiotic use for respiratory tract infections in primary care?	2013	n.d.	duo.uio.no
0	J Jerlström-Hultqvist	Hidden Diversity Revealed: Genomic, Transcriptomic and Functional Studies of Diplomonads	2012	n.d.	diva-portal.org
0	I Buezo Reina	Anàlisi de tres estratègies de detecció de la infecció oculta pel virus de l'hepatitis C l'Atenció Primària	2013	n.d.	recercat.net
0	ALA PRIMÀRIA	ANÀLISI DE TRES ESTRATÈGIES DE DETECCIÓ DE LA INFECCIÓ OCULTA PEL VIRUS DE L'HEPATITIS C	0	ddd.uab.cat	n.d.
0	P de Programa, R de Vacunaciones	Vacuna frente a enfermedad meningocócica invasora por serogrupo B y su posible utilización en salud pública	0	meps.es	n.d.
0	LP Fernandes	Transmissão de Salmonella Typhimurium monofásica após o nascimento em suínos	2012	n.d.	repository.utl.pt
0	I Velicko, M Unemo	Real-time laboratory surveillance of sexually-transmissible infections in Marseille University hospitals reveals rise of gonorrhoea, syphilis and human ...	0	eurosurveillance.org	n.d.
0	M Romanowska, I Stefańska...	Influenza and Influenza-Like Illnesses in Poland in the Epidemic Season 2010/2011 According to the SENTINEL Influenza Surveillance System	2013	Polish journal of ...	pjm.microbiology.pl
0	IF Kretzer, A do Livramento, J da Cunha, S Gonçalves...	Hepatitis C worldwide and in Brazil: Silent Epidemic—Data on disease including incidence, transmission, prevention and treatment.	0	downloads.hindawi.com	n.d.
0	HM Húngaro, VO Alvarenga, WEL Peña...	Hearts of palms preserves and botulism in Brazil: An overview of outbreaks, causes and risk management strategies	2013	Trends in Food Science & ...	Elsevier
0	P Grohs, I Podglajen, E Guerot...	Assessment of five screening strategies for optimal detection of carriers of third-generation cephalosporin-resistant Enterobacteriaceae in intensive care units using ...	2014	Clinical Microbiology ...	Wiley Online Library
0	H Hosseinzadeh, A Dadich, C Bourne...	Clinician resources to improve evidence-based sexual healthcare: Does content and design matter?	2014	International Journal of ...	Inderscience
0	P Smeti, A Pavli, P Katerelos...	Typhoid vaccination for international travelers from Greece visiting developing countries	2014	Journal of travel ...	Wiley Online Library
0	G Makrutzki, K Riehn, A Hamedy...	Detecting< i> Trichinella</i> infections using inverse microscopy and an improved larval counting technique	2013	Journal of ...	Cambridge Univ Press
0	W Feleszko, M Ruszczyński, BM Zalewski	Non-specific immune stimulation in respiratory tract infections. Separating the wheat from the chaff	2014	Paediatric respiratory reviews	Elsevier
0	N Low, S Redmond, A Uusküla...	Screening for genital chlamydia infection	2013	The Cochrane ...	Wiley Online Library
0	KL Pablonia, KJ Cadmus, TM Lingus...	Environmental Salmonella in Agricultural Fair Poultry Exhibits in Colorado	2014	Zoonoses and public ...	Wiley Online Library
0	EA Maged	Q Fever: A Re-Emerging Disease?	2012	Journal of Veterinary Science & Technology	omicsonline.org

0	ZD McCormic, MN Balihe, KA Havas	MSMR	2013	n.d.	phc.amedd.army.mil
0	P Lasch, C Fleige, M Stämmeler, F Layer...	Insufficient discriminatory power of MALDI-TOF mass spectrometry for typing of <i>Enterococcus faecium</i> and <i>Staphylococcus aureus</i> isolates	2014	Journal of ...	Elsevier
0	S Huhulescu	Nationale Referenzzentrale für Listeriose Jahresbericht 2013	0	bmg.gv.at	n.d.
0	MA Novo	Los casos	0	vacunas.org	n.d.
0	I Losada-López, M García-Gasalla, R Taberner...	Tuberculosis cutánea en una zona de Mallorca (2003-2011)	2012	Revista Clínica ...	Elsevier
0	S Huhulescu	Nationale Referenzzentrale für Listeriose	0	bmg.gv.at	n.d.
0	C Stănescu, D Muntean, E Hoge, M Licker...	IDENTIFICATION OF ANTIBIOTIC RESISTANCE PHENOTYPES IN ESCHERICHIA COLI ISOLATES FROM URINARY TRACT INFECTIONS	0	revistaigiena.umft.ro	n.d.
0	HM Crane, S Dhanireddy, HN Kim...	Hepatitis A vaccination among human immuno-deficiency virus (HIV)-infected adults: Current evidence and unanswered questions	2012	Journal of AIDS and ...	academicjournals.org
0	LM Gras	EPIDEMIOLOGIA DELLE GASTROENTERITI ACUTE A EZIOLOGIA INFETTIVA IN ITALIA: LE ESPERIENZE DELLE REGIONI LOMBARDIA E PIEMONTE, 1992- ...	0	ISTITUTO SUPERIORE DI SANITÀ	alleanzacontroilcancro.it
0	KM Gravningen	Genital Chlamydia trachomatis infections among adolescents in a high-incidence area in Norway: genotypes, prevalence, early sexual behaviour and testing patterns ...	2013	n.d.	munin.uit.no
0	A Martínez, N Torner, S Broner...	Norovirus: A Growing Cause of Gastroenteritis in Catalonia (Spain)?	2013	Journal of Food ...	ingentaconnect.com
0	P Mação, G Januário, S Ferreira...	Doença Invasiva Meningocócica em Cuidados Intensivos Pediátricos	2014	Acta Médica ...	actamedicaportuguesa.com
0	MC Paty	Expansion des arboviroses et gestion du risque transfusionnel: exemple des virus West Nile, de la dengue et du chikungunya	2013	Transfusion clinique et biologique	Elsevier
0	MJ Struelens, S Brisse, BA Lindstedt, M Torpdahl...	Vol. 18 Weekly issue 04 24 January 2013	0	Citeseer	n.d.
0	MS Rini, G D'Urso, M Gatti	Aspetti clinici e medico-legali del primo caso di legionellosi contratta in uno studio odontoiatrico	2013	Dental Cadmos	Elsevier
0	N Anwar	Oxidoreductases and RNA Degradosome Controlling Virulence-Associated Traits of Salmonella enterica serovar Typhimurium	2013	n.d.	publications.ki.se
0	C Klinc, B von Wissmann, W Hautmann, B Liebl...	Auswirkungen des Klimawandels in Bayern: Einfluss auf die Verbreitung von Lyme-Borreliose, Hantavirus-Infektionen und Leishmaniose?	2012	n.d.	lgl.bayern.de
0	M Ejov	Abrop: Henk van den Berg Raman Velayudhan	2013	n.d.	euro.who.int
0	T Hald	EFSA Panel on Biological Hazards (BIOHAZ) and EFSA Panel on Contaminants in the Food Chain (CONTAM); Scientific Opinion on the minimum hygiene ...	2012	n.d.	orbit.dtu.dk

0	A Rouzé, A Cottreau, S Nseir	CURRENT OPINION Chronic obstructive pulmonary disease and the risk for ventilator-associated pneumonia	2014	Curr Opin Crit Care	pdfs.journals.lww.com
0	P de Programa, R de Vacunaciones	Vacuna frente a enfermedad meningocócica invasora por serogrupo B y su posible utilización en salud pública	0	msps.es	n.d.
0	S Høye	Delayed prescribing—a feasible strategy to lower antibiotic use for respiratory tract infections in primary care?	2013	n.d.	duo.uio.no
0	EM Hartmann	Mass Spectrometric and Molecular Analyses of Biological Agents In Environmental Compartments	2012	n.d.	repository.asu.edu
0	LP Fernandes	Transmissão de Salmonella Typhimurium monofásica após o nascimento em suínos	2012	n.d.	repository.utl.pt
0	I Buezo Reina	Anàlisi de tres estratègies de detecció de la infecció oculta pel virus de l'hepatitis C l'Atenció Primària	2013	n.d.	recercat.net
0	ALA PRIMÀRIA	ANÀLISI DE TRES ESTRATÈGIES DE DETECCIÓ DE LA INFECCIÓ OCULTA PEL VIRUS DE L'HEPATITIS C	0	ddd.uab.cat	n.d.
0	J Jerlström-Hultqvist	Hidden Diversity Revealed: Genomic, Transcriptomic and Functional Studies of Diplomonads	2012	n.d.	diva-portal.org

4. European Centre for Disease Prevention and Control. Annual Epidemiological Report 2012. Reporting on 2010 surveillance data and 2011 epidemic intelligence data. Stockholm: ECDC; 2013

Total nr. of papers: 52

H-index: 3

Cites	Authors	Title	Year	Source	Publisher
5	RZ Jafri, A Ali, NE Messonnier, C Tevi-Benissan...	Global epidemiology of invasive meningococcal	2013	n.d.	biomedcentral.com
4	M Gabriel, P Emmerich, C Frank, M Fiedler...	Increase in West Nile virus infections imported to Germany in 2012	2013	Journal of Clinical ...	Elsevier
3	WHB Demczuk, I Martin, A Griffith...	Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010–2012	2013	Canadian journal of ...	NRC Research Press
2	HL Nielsen, J Engberg, T Ejlertsen...	Clinical manifestations of Campylobacter concisus infection in children	2013	The Pediatric infectious ...	journals.lww.com
2	P Jaros, AL Cookson, DM Campbell...	A prospective case--control and molecular epidemiological study of human cases of Shiga toxin-producing Escherichia coli in New Zealand	2013	BMC infectious ...	biomedcentral.com
1	K Zakikhany, S Neal, A Efstratiou	Emergence and molecular characterisation of non-toxigenic tox gene-bearing Corynebacterium diphtheriae biovar mitis in the United Kingdom, 2003-2012.	2014	Euro Surveill	eurosurveillance.org
1	J Dupouey, B Faucher, S Edouard, H Richet...	Human leptospirosis: An emerging risk in Europe?	2014	... and infectious diseases	Elsevier

1	J Moran-Gilad, M Mentasti...	Molecular epidemiology of Legionnaires' disease in Israel	2013	Clinical Microbiology ...	Wiley Online Library
1	L Petrone, G Cuzzi, L Colace, GM Ettorre...	Cystic echinococcosis in a single tertiary care center in Rome, Italy	2013	BioMed research ...	hindawi.com
1	A Renvoisé, D Decré, R Amarsy-Guerle...	Evaluation of the β Lacta test, a rapid test detecting resistance to third-generation cephalosporins in clinical strains of Enterobacteriaceae	2013	Journal of clinical ...	Am Soc Microbiol
1	RM Johnson, MS Kerr, JE Slaven	An atypical CD8 T-cell response to Chlamydia muridarum genital tract infections includes T cells that produce interleukin-13	2014	Immunology	Wiley Online Library
0	M Edelstein, R Rimhanen-Finne, L Vold	Disease background information	2013	n.d.	usl3.toscana.it
0	K Zakikhany, S Neal, A Efstratiou	Schistosoma haematobium infections acquired in Corsica, France, August 2013 Uptake and impact of a new live attenuated influenza vaccine programme in ...	0	eurosurveillance.org	n.d.
0	M Weinberger, L Lerner, L Valinsky...	Increased Incidence of Campylobacter spp. Infection and High Rates among Children, Israel	2013	Emerging infectious ...	ncbi.nlm.nih.gov
0	R Fears, V ter Meulen	What do we need to do to tackle antimicrobial resistance?	2014	The Lancet Global Health	thelancet.com
0	A Würz, ÜK Nurm, K Ekdahl	Enhancing the Role of Health Communication in the Prevention of Infectious Diseases	2013	Journal of health communication	Taylor & Francis
0	FU Kryeziu, SA Abdushi, VX Kryeziu...	Retrospective evaluation of Humane brucellosis in the region of Prizren	2013	Scientific Journal of ...	sjournals.com
0	LJ Robertson	Introduction to Cryptosporidium: The Parasite and the Disease	2014	Cryptosporidium as a Foodborne Pathogen	Springer
0	T Mayerhöfer, C Krafft, U Neugebauer, J Popp	Moving Raman Spectroscopy into the Clinic	0	photonics.com	n.d.
0	S Abrams, P Beutels, N Hens	Assessing mumps outbreak risk in highly vaccinated populations using spatial seroprevalence data	2014	American journal of epidemiology	Oxford Univ Press
0	RO ASSESSMENT	Update: Outbreak of hepatitis A virus infection in Italy and Ireland	2013	n.d.	vzbb.sk
0	P Durando, SN Faust, M Fletcher...	Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults	2013	Clinical Microbiology ...	Wiley Online Library
0	KW Larssen, K Bergh, BT Heier, L Vold...	All-time high tularaemia incidence in Norway in 2011: report from the national surveillance	2014	European Journal of ...	Springer
0	JM Rijks, M Kik, MG Koene...	Tularaemia in a brown hare (Lepus europaeus) in 2013: first case in the Netherlands in 60 years	2013	... Européen sur les ...	eurosurveillance.org
0	G De Angelis, MA Cataldo...	Infection control and prevention measures to reduce the spread of vancomycin-resistant enterococci in hospitalized patients: a systematic review and meta-analysis	2014	Journal of ...	Br Soc Antimicrob Chemo
0	P Ay, MA Torunoglu, S Com, Z Çipil, S Mollahaliloğlu...	Trends of hepatitis B notification rates in Turkey, 1990 to 2012	2005	Target	eurosurveillance.org

0	A Filia, A Bella, C von Hunolstein, A Pinto, G Alfarone...	Tetanus in Italy 2001–2010: A continuing threat in older adults	2014	Vaccine	Elsevier
0	TJ Gray, CE Webb	A review of the epidemiological and clinical aspects of West Nile virus	2014	International journal of general medicine	ncbi.nlm.nih.gov
0	RO ASSESSMENT	Outbreak of hepatitis A virus infection in residents and travellers to Italy	2013	n.d.	Citeseer
0	B Guzman Herrador, E Nilsen, KS Cudjoe, L Jensvoll...	A Shigella sonnei outbreak traced to imported basil-The importance of good typing tools and produce traceability systems, Norway, 2011	2013	n.d.	129.242.170.252
0	EL Corbeto, V Gonzalez, R Lugo...	Discordant prevalence of Chlamydia trachomatis in asymptomatic couples screened by two screening approaches	2014	... journal of STD & ...	std.sagepub.com
0	H Theeten, H Nohynek, TMM Coenen	EuSANH workshop “Reasons behind the differences in national vaccination schedules for under-five”, European Public Health pre-conference workshop, Malta, 8 ...	2013	Vaccine	Elsevier
0	HC Cruickshank, JM Jefferies, SC Clarke	Lifestyle risk factors for invasive pneumococcal disease: a systematic review	2014	BMJ open	bmjopen.bmj.com
0	SOF FUNDING	Epidemiology and Clinical Outcomes of Multidrug-Resistant Gram-Negative Bloodstream Infections in a European Tertiary Pediatric Hospital during a 12-Month ...	2014	n.d.	pdfs.journals.lww.com
0	H Harvala, V Wong, P Simmonds, I Johannessen...	Acute viral hepatitis–Should the current screening strategy be modified?	2014	Journal of Clinical ...	Elsevier
0	C Brehony, CL Trotter, ME Ramsay...	Implications of Differential Age Distribution of Disease-Associated Meningococcal Lineages for Vaccine Development	2014	Clinical and Vaccine ...	Am Soc Microbiol
0	N Allocati, M Masulli, MF Alexeyev, C Di Ilio	Escherichia coli in Europe: An Overview	2013	International journal of ...	mdpi.com
0	MC Holtfreter, H Moné, I Müller-Stöver...	Schistosoma haematobium infections acquired in Corsica, France, August 2013	2013	... Europeen sur les ...	eurosurveillance.eu
0	A Spiliopoulou, E Jelastopulu...	In vitro activity of tigecycline and colistin against A. baumannii clinical bloodstream isolates during an 8-year period	2014	Journal of ...	maneyonline.com
0	A Nutman, R Glick, E Temkin, M Hoshen...	A case-control study to identify predictors of 14-day mortality following carbapenem-resistant Acinetobacter baumannii bacteremia	2014	Clinical Microbiology ...	Wiley Online Library
0	A Bearth, ME Cousin, M Siegrist	Investigating novice cooks' behaviour change: Avoiding cross-contamination	2014	Food Control	Elsevier
0	M Marks, A Gupta-Wright, JF Doherty...	Managing malaria in the intensive care unit	2014	British journal of ...	British Jnl Anaesthesia
0	D Panatto, D Amicizia, PL Lai, ML Cristina...	New versus old meningococcal Group B vaccines: How the new ones may benefit infants & toddlers	2013	The Indian journal of ...	ncbi.nlm.nih.gov
0	C Charnock, AL Nordlie, B Hjeltnes	Toxin Production and Antibiotic Resistances in Escherichia coli Isolated from Bathing Areas Along the Coastline of the Oslo Fjord	2014	Current microbiology	Springer

0	E Rodríguez Valín, O Díaz García...	Situación del paludismo en España, 2012.	2013	Boletín epidemiológico ...	revista.isciii.es
0	M Trkov, T Rupel, D Žgur-Bertok, S Trontelj...	Molecular Characterization of Escherichia coli Strains Isolated from Different Food Sources	2014	Food Technology and ...	hrcak.srce.hr
0	M Yanushevych, A Komorowska-Piotrowska...	TULAREMIA CHOROBA ZAPOMNIANA DOŚWIADCZENIA WIASNE	0	medwiekurozwoj.pl	n.d.
0	J Hietalahti	Meningokokki ja uuden polven rokotteet	2014	n.d.	helda.helsinki.fi
0	GR Bernalá, AVL Sagahóna, CGG Tovar...	Virulencia de cepas de Listeria monocytogenes procedentes de cabras y sus derivados	0	tecnicapecuaria.org.mx	n.d.
0	ARS Oliveira	Avaliação do conhecimento dos proprietários de animais sobre a toxoplasmose	2013	n.d.	repository.utl.pt

5. European Centre for Disease Prevention and Control. Assessing the potential impacts of climate change on food-and waterborne diseases in Europe. Stockholm: ECDC;2012.

Total nr. of papers: 4

H-index: 0

Cites	Authors	Title	Year	Source	Publisher
0	T Kistemann, A Rechenburg, C Höser, C Schreiber...	Assessing the potential impacts of climate change on food-and waterborne diseases in Europe	2012	n.d.	envia.bl.uk
0	T Hambling	Environmental Health Indicators: development of a tool to assess and monitor the impacts of climate change on human health	2012	n.d.	haifa.esr1.cwp.govt.nz
0	J Otte, D Grace	Human health risks from the human-animal interface in Asia	2012	Asian livestock	results.waterandfood.org
0	D Karthe	Trinkwasserversorgung und-hygiene in Deutschland: Herausforderungen im Kontext sich verändernder Rahmenbedingungen	2006	ndtext!	geo.uni-augsburg.de

6. European Centre for Disease Prevention and Control. Evidence-based methodologies for public health – How to assess the best available evidence when time is limited and there is lack of sound evidence. Stockholm: ECDC;2011.

Total nr. of papers: 10

H-index: 2

Cites	Authors	Title	Year	Source	Publisher
8	PH Voss, EA Rehfuss	Quality appraisal in systematic reviews of public health interventions: an empirical study on the impact of choice of tool on meta-analysis	2013	Journal of epidemiology and community ...	jech.bmj.com
3	J Latham, L Murajda, F Forland...	Capacities, practices and perceptions of evidence-based public health in Europe	2013	Vol. 18 Weekly issue 10 ...	eurosurveillance.eu
1	JP Vogel, AD Oxman, C Glenton...	Policymakers' and other stakeholders' perceptions of key considerations for health system decisions and the presentation of evidence to inform those ...	2013	... Research Policy and ...	biomedcentral.com
1	JR Latham, AP Magiorakos, DL Monnet...	The role and utilisation of public health evaluations in Europe: a case study of national hand hygiene campaigns	2014	BMC public ...	biomedcentral.com
0	LR Salmi, S Leproust, C Helmer...	Assessing fitness to drive in the elderly and those with medical conditions: guidelines should specify methods and evidence	2014	Injury ...	injuryprevention.bmj.com
0	T Harder, A Takla, E Rehfuss...	Evidence-based decision-making in infectious diseases epidemiology, prevention and control: matching research questions to study designs and quality appraisal ...	2014	BMC Medical ...	biomedcentral.com
0	M Cruz, I Mahillo-Fernandez, A Rábano...	Late-in-life surgery associated with Creutzfeldt-Jakob disease: a methodological outline for evidence-based guidance	2013	Emerging themes in ...	Springer
0	NM Cediell-Becerra, G Krause	Evidence-based public health decision-making tools which can also be used for prioritising disease	2013	Revista de ...	Instituto de Salud Publica, Facultad ...
0	ОГ Пузанова	ДОКАЗАТЕЛЬНАЯ ПРОФИЛАКТИКА В ЗДРАВООХРАНЕНИИ: МЕТОДОЛОГИЧЕСКИЕ ОСНОВЫ И ИНФОРМАЦИОННОЕ ОБЕСПЕЧЕНИЕ	2013	... ЗДОРОВЬЯ И ЭКОЛОГИИ PROBLEMS OF HEALTH ...	gsmu.by
0	NM Cediell-Becerra, G Krause	Herramientas para la toma de decisiones en salud pública basadas en la evidencia y priorización de enfermedades	2013	Revista de ...	Universidad Nacional de Colombia

7. European Centre for Disease Prevention and Control. ECDC scientific advice on Seasonal influenza vaccination of children and pregnant women. Stockholm: ECDC; 2012.

Total nr. of papers: 1

H-index: 0

Cites	Authors	Title	Year	Source	Publisher
0	J Mereckiene, S Cotter, A Nicoll, P Lopalco, T Noori...	Seasonal influenza immunisation in Europe. Overview of recommendations and vaccination coverage for three seasons: pre-pandemic (2008/09), pandemic (2009/10 ...	2014	n.d.	edoc.rki.de

8. European Centre for Disease Prevention and Control. Narcolepsy in association with pandemic Influenza vaccination (a multi-country European epidemiological investigation) Stockholm: ECDC; September 2012

Total nr. of papers: 49

H-index: 7

Cites	Authors	Title	Year	Source	Publisher
66	E Miller, N Andrews, L Stelitano, J Stowe...	Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis	2013	BMJ: British Medical ...	bmj.com
42	L Wijnans, C Lecomte, C de Vries, D Weibel...	The incidence of narcolepsy in Europe: before, during, and after the influenza A (H1N1) pdm09 pandemic and vaccination campaigns	2013	Vaccine	Elsevier
18	Y Dauvilliers, I Arnulf, M Lecendreux, CM Charley...	Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France	2013	Brain	Oxford Univ Press
17	F Han, L Lin, J Li, XS Dong, E Mignot	Decreased incidence of childhood narcolepsy 2 years after the 2009 H1N1 winter flu pandemic	2012	Ann Neurol	med.stanford.edu
14	YJ Choe, GR Bae, D Lee	No association between influenza A (H1N1) pdm09 vaccination and narcolepsy in South Korea: an ecological study	2012	Vaccine	Elsevier
8	SV Kothare, M Wiznitzer	Association between H1N1 vaccination and narcolepsy-cataplexy Flu to sleep	2013	Neurology	AAN Enterprises
8	CIS Barker, MD Snape	Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action	2014	The Lancet infectious diseases	Elsevier
7	I Persson, F Granath, J Askling...	Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population-and registry-based cohort study with over 2 ...	2014	Journal of internal ...	Wiley Online Library
7	CB Fox, J Haensler	An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants	2013	n.d.	informahealthcare.com

4	SS Ahmed, PH Schur, NE MacDonald...	Narcolepsy, 2009 A (H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for ...	2014	Journal of autoimmunity	Elsevier
4	O Even-Or, S Samira, R Ellis, E Kedar...	Adjuvanted influenza vaccines	2013	Expert review of ...	Informa UK, Ltd. London
3	E Mansnerus	Using model-based evidence in the governance of pandemics	2013	Sociology of health & illness	Wiley Online Library
1	L Wijnans, D Weibel, M Sturkenboom	Adjuvanted versus nonadjuvanted influenza vaccines in young children: comparing results from recent clinical trials	2013	Clinical Investigation	Future Science
0	D O'Flanagan, AS Barret, M Foley, S Cotter, C Bonner...	Emergence of Escherichia coli encoding Shiga toxin 2f in human Shiga toxin-producing E. coli (STEC) infections in the Netherlands, January 2008 to ...	0	eurosurveillance.org	n.d.
0	AM Winstone, L Stellitano, C Verity...	Clinical features of narcolepsy in children vaccinated with AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine in England	2014	... Medicine & Child ...	Wiley Online Library
0	D O'Flanagan, AS Barret, M Foley, S Cotter...	Investigation of an association between onset of narcolepsy and vaccination with pandemic influenza vaccine, Ireland April 2009-December 2010	2009	vaccine	eurosurveillance.org
0	O Launay, X Duval, S Fitoussi, W Jilg...	Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted ...	2013	BMC infectious ...	biomedcentral.com
0	T Nolan, P Izurieta, BW Lee, PC Chan...	Heterologous Prime-boost Vaccination Using an H5N1-AS03-adjuvanted Influenza Vaccine in Infants and Children Under 3 Years of Age	2014	Journal of Infectious ...	jid.oxfordjournals.org
0	S Kumar, HH Sagili	Etiopathogenesis and Neurobiology of Narcolepsy: A review	2014	Journal of clinical and diagnostic research: ...	ncbi.nlm.nih.gov
0	JH Deng, WH Cai, F Jin	A novel oil-in-water emulsion as a potential adjuvant for influenza vaccine: Development, characterization, stability and <i>in vivo</i> evaluation	2014	International journal of pharmaceuticals	Elsevier
0	O Flaten	Nordic Health Registers as a Source for Value-Based Evidence	2014	Pharmaceutical Medicine	Springer
0	KE Lafond, JA Englund, JS Tam...	Overview of Influenza Vaccines in Children	2013	Journal of the Pediatric ...	jpids.oxfordjournals.org
0	T Nolan, S Roy-Ghanta, M Montellano...	Relative Efficacy of AS03-adjuvanted Pandemic H1N1 Influenza Vaccine in Children: Results of a Controlled, Randomized Efficacy Trial	2014	Journal of Infectious ...	jid.oxfordjournals.org
0	EJM Mignot	History of narcolepsy at Stanford University	2014	Immunologic research	Springer
0	D Tappe, M Plauth, T Bauer, B Muntau...	A case of autochthonous human Dirofilaria infection, Germany, March 2014	2013	... Europeen sur les ...	eurosurveillance.org
0	VL Wong	Background Paper 6.2 Pandemic Influenza	2013	n.d.	who.int
0	C Moussa	Recent letters	0	Can Med Assoc	n.d.
0	DA Cabrera-Gaytán, E Krug-Llamas...	Influenza: enfermedad que cambia al mundo	2013	Rev Med Inst Mex ...	mediagraphic.com
0	J de Arístegui Fernández	Recomendación de vacunación antigripal (CAV-AEP 2014)	0	cursosaeap.exlibrisediciones.com	n.d.
0	S Sabia, A Singh-Manoux, M Kivimaki	Recent letters	0	Can Med Assoc	n.d.

0	H Butler	Search Results for: ROR	2013	Science Daily	therefusers.com
0	DW Light, J Lexchin, JJ Darrow	Search Results for: lead test	2013	Journal of Law, Medicine and ...	therefusers.com
0	H Pupko	Recent letters	0	Can Med Assoc	n.d.
0	J Papenburg	Recent letters	0	Can Med Assoc	n.d.
0	JB Taller, L Partner	Recent letters	0	Can Med Assoc	n.d.
0	DM Skowronski, DM Patrick	Recent letters	0	Can Med Assoc	n.d.
0	ED Gorham	Recent letters	0	Can Med Assoc	n.d.
0	C Gilruth	Search Results for: 50 cents dose	0	therefusers.com	n.d.
0	M Mangin, CI Recovery	Recent letters	0	Can Med Assoc	n.d.
0	S Loeb, PM Roobol, CH Bangma	Recent letters	0	Can Med Assoc	n.d.
0	M Tonelli	Recent letters	0	Can Med Assoc	n.d.
0	M Killin, S Work	Recent letters	0	Can Med Assoc	n.d.
0	MJ Kadatz, RDM Kadatz, MD Jordanna Kapeluto...	Recent letters	0	Can Med Assoc	n.d.
0	I GRANT-WHYTE	Recent letters	0	Can Med Assoc	n.d.
0	GW BOTA	Recent letters	0	Can Med Assoc	n.d.
0	R Long, D Langlois-Klassen	Recent letters	0	Can Med Assoc	n.d.
0	T Olsson, I Persson, N Feltelius, E Svanborg...	Läkemedelsbehandling vid narkolepsi-bakgrundsdokumentation	0	lakemedelsverket.se	n.d.
0	MÁ Mendoza-Romo...	Causas demográficas y de comorbilidad de la prehipertensión arterial	2013	Rev Med Inst Mex ...	revistamedica.imss.gob.mx
0	C Santuccio, F Trotta, P Felicetti, R Da Cas...	Rapporto sulla sorveglianza postmarketing dei vaccini in Italia Anno 2011	2011	n.d.	regione.lazio.it

9. European Centre for Disease Prevention and Control. The 2009 A(H1N1) pandemic in Europe .Stockholm: ECDC; 2010.

Total nr. of papers: 45

H-index: 9

Cites	Authors	Title	Year	Source	Publisher
41	A Amato-Gauci, P Zucs, R Snacken, BC Ciancio...	Surveillance trends of the 2009 influenza A (H1N1) pandemic in Europe	2011	n.d.	edoc.rki.de
36	I Steffens, R Martin, P Lopalco	Spotlight on measles 2010: measles elimination in Europe—a new commitment to meet the goal by 2015	2010	Euro Surveill	researchgate.net
34	C Savulescu, S Jiménez-Jorge, S de Mateo...	Effectiveness of the 2010/11 seasonal trivalent influenza vaccine in Spain: preliminary results of a case–control study	2011	Editorial team Editorial ...	Citeseer
16	I Devaux, P Kreidl, P Penttinen, M Salminen, P Zucs...	Initial surveillance of 2009 influenza A (H1N1) pandemic in the European Union and European economic area, April–September 2009	2010	n.d.	edoc.rki.de
16	A Nicoll, BC Ciancio, V Lopez Chavarrias...	Influenza-related deaths—available methods for estimating numbers and detecting patterns for seasonal and pandemic influenza in Europe	2012	Euro ...	eurosurveillance.org
14	S Puzelli, M Facchini, A Di Martino, C Fabiani...	Evaluation of the antiviral drug susceptibility of influenza viruses in Italy from 2004/05 to 2009/10 epidemics and from the recent 2009 pandemic	2011	Antiviral research	Elsevier
14	JG Breman	Resistance to artemisinin-based combination therapy	2012	The Lancet infectious diseases	Elsevier
13	JM Luteijn, H Dolk, GJ Marnoch	Differences in pandemic influenza vaccination policies for pregnant women in Europe	2011	BMC public health	biomedcentral.com
12	T del Rosal, F Baquero-Artigao, C Calvo...	Pandemic H1N1 influenza-associated hospitalizations in children in Madrid, Spain	2011	Influenza and other ...	Wiley Online Library
8	G Thomson, A Nicoll	Responding to new severe diseases—the case for routine hospital surveillance and clinical networks in Europe	2010	Euro Surveill	eurosurveillance.org
5	V Sypsa, S Bonovas, S Tsiodras, A Baka, P Efstathiou...	Estimating the disease burden of 2009 pandemic influenza A (H1N1) from surveillance and household surveys in Greece	2011	PloS one	dx.plos.org
5	M Romanowska, I Stefanska, S Donevski...	Infections with A (H1N1) 2009 influenza virus in Poland during the last pandemic: experience of the National Influenza Center	2013	... -The Molecular Approach	Springer
4	DL Monnet, M Sprenger	Hand hygiene practices in healthcare: measure and improve	2012	Euro. Surveill	eurosurveillance.eu
3	I Team	Start of the influenza season 2010-11 in Europe dominated by 2009 pandemic influenza A (H1N1) virus	2010	Euro Surveill	eurosurveillance.eu
3	BRG Herrador, P Aavitsland, B Feiring...	Usefulness of health registries when estimating vaccine effectiveness during the influenza A (H1N1) pdm09 pandemic in Norway	2012	BMC infectious ...	biomedcentral.com

3	J Zhao, Y Li, L Pan, N Zhu, H Ni, G Xu, Y Jiang, X Huo...	Genetic characteristics of 2009 pandemic H1N1 influenza A viruses isolated from Mainland China	2011	Virologica Sinica	Springer
3	P Doyle, J Sixsmith, M Barry, S Mahmood...	Public health stakeholders' perceived status of health communication activities for the prevention and control of communicable diseases across the EU and EEA/EFTA ...	2012	European Centre for ...	dspace.stir.ac.uk
2	V Šubelj, K Prosenč, M Sočan	Seroprevalence study of antibodies against influenza A (H1N1) 2009 virus after the second pandemic wave in Slovenia	2012	Wiener klinische Wochenschrift	Springer
2	CR Beck, R Sokal, N Arunachalam...	Neuraminidase inhibitors for influenza: a review and public health perspective in the aftermath of the 2009 pandemic	2013	Influenza and other ...	Wiley Online Library
2	E Brattberg, M Rhinard	Multilevel Governance and Complex Threats: The Case of Pandemic Preparedness in the European Union and the United States	2011	GLOBAL HEALTH	researchgate.net
2	P Loulergue, O Launay	Vaccinations among medical and nursing students: Coverage and opportunities	2014	Vaccine	Elsevier
1	AJ Amato Gauci, P Zucs, R Snacken, B Cianco...	European Centre for Disease Prevention and Control. The 2009 A (H1N1) pandemic in Europe	2010	n.d.	Stockholm: ECDC.[Online version]. ...
1	N Rosenkötter, A Ziemann, LGC Riesgo...	Validity and timeliness of syndromic influenza surveillance during the autumn/winter wave of A (H1N1) influenza 2009: results of emergency medical dispatch, ...	2013	BMC public ...	biomedcentral.com
1	J Pöder, I Lutsar	Clinical and Pathological Findings of Fatal 2009–2010 Pandemic Influenza A (H1N1) Infection in Estonia	2012	Medicina (Kaunas)	medicina.lsmuni.lt
1	P Ranjan, A Kumari, R Das, L Gupta, SK Singh...	Evaluation of clinical features scoring system as screening tool for influenza A (H1N1) in epidemic situations	2012	Journal of postgraduate ...	Medknow
0	G Thomson, A Nicoll	National surveillance of pandemic influenza A (H1N1) infection-related admissions to intensive care units during the 2009–10 winter peak in Denmark: two ...	0	eurosurveillance.org	n.d.
0	W Hass, RKI Germany, R Pebody, N Phin, J Watson...	ECDC Threat Assessment	0	84.206.43.26	n.d.
0	EC Sánchez, A Holmes	Public behaviour and the response to pandemic influenza	2012	The Lancet infectious diseases	Elsevier
0	S Duroña, A Mayeta, F Lienharda, R Haus-Cheymola...	The French Military influenza surveillance system (MISS): overview of epidemiological and virological results during four influenza seasons–	2013	Swiss Med Wkly	smw.ch
0	J Mladenović, R Čekanac, S Lazić...	Pandemic influenza H1N1 outbreak in the Military School	2013	Vojnosanitetski ...	scindeks.ceon.rs
0	S Cauchemez, MD Van Kerkhove...	School closures during the 2009 influenza pandemic: national and local experiences	2014	BMC infectious ...	biomedcentral.com
0	E Kuchar, A Nitsch-Osuch, T Karpinska...	Pandemic influenza in the 2009/2010 season in central Poland: The surveillance study of laboratory confirmed cases	2013	Respiratory physiology ...	Elsevier
0	G Marnoch, M Luteijn, H Dolk	Differences in pandemic influenza vaccination policies for pregnant women in Europe	2011	BMC Public Health	works.bepress.com
0	SM Belderok, GF Rimmelzwaan...	Effect of Travel on Influenza Epidemiology	2013	Emerging infectious ...	ncbi.nlm.nih.gov

0	T Solbrig	An ecological study on influenza vaccination coverage and mortality in Europe	2012	n.d.	edoc.sub.uni-hamburg.de
0	LC JENNINGS, J Van-Tam, C Sellwood	Case study 3: New Zealand.	2012	Pandemic influenza	books.google.com
0	C Klemm, E Das, T Hartmann	Swine flu and hype: a systematic review of media dramatization of the H1N1 influenza pandemic	2014	Journal of Risk Research	Taylor & Francis
0	S Carbonara, G Bruno, G Di Ciaula, AD Pantaleo...	Limiting Severe Outcomes and Impact on Intensive Care Units of Moderate-Intermediate 2009 Pandemic Influenza: Role of Infectious Diseases Units	2012	PloS one	dx.plos.org
0	G Nylén, A Linde, Å Örtqvist	Titel: Förenklat och missvisande om influensapandemin 2009 (jämte) Replik: Skjuter över målet, igen! av Staffan Sylvan, Brith Christenson 2012 nr 43 sid ...	0	ltarkiv.lakartidningen.se	n.d.
0	AL Lecapitaine, J Barthe, G Audran, N Gauffier...	Pandémie grippale à virus hautement pathogène: étude de faisabilité en cabinet (SIMUGRIP-MG2)	2011	Santé Publique	cairn.info
0	J Félix, L Oletta, AC Carvajal	Red de Sociedades Científicas Médicas de Venezuela	0	rscmv.org.ve	n.d.
0	G Nylén, A Linde, Å Örtqvist	Förenklat och missvisande om influensapandemin 2009	0	lakartidningen.se	n.d.
0	S Lundberg	Att kommunicera med allmänheten i händelse av en pandemi: En fallstudie av ett landsting	2013	n.d.	diva-portal.org
0	BJA Petrovská	Působení Evropské unie ve zdravotní politice se zaměřením na reakci v době pandemie	2011	n.d.	is.muni.cz
0	BT Knířová	Dva mediální obrazy konstrukce rizika prasečí chřipky (The Times vs. MF Dnes)	2011	n.d.	is.muni.cz

10. Amato-Gauci A, Zucs P, Snacken R, Ciancio B, Lopez V, Broberg E, Penttinen P, Nicoll A, on behalf of the European Influenza Surveillance Network (EISN). Surveillance trends of the 2009 influenza A(H1N1) pandemic in Europe. Euro Surveill. 2011;16(26):pii=19903. Available online: <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19903>

Total nr. of papers: 140

H-index: 9

Cites	Authors	Title	Year	Source	Publisher
49	F Odaira, H Takahashi, T Toyokawa...	Assessment of secondary attack rate and effectiveness of antiviral prophylaxis among household contacts in an influenza A (H1N1) v outbreak in Kobe, Japan ...	2009	Euro ...	eurosurveillance.org
35	P Follin, A Lindqvist, K Nyström, M Lindh	A variety of respiratory viruses found in symptomatic travellers returning from countries with ongoing spread of the new influenza A (H1N1) v virus strain	2009	Euro Surveill	eurosurveillance.org

23	V Sypsa, I Pavlopoulou, A Hatzakis	Use of an inactivated vaccine in mitigating pandemic influenza A (H1N1) spread: a modelling study to assess the impact of vaccination timing and ...	2009	Euro Surveill	eurosurveillance.org
16	A Nicoll, BC Ciancio, V Lopez Chavarrias...	Influenza-related deaths—available methods for estimating numbers and detecting patterns for seasonal and pandemic influenza in Europe	2012	Euro ...	eurosurveillance.org
13	JC Rahamat-Langendoen, ED Tutuhahunewa...	Influenza in the immediate post-pandemic era: a comparison with seasonal and pandemic influenza in hospitalized patients	2012	Journal of Clinical ...	Elsevier
11	YC Lo, WC Chen, WT Huang, YC Lin, MC Liu...	Surveillance of avian influenza A (H7N9) virus infection in humans and detection of the first imported human case in Taiwan, 3 April to 10 May 2013	2013	Euro ...	eurosurveillance.eu
9	J Hippisley-Cox, S Smith, G Smith, A Porter...	QFLU: new influenza monitoring in UK primary care to support pandemic influenza planning	2006	Euro ...	eurosurveillance.org
9	SJ Carlson, CB Dalton, DN Durrheim...	Online Flutracking survey of influenza-like illness during pandemic (H1N1) 2009, Australia	2010	Emerging infectious ...	ncbi.nlm.nih.gov
9	KA Grant, LJ Franklin, M Kaczmarek, AC Hurt...	Continued dominance of pandemic A (H1N1) 2009 influenza in Victoria, Australia in 2010	2011	... and Response Journal	wpro.who.int
7	MG Plagianos, WY Wu, C McCullough...	Syndromic surveillance during pandemic (H1N1) 2009 outbreak, New York, New York, USA	2011	Emerging infectious ...	ncbi.nlm.nih.gov
7	A Jacks, J Ollgren, T Ziegler, O Lyytikäinen	Frequency of oseltamivir resistance in Sydney, during the Newcastle outbreak of community transmitted oseltamivir-resistant influenza A (H1N1) pdm09 virus, ...	2012	n.d.	eurosurveillance.org
7	JW Rhim, EJ Go, KY Lee, YS Youn, MS Kim...	Pandemic 2009 H1N1 virus infection in children and adults: A cohort study at a single hospital throughout the epidemic	2012	Int Arch ...	biomedcentral.com
5	K Gache, A Mayet, G Manet, C Ligier...	The 2009 A (H1N1) influenza pandemic in the French Armed Forces: evaluation of three surveillance systems	2013	... European Journal of ...	Oxford Univ Press
5	A Jacks, J Ollgren, T Ziegler, O Lyytikäinen	Influenza-associated hospitalisations in Finland from 1996 to 2010: unexpected age-specific burden during the influenza A (H1N1) pdm09 pandemic from 2009 ...	2012	Euro Surveill	eurosurveillance.eu
5	M Lajous, L Danon, R López-Ridaura...	Mobile messaging as surveillance tool during pandemic (H1N1) 2009, Mexico	2010	Emerging infectious ...	ncbi.nlm.nih.gov
5	MJ Hale, RS Hoskins, MG Baker	Screening for Influenza A (H1N1) pdm09, Auckland International Airport, New Zealand	2012	Emerging infectious diseases	ncbi.nlm.nih.gov
5	C Schenk, D Plachouras, N Danielsson...	Outbreak with a novel avian influenza A (H7N9) virus in China-scenarios and triggers for assessing risks and planning responses in the European Union, May ...	2013	Emergence of a novel ...	tcmiffection.com
5	A Bradley-Stewart, L Jolly, W Adamson...	Cytokine responses in patients with mild or severe influenza A (H1N1) pdm09	2013	Journal of Clinical ...	Elsevier
4	HA Kelly, BJ Cowling	Insights from Europe related to pandemic influenza A (H1N1) 2009 have international relevance	2011	Editorial team Editorial board	Citeseer
4	TC Rodwell, AM Robertson, N Aguirre...	Pandemic (H1N1) 2009 surveillance in marginalized populations, Tijuana, Mexico	2010	Emerging infectious ...	ncbi.nlm.nih.gov
4	M Masiá, S Padilla, P Antequera...	Predictors of pneumococcal co-infection for patients with pandemic (H1N1) 2009	2011	Emerging infectious ...	ncbi.nlm.nih.gov
3	R Gasparini, P Bonanni, D Amicizia...	Influenza epidemiology in Italy two years after the 2009–2010 pandemic: Need to improve vaccination coverage	2013	Human vaccines & ...	ncbi.nlm.nih.gov

3	A Larrauri Cámara, S Jiménez-Jorge...	Epidemiology of the 2009 influenza pandemic in Spain. The Spanish Influenza Surveillance System	2012	... y Microbiología Clínica	Elsevier
2	L Filleul, E Brottet, BA Gauzere, A Winer...	Reunion, a sentinel territory for influenza surveillance in Europe	2006	n.d.	eurosurveillance.eu
2	Portuguese Laboratory Network for the Diagnosis of ...	Contribution of the Portuguese Laboratory Network for the Diagnosis of Influenza A (H1N1) pdm09 Infection during the 2009/2010 and 2010/2011 influenza seasons	2012	n.d.	repositorio.insa.pt
2	B Acosta, A Piñón, O Valdés, C Savón...	Rapid diagnosis of pandemic (H1N1) 2009 in Cuba	2012	Emerging infectious ...	ncbi.nlm.nih.gov
2	R Jiménez-García...	Hospitalizations from pandemic influenza [A (H1N1) pdm09] infections among type 1 and 2 diabetes patients in Spain	2013	Influenza and other ...	Wiley Online Library
2	B Nunes, I Natário, M Lucília Carvalho	Nowcasting influenza epidemics using non-homogeneous hidden Markov models	2013	Statistics in medicine	Wiley Online Library
1	B Gröndahl, T Ankermann, P von Bismarck, S Rockahr...	The 2009 pandemic influenza A (H1N1) coincides with changes in the epidemiology of other viral pathogens causing acute respiratory tract infections in children	2014	Infection	Springer
1	N Rosenkötter, A Ziemann, LGC Riesgo...	Validity and timeliness of syndromic influenza surveillance during the autumn/winter wave of A (H1N1) influenza 2009: results of emergency medical dispatch, ...	2013	BMC public ...	biomedcentral.com
1	M Svensson, A Ramelius, AL Nilsson...	Antibodies to Influenza Virus A/H1N1 Hemagglutinin in Type 1 Diabetes Children Diagnosed Before, During and After the SWEDISH A (H1N1) pdm09 Vaccination ...	2014	Scandinavian ...	Wiley Online Library
1	M Obuchi, Y Adachi, T Takizawa, T Sata	Influenza A (H1N1) pdm09 virus and asthma	2013	Frontiers in microbiology	ncbi.nlm.nih.gov
1	J Simpson, M Roberts	Modelling heterogeneous host immune response in a multi-strain system	2012	Journal of theoretical biology	Elsevier
0	BN Archer, C Cohen, D Naidoo, J Thomas, C Makunga...	Pandemic H1N1 influenza lessons from the southern hemisphere Preliminary analysis of the pandemic H1N1 influenza on Réunion Island (Indian Ocean): ...	0	eurosurveillance.org	n.d.
0	C Turbelin, C Pelat, PY Boëlle, D Lévy-Bruhl, F Carrat...	Residual immunity in older people against the influenza A (H1N1)—recent experience in northern Spain Early estimates of 2009 pandemic influenza A (H1N1) ...	0	eurosurveillance.org	n.d.
0	S Manning, T Barry, N Wilson, MG Baker	Update: Follow-up study showing post-pandemic decline in hand sanitiser use, New Zealand, December 2009 School absence data for influenza surveillance ...	0	eurosurveillance.org	n.d.
0	J Giesecke	Adverse drug effects following oseltamivir mass treatment and prophylaxis in a school outbreak of 2009 pandemic influenza A (H1N1) in June 2009, Sheffield, ...	0	eurosurveillance.org	n.d.
0	TM van't Klooster, CC Welders, T Donker, L Isken...	Letter to the editor. Virological analysis of fatal influenza cases in the United Kingdom during the early wave of influenza in winter 2010/11 Pandemic influenza ...	0	eurosurveillance.org	n.d.
0	JE Fielding, N Higgins, JE Gregory, KA Grant...	Pandemic H1N1 influenza lessons from the southern hemisphere Preliminary analysis of the pandemic H1N1 influenza on Réunion Island (Indian Ocean): ...	0	eurosurveillance.org	n.d.

0	A Nicoll, M Sprenger	The end of the pandemic–what will be the pattern of influenza in the 2010-11 European winter and beyond? Ongoing outbreak of aseptic meningitis ...	0	eurosurveillance.org	n.d.
0	C Terregino, R De Nardi, R Nisi, F Cilloni, A Salviato...	Use of an inactivated vaccine in mitigating pandemic influenza A (H1N1) spread: a modelling study to assess the impact of vaccination timing and ...	0	eurosurveillance.org	n.d.
0	M Panning, M Eickmann, O Landt, M Monazahian...	Letter to the editor. Virological analysis of fatal influenza cases in the United Kingdom during the early wave of influenza in winter 2010/11 Pandemic influenza ...	0	eurosurveillance.org	n.d.
0	G La Torre, D Di Thiene, C Cadeddu, W Ricciardi...	Public perceptions in relation to intention to receive pandemic influenza vaccination in a random population sample: evidence from a cross-sectional ...	0	eurosurveillance.org	n.d.
0	J Olalla, M Marcos, F Fernández, J Oulkadi...	Screening for Pandemic (H1N1) 2009 Virus among Hospital Staff, Spain	2011	Emerging infectious ...	ncbi.nlm.nih.gov
0	G Gault, FX Weill, P Mariani-Kurkdjian...	Colonic ischaemia as a severe Shiga toxin/verotoxin producing Escherichia coli O104: H4 complication in a patient without haemolytic uraemic syndrome, ...	0	eurosurveillance.org	n.d.
0	C Schenk, D Plachouras, N Danielsson, A Nicoll...	Surveillance of avian influenza A (H7N9) virus infection in humans and detection of the first imported human case in Taiwan, 3 April to 10 May 2013 ...	0	eurosurveillance.org	n.d.
0	B Ciancio, KF de la Hoz, P Kreidl, H Needham, A Nicoll...	Public Health Measures in an Influenza Pandemic–the importance of surveillance	0	eurosurveillance.org	n.d.
0	L Jossieran, A Fouillet	Influenza A (H1N1) pdm09 in England, 2009 to 2011: a greater burden of severe illness in the year after the pandemic than in the pandemic year	0	eurosurveillance.org	n.d.
0	A Solovyov, G Palacios, T Briese, WI Lipkin...	Letter to the editor. Virological analysis of fatal influenza cases in the United Kingdom during the early wave of influenza in winter 2010/11 Pandemic influenza ...	0	eurosurveillance.org	n.d.
0	L Filleul, E Brottet, BA Gauzere, A Winer, D Vandroux...	Frequency of oseltamivir resistance in Sydney, during the Newcastle outbreak of community transmitted oseltamivir-resistant influenza A (H1N1) pdm09 virus, ...	0	eurosurveillance.org	n.d.
0	I Huber, H Campe, D Sebah, C Hartberger, R Konrad...	Rabies in an Arctic fox on the Svalbard archipelago, Norway, January 2011 Effectiveness of trivalent seasonal and monovalent influenza A (H1N1) 2009 ...	0	eurosurveillance.org	n.d.
0	U Buchholz, S Brockmann, S Duwe, B Schweiger...	Oseltamivir susceptibility in south-western France during the 2007-8 and 2008-9 influenza epidemics and the ongoing influenza pandemic 2009 Influenza A (...)	0	eurosurveillance.org	n.d.
0	J Ellis, M Galiano, R Pebody, A Lackenby...	Cases of community-acquired meticillin-resistant Staphylococcus aureus in an asylum seekers centre in Germany, November 2010 Usefulness of porA ...	0	eurosurveillance.org	n.d.
0	A Khattab, M Shaheen, T Kamel, AE Faramay...	Burden of pediatric influenza A virus infection post swine-flu H1N1 pandemic in Egypt	2013	Asian Pacific journal of ...	Elsevier
0	P Carrillo-Santistevé, S Renard-Dubois, G Cheron...	Influenza A (H1N1) pdm09 in England, 2009 to 2011: a greater burden of severe illness in the year after the pandemic than in the pandemic year	0	eurosurveillance.org	n.d.

0	WP Schmidt, R Pebody, P Mangtani	Update: Follow-up study showing post-pandemic decline in hand sanitiser use, New Zealand, December 2009 School absence data for influenza surveillance ...	0	eurosurveillance.org	n.d.
0	J Gómez, CV Munayco, JC Arrasco, L Suarez...	Pandemic H1N1 influenza lessons from the southern hemisphere Preliminary analysis of the pandemic H1N1 influenza on Réunion Island (Indian Ocean): ...	0	eurosurveillance.org	n.d.
0	AG Center	LICENCURE-CERTIFICATION	0	school.med.uoa.gr	
0	S Smith, GE Smith, B Olowokure, S Ibbotson, D Foord...	Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A (H1N1) 2009 pandemic in the Asia-Pacific region, March 2009 to ...	0	eurosurveillance.org	n.d.
0	C Rizzo, S Declich, A Bella, MG Caporali, S Lana...	Foresight Infectious Diseases China Project-A novel approach to anticipating future trends in risk of infectious diseases in China: methodology and results ...	0	eurosurveillance.org	n.d.
0	M Keramarou, S Cottrell, MR Evans, C Moore, RE Stiff...	Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A (H1N1) 2009 pandemic in the Asia-Pacific region, March 2009 to ...	0	eurosurveillance.org	n.d.
0	L Brouwers, B Cakici, M Camitz, A Tegnell, M Boman	Sub-optimal hand sanitiser usage in a hospital entrance during an influenza pandemic, New Zealand, August 2009 Economic consequences to society of ...	0	eurosurveillance.org	n.d.
0	A Guinard, L Grout, C Durand, V Schwoebel	Foresight Infectious Diseases China Project-A novel approach to anticipating future trends in risk of infectious diseases in China: methodology and results ...	0	eurosurveillance.org	n.d.
0	WE Adamson, EC McGregor, K Kavanagh...	Long term trends introduce a potential bias when evaluating the impact of the pneumococcal conjugate vaccination programme in England and Wales WHO ...	0	eurosurveillance.org	n.d.
0	O Lyytikäinen, M Kuusi, M Snellman, MJ Virtanen...	Influenza A (H1N1) pdm09 in England, 2009 to 2011: a greater burden of severe illness in the year after the pandemic than in the pandemic year	0	eurosurveillance.org	n.d.
0	V Trifonov, H Khiabaniyan, B Greenbaum, R Rabadan	Letter to the editor. Virological analysis of fatal influenza cases in the United Kingdom during the early wave of influenza in winter 2010/11 Pandemic influenza A (...)	0	eurosurveillance.org	n.d.
0	A Koetsier, L van Asten, F Dijkstra, W van der Hoek...	Do intensive care data on respiratory infections reflect influenza epidemics?	2013	PloS one	dx.plos.org
0	RC Silva, MAM Siqueira, EM Netto...	Epidemiological aspects of influenza A related to climatic conditions during and after a pandemic period in the city of Salvador, northeastern Brazil	2014	Memórias do Instituto ...	SciELO Brasil
0	H Wilking, S Buda, E von der Lippe, D Altmann...	National surveillance of pandemic influenza A (H1N1) infection-related admissions to intensive care units during the 2009–10 winter peak in Denmark: two ...	0	eurosurveillance.org	n.d.
0	O Wichmann, P Stöcker, G Poggensee, D Altmann...	Letter to the editor. Virological analysis of fatal influenza cases in the United Kingdom during the early wave of influenza in winter 2010/11 Pandemic influenza ...	0	eurosurveillance.org	n.d.

0	G Cruz-Pacheco, L Duran, L Esteva, AA Minzoni...	Letter to the editor. Virological analysis of fatal influenza cases in the United Kingdom during the early wave of influenza in winter 2010/11 Pandemic influenza ...	0	eurosurveillance.org	n.d.
0	RG Pebody, E McLean, H Zhao, P Cleary...	Influenza A (H1N1) pdm09 in England, 2009 to 2011: a greater burden of severe illness in the year after the pandemic than in the pandemic year	0	eurosurveillance.org	n.d.
0	A Gianella, A Walter, R Revollo, R Loayza, J Vargas...	Assessment of secondary attack rate and effectiveness of antiviral prophylaxis among household contacts in an influenza A (H1N1) v outbreak in Kobe, Japan ...	0	eurosurveillance.org	n.d.
0	G Cullen, J Martin, J O'Donnell, M Boland, M Canny...	"I-MOVE" towards monitoring seasonal and pandemic influenza vaccine effectiveness: lessons learnt from a pilot multi-centric case-control study in Europe, ...	0	eurosurveillance.org	n.d.
0	M Nishiyama, Y Yoshida, M Sato, M Nishioka, T Kato...	Letter to the editor. Virological analysis of fatal influenza cases in the United Kingdom during the early wave of influenza in winter 2010/11 Pandemic influenza ...	0	eurosurveillance.org	n.d.
0	I Steffens	Our first impact factor	2012	Euro Surveill	eurosurveillance.eu
0	D Carcione, CM Giele, LS Goggin, KSH Kwan...	Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A (H1N1) 2009 pandemic in the Asia-Pacific region, March 2009 to ...	0	eurosurveillance.org	n.d.
0	C Sellwood	Pandemic influenza preparedness	0	Influenza surveillance	Future Medicine
0	E Depoortere, J Mantero, A Lenglet, P Kreidl...	A variety of respiratory viruses found in symptomatic travellers returning from countries with ongoing spread of the new influenza A (H1N1) v virus strain ...	0	eurosurveillance.org	n.d.
0	G Thomson, A Nicoll	National surveillance of pandemic influenza A (H1N1) infection-related admissions to intensive care units during the 2009–10 winter peak in Denmark: two ...	0	eurosurveillance.org	n.d.
0	M Socan, K Proscenc, N Tevž-Cizej	Influenza A (H1N1) pdm09 in England, 2009 to 2011: a greater burden of severe illness in the year after the pandemic than in the pandemic year	0	eurosurveillance.org	n.d.
0	A Mazick, B Gergonne, F Wuillaume, K Danis...	Estimating influenza-related sick leave in Norway: Was work absenteeism higher during the 2009 A (H1N1) pandemic compared to seasonal epidemics? ...	0	eurosurveillance.org	n.d.
0	S Towers, Z Feng	Use of an inactivated vaccine in mitigating pandemic influenza A (H1N1) spread: a modelling study to assess the impact of vaccination timing and ...	0	eurosurveillance.org	n.d.
0	BF de Blasio, Y Xue, B Iversen, JM Gran	Influenza A (H1N1) pdm09 in England, 2009 to 2011: a greater burden of severe illness in the year after the pandemic than in the pandemic year	0	eurosurveillance.org	n.d.
0	T Panagiotopoulos, S Bonovas, K Danis, D Iliopoulos...	Letter to the editor. Virological analysis of fatal influenza cases in the United Kingdom during the early wave of influenza in winter 2010/11 Pandemic influenza ...	0	eurosurveillance.org	n.d.
0	A Wallensten, I Oliver, D Lewis, S Harrison	Oseltamivir adherence and side effects among children in three London schools affected by influenza A (H1N1) v, May 2009—an internet-based cross- ...	0	eurosurveillance.org	n.d.
0	C Rizzo, MC Rota, A Bella, S Giannitelli, S De Santis...	National surveillance of pandemic influenza A (H1N1) infection-related admissions to intensive care units during the 2009–10 winter peak in Denmark: two ...	0	eurosurveillance.org	n.d.

0	N Komiya, Y Gu, H Kamiya, Y Yahata, T Matsui...	Call for papers for a special issue on HIV/AIDS and other sexually transmitted infections in men who have sex with men New issue of EpiNorth is online	0	eurosurveillance.org	n.d.
0	BC Ciancio, TJ Meerhoff, P Kramarz, I Bonmarin...	Differentiation of two distinct clusters among currently circulating influenza A (H1N1) v viruses, March-September 2009 "RAISIN"-a national programme for ...	0	eurosurveillance.org	n.d.
0	N Ikonen, M Strengell, L Kinnunen, P Österlund...	Letter to the editor. Virological analysis of fatal influenza cases in the United Kingdom during the early wave of influenza in winter 2010/11 Pandemic influenza ...	0	eurosurveillance.org	n.d.
0	M Hofshagen, B Gjerset, C Er, A Tarpai, E Brun...	Influenza A (H1N1) pdm09 in England, 2009 to 2011: a greater burden of severe illness in the year after the pandemic than in the pandemic year	0	eurosurveillance.org	n.d.
0	I Kar-Purkayastha, C Ingram, H Maguire, A Roche	Increased detection in Australia and Singapore of a novel influenza A (H1N1) 2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N ...	0	eurosurveillance.org	n.d.
0	A Meijer, TJ Meerhoff, LE Meuwissen...	Very little influenza activity in Europe up until the end of 2005.	2006	... Européen sur les ...	eurosurveillance.org
0	A Poder, P Simurka, P Li, S Roy-Ghanta, D Vaughn	An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines ...	2014	Vaccine	Elsevier
0	S Paine, GN Mercer, PM Kelly, D Bandaranayake...	Influenza A (H1N1) pdm09 in England, 2009 to 2011: a greater burden of severe illness in the year after the pandemic than in the pandemic year	0	eurosurveillance.org	n.d.
0	H Fleury, S Burrel, CB Weber, R Hadrien, P Blanco...	Public perceptions in relation to intention to receive pandemic influenza vaccination in a random population sample: evidence from a cross-sectional ...	0	eurosurveillance.org	n.d.
0	G Sigmundsdottir, T Gudnason, Ö Ólafsson...	National surveillance of pandemic influenza A (H1N1) infection-related admissions to intensive care units during the 2009–10 winter peak in Denmark: two ...	0	eurosurveillance.org	n.d.
0	K Ekdahl, I Steffens, K Hagmaier, A Buzdugan...	Editorial team Editorial board	2010	hospital	Citeseer
0	J Turner	Citation style for this article: Turner J, Kelly H. A medical locum service as a site for sentinel influenza surveillance. Euro Surveill. 2005; 10 (4): pii= 530. ...	0	eurosurveillance.org	n.d.
0	H Yasuda, K Suzuki	"I-MOVE" towards monitoring seasonal and pandemic influenza vaccine effectiveness: lessons learnt from a pilot multi-centric case-control study in Europe, ...	0	eurosurveillance.org	n.d.
0	H Nishiura, K Iwata	Increased detection in Australia and Singapore of a novel influenza A (H1N1) 2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N ...	0	eurosurveillance.org	n.d.
0	G Rachiotis, VA Mouchtouri, J Kremastinou...	Letter to the editor. Virological analysis of fatal influenza cases in the United Kingdom during the early wave of influenza in winter 2010/11 Pandemic influenza ...	0	eurosurveillance.org	n.d.
0	I Kar-Purkayastha, C Ingram, H Maguire, A Roche	... influenza A (H1N1) 2009 have international relevance Surveillance trends of the 2009 influenza A (H1N1) pandemic in Europe Increased detection in ...	0	eurosurveillance.org	n.d.

0	T Tran, BT Chien, G Papadakis, J Druce, C Birch...	Respiratory virus laboratory pandemic planning and surveillance in central Viet Nam, 2008–2010	2010	EDITORIAL ...	wpro.who.int
0	A Kilander, R Rykkvin, SG Dudman, O Hungnes	Letter to the editor. Virological analysis of fatal influenza cases in the United Kingdom during the early wave of influenza in winter 2010/11 Pandemic influenza A (...)	0	eurosurveillance.org	n.d.
0	H Kelly, K Grant	Eurosurveillance, Volume 14, Issue 31, 06 August 2009 Rapid communications	0	herbogeminis.com	n.d.
0	WE Adamson, S Maddi, C Robertson, S McDonagh...	Influenza A (H1N1) pdm09 in England, 2009 to 2011: a greater burden of severe illness in the year after the pandemic than in the pandemic year	0	eurosurveillance.org	n.d.
0	HA Kelly, BJ Cowling	Surveillance trends of the 2009 influenza A (H1N1) pandemic in Europe Authors' reply. Virological analysis of fatal influenza cases in the United Kingdom ...	0	eurosurveillance.org	n.d.
0	CV Munayco, J Gómez, VA Laguna-Torres, J Arrasco...	Cases of influenza A (H1N1) v reported in Turkey, May-July 2009 Epidemiological and transmissibility analysis of influenza A (H1N1) v in a southern ...	0	eurosurveillance.org	n.d.
0	F Baldanti, A Zanetti	Cases of community-acquired meticillin-resistant Staphylococcus aureus in an asylum seekers centre in Germany, November 2010 Usefulness of porA ...	0	eurosurveillance.org	n.d.
0	E Pérez-Trallero, L Piñeiro, D Vicente, M Montes...	Residual immunity in older people against the influenza A (H1N1)–recent experience in northern Spain Early estimates of 2009 pandemic influenza A (H1N1) ...	0	eurosurveillance.org	n.d.
0	H Kelly, GN Mercer, K Glass, S Paine	Letter to the editor. Virological analysis of fatal influenza cases in the United Kingdom during the early wave of influenza in winter 2010/11 Pandemic influenza ...	0	eurosurveillance.org	n.d.
0	A Cox, P Guglielmetti, D Coulombier	Increased detection in Australia and Singapore of a novel influenza A (H1N1) 2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N ...	0	eurosurveillance.org	n.d.
0	H Kelly, K Grant	Description of the early stage of pandemic (H1N1) 2009 in Germany, 27 April-16 June 2009 Interim analysis of pandemic influenza (H1N1) 2009 in Australia: ...	0	eurosurveillance.org	n.d.
0	D Coulombier, J Giesecke	Can the Swedish new variant of Chlamydia trachomatis (nvCT) be detected by UK NEQAS participants from seventeen European countries and five additional ...	0	eurosurveillance.org	n.d.
0	F Thouillot, C Do, E Balleydier, E Rachou, F Staikowsky...	Pandemic H1N1 influenza lessons from the southern hemisphere Preliminary analysis of the pandemic H1N1 influenza on Réunion Island (Indian Ocean): ...	0	eurosurveillance.org	n.d.
0	TD Huang, P Bogaerts, C Berhin, B Jans, A Deplano...	Latent introduction to the Netherlands of multiple antibiotic resistance including NDM-1 after hospitalisation in Egypt, August 2013 Trends in yearly prevalence ...	0	eurosurveillance.org	n.d.
0	I Gutiérrez, A Litzroth, S Hammadi, H Van Oyen...	Description of the early stage of pandemic (H1N1) 2009 in Germany, 27 April-16 June 2009 Interim analysis of pandemic influenza (H1N1) 2009 in Australia: ...	0	eurosurveillance.org	n.d.

0	M Aho, O Lyytikäinen, JE Nyholm, T Kuitunen...	Letter to the editor. Virological analysis of fatal influenza cases in the United Kingdom during the early wave of influenza in winter 2010/11 Pandemic influenza ...	0	eurosurveillance.org	n.d.
0	ES McBryde, I Bergeri, C van Gemert, J Rotty...	Pandemic H1N1 influenza lessons from the southern hemisphere Preliminary analysis of the pandemic H1N1 influenza on Réunion Island (Indian Ocean): ...	0	eurosurveillance.org	n.d.
0	H Uphoff, S Geis, A Grüber, AM Hauri	Cases of influenza A (H1N1) v reported in Turkey, May-July 2009 Epidemiological and transmissibility analysis of influenza A (H1N1) v in a southern ...	0	eurosurveillance.org	n.d.
0	C Fuhrman, I Bonmarin, AC Paty, N Dupont, E Chiron...	Letter to the editor. Virological analysis of fatal influenza cases in the United Kingdom during the early wave of influenza in winter 2010/11 Pandemic influenza ...	0	eurosurveillance.org	n.d.
0	MA Ciblak, N Albayrak, Y Odabas, AB Altas...	Cases of influenza A (H1N1) v reported in Turkey, May-July 2009 Epidemiological and transmissibility analysis of influenza A (H1N1) v in a southern ...	0	eurosurveillance.org	n.d.
0	S Tsiodras, V Sypsa, A Hatzakis	Update: Follow-up study showing post-pandemic decline in hand sanitiser use, New Zealand, December 2009 School absence data for influenza surveillance ...	0	eurosurveillance.org	n.d.
0	A Hulth, G Rydevik	Letter to the editor. Virological analysis of fatal influenza cases in the United Kingdom during the early wave of influenza in winter 2010/11	0	eurosurveillance.org	n.d.
0	IL Amine, T Bajjou, H El Rhaffouli, A Laraqui, F Hilali...	Increased detection in Australia and Singapore of a novel influenza A (H1N1) 2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N ...	0	eurosurveillance.org	n.d.
0	AJ Elliot	"I-MOVE" towards monitoring seasonal and pandemic influenza vaccine effectiveness: lessons learnt from a pilot multi-centric case-control study in Europe, ...	0	eurosurveillance.org	n.d.
0	KA Grant	Western Pacific Surveillance and Response Journal	0	wpro.who.int	n.d.
0	V Sypsa, A Hatzakis	A variety of respiratory viruses found in symptomatic travellers returning from countries with ongoing spread of the new influenza A (H1N1) v virus strain ...	0	eurosurveillance.org	n.d.
0	JS Casalegno, M Ottmann, M Bouscambert-Duchamp...	Letter to the editor. Virological analysis of fatal influenza cases in the United Kingdom during the early wave of influenza in winter 2010/11 Pandemic influenza ...	0	eurosurveillance.org	n.d.
0	D Walter, MM Böhmer, S Reiter, G Krause...	An outbreak of severe respiratory tract infection caused by human metapneumovirus in a residential care facility for elderly in Utrecht, the Netherlands, ...	0	eurosurveillance.org	n.d.
0	G Loncarevic, L Payne, P Kon, V Petrovic...	Description of the early stage of pandemic (H1N1) 2009 in Germany, 27 April-16 June 2009 Interim analysis of pandemic influenza (H1N1) 2009 in Australia: ...	0	eurosurveillance.org	n.d.
0	GE Smith	Citation style for this article: Smith GE, Cooper DL, Loveridge P, Chinemana F, Gerard E, Verlander N. A national syndromic surveillance system for England ...	0	eurosurveillance.org	n.d.
0	M Uchida, M Kaneko, T Tsukahara...	Evaluation of the spread of pandemic influenza A/H1N1 2009 among Japanese university students	2014	... health and preventive ...	Springer

0	V Keßler	Dynamics of the 2009 A/H1N1 pandemic in the UK, Germany and Spain: An overview of public health interventions and recommendations	2012	n.d.	edoc.sub.uni-hamburg.de
0	P Mook, C Joseph, P Gates, N Phin	Why a burden of disease study? The burden of infectious diseases in Europe: a pilot study Exploration of cost effectiveness of active vaccination in the control ...	0	eurosurveillance.org	n.d.
0	A Smith, S Coles, S Johnson, L Saldana, C Ihekweazu...	Foresight Infectious Diseases China Project-A novel approach to anticipating future trends in risk of infectious diseases in China: methodology and results ...	0	eurosurveillance.org	n.d.
0	A Nicoll, D Coulombier	Call for papers for a special issue on HIV/AIDS and other sexually transmitted infections in men who have sex with men New issue of EpiNorth is online	0	eurosurveillance.org	n.d.
0	ИПСС ЭКОЛОГО- ...	СОВРЕМЕННЫЕ СПОСОБЫ МОНИТОРИНГА ВИРУСНЫХ ПАТОГЕНОВ И ПЕРСПЕКТИВЫ СОЗДАНИЯ СИСТЕМЫ ЭКОЛОГО- ...	2006	n.d.	vsnc.ru
0	T Trana, BT Chieb, G Papadakisa, J Drucea, C Bircha...	2008-2010 年越南中部地区呼吸道病毒实验室流感大流行计划和监测	0	wpro.who.int	n.d.

11. European Centre for Disease Prevention and Control and European Monitoring Centre for Drugs and Drug Addiction. Prevention and control of infectious diseases among people who inject drugs. Stockholm: ECDC; 2011

Total nr. of papers: 33

H-index: 7

Cites	Authors	Title	Year	Source	Publisher
20	H Belani, T Chorba, F Fletcher, K Hennessey...	Integrated prevention services for HIV infection, viral hepatitis, sexually transmitted diseases, and tuberculosis for persons who use drugs illicitly: summary ...	2012	n.d.	origin.glb.cdc.gov
20	JP Millet, A Moreno, L Fina, L del Baño, A Orcau...	Factors that influence current tuberculosis epidemiology	2013	European Spine ...	Springer
19	G Likatavicius, MJ Van de Laar	HIV infection and AIDS in the European Union and European Economic Area, 2010	2011	Euro Surveill	eurosurveillance.eu
18	A Pharris, L Wiessing, O Sfetcu, D Hedrich...	Human immunodeficiency virus in injecting drug users in Europe following a reported increase of cases in Greece and Romania, 2011	2011	Euro ...	eurosurveillance.eu
17	L Wiessing, G Likatavicius, D Hedrich, B Guarita...	Trends in HIV and hepatitis C virus infections among injecting drug users in Europe, 2005 to 2010	2011	Euro ...	eurosurveillance.org
8	A Hatzakis, P Damme, K Alcorn, C Gore...	The state of hepatitis B and C in the Mediterranean and Balkan countries: report from a summit conference	2013	Journal of viral ...	Wiley Online Library

7	NK Martin, M Hickman, SJ Hutchinson...	Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe ...	2013	Clinical infectious ...	cid.oxfordjournals.org
5	M Rondy, L Wiessing, SJ Hutchinson...	Hepatitis C prevalence in injecting drug users in Europe, 1990–2007: impact of study recruitment setting	2013	Epidemiology and ...	Cambridge Univ Press
5	NA van Hest, RW Aldridge, G de Vries, A Sandgren...	Tuberculosis control in big cities and urban risk groups in the European Union: a consensus statement	2014	n.d.	edoc.rki.de
4	GJ MacArthur, E van Velzen, N Palmateer...	Interventions to prevent HIV and hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness	2014	International Journal of ...	Elsevier
4	V Sypsa, D Paraskevis, M Malliori...	Homelessness and Other Risk Factors for HIV Infection in the Current Outbreak Among Injection Drug Users in Athens, Greece	2014	... journal of public ...	ajph.aphapublications.org
4	A Taylor, A Munro, E Allen, K Dunleavy, S Cameron...	Low incidence of hepatitis C virus among prisoners in Scotland	2013	n.d.	Wiley Online Library
3	BB Pauly, D Reist, L Belle-Isle, C Schactman	Housing and harm reduction: What is the role of harm reduction in addressing homelessness?	2013	International Journal of Drug ...	Elsevier
1	J Janiec, K Haar, G Spiteri, G Likatavicius...	Surveillance of human immunodeficiency virus suggests that younger men who have sex with men are at higher risk of infection, European Union, 2003 to 2012	2013	Euro ...	eurosurveillance.org
1	K Malinowska-Sempruch, M Dąbkowska	Nowe zakażenia HIV wśród osób używających narkotyków drogą iniekcji Czy możemy spać spokojnie?	2013	Alkoholizm i Narkomania	ipin.edu.pl
0	M Salminen, D Hedrich	ECDC and EMCDDA joint guidance report on reducing infections among people who inject drugs	2011	Euro surveillance: bulletin Européen ...	eurosurveillance.org
0	D Hedrich, E Kalamara, O Sfetcu, A Pharris, A Noor...	Surveillance of human immunodeficiency virus suggests that younger men who have sex with men are at higher risk of infection, European Union, 2003 to ...	0	eurosurveillance.org	
0	M Ferri, A Bo	Best practice promotion in Europe: A web-based tool for the dissemination of evidence-based demand reduction interventions	2012	Drugs: education, prevention and policy	informahealthcare.com
0	D Hedrich, E Kalamara, O Sfetcu...	Human immunodeficiency virus among people who inject drugs: Is risk increasing in Europe?	2013	... Européen sur les ...	eurosurveillance.org
0	A Uusküla, M Raag, C Folch, L Prasad, A Karnite...	Self-reported testing, HIV status and associated risk behaviours among people who inject drugs in Europe: important differences between East and West	2014	AIDS	pdfs.journals.lww.com
0	MJ van de Laar, A Pharris	Treatment as prevention: will it work?	2011	Euro surveillance: bulletin ...	eurosurveillance.org
0	G Hâtu, MI Brumboiu, P Czernichow...	The risk for hepatitis C infection in blood donors in Cluj County, Romania	2014	Transfusion Clinique et ...	Elsevier
0	A Botescu, A Abagiu, M Mardarescu, M Ursan	HIV/AIDS among injecting drug users in Romania	0	hepatitisscotland.co.uk	n.d.
0	S Session	AIDS/HIV in view of the XVIII International AIDS Conference (Vienna July 18	2009	n.d.	west-info.eu
0	PG de Olalla, JA Caylà	Juan-Pablo Millet, Antonio Moreno, Laia Fina, Lucía del Baño, Angels Orcau	2013	Eur Spine J	aspb.cat

0	F Fletcher, T Vogt, PDDB Wynn	Integrated Prevention Services for HIV Infection, Viral Hepatitis, Sexually Transmitted Diseases, and Tuberculosis for Persons Who Use Drugs Illicitly: Summary ...	0	lcgdbzz.org	n.d.
0	H Stöver, A Kastelic	14. Drug treatment and harm reduction in prisons	2014	Prisons and Health	euro.who.int
0	A Leicht, M Dau, M Frötschl	Resultate der Spritzentausch-Sortimentsergänzung „Nevershare“-Spritzen	0	fixpunkt-berlin.de	n.d.
0	C Stöter	HIV, HEPATITIS C UND TUBERKULOSE IN HAFT	0	BETREUUNG IM STRAFVOLLZUG HANDBUCH ...	aidshilfe.de
0	RNODDAS DROGAS, EM PORTUGAL	30 de setembro, 2013	2013	comum.rcaap.pt	n.d.
0	A Luizov, A Rusev	Инжекционно употребляващи наркотици и туберкулоза – информирани невинаги означава здрави	2013	n.d.	research.bfu.bg
0	G Cholewińska, K Puławska-Popielarz, J Gąsiorowski	STANDARDY OPIEKI MEDYCZNEJ I PSYCHOTERAPEUTYCZNEJ DLA PACJENTA Z INFЕКCJĄ HIV, UZALEŻNIONEGO OD DOŻYLNÝCH ŚRODKÓW ...	0	WYKAZ AUTORÓW	gis.gov.pl
0	JP Millet Vilanova, JA Caylà Buqueras, JM Miró Meda	Otros portales de tesis	0	tdx.cat	n.d.

12. European Centre for Disease Prevention and Control. HIV testing: increasing uptake and effectiveness in the European Union. Stockholm: ECDC;2010.

Total nr. of papers: 66
H-index: 8

Cites	Authors	Title	Year	Source	Publisher
20	AC Thornton, V Delpech, MM Kall, A Nardone	HIV testing in community settings in resource-rich countries: a systematic review of the evidence	2012	HIV medicine	Wiley Online Library
16	AK Sullivan, D Raben, J Reekie, M Rayment, A Mcroft...	Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study)	2013	PLoS One	dx.plos.org
16	P Flowers, C Knussen, J Li, L McDaid	Has testing been normalized? An analysis of changes in barriers to HIV testing among men who have sex with men between 2000 and 2010 in Scotland, UK	2013	HIV medicine	Wiley Online Library
13	OS Søggaard, N Lohse, L Østergaard, G Kronborg...	Morbidity and risk of subsequent diagnosis of HIV: a population based case control study identifying indicator diseases for HIV infection	2012	PloS one	dx.plos.org
12	J Deblonde, H Meulemans, S Callens, S Luchters...	HIV testing in Europe: mapping policies	2011	Health policy	Elsevier

12	L de la Fuente, ME Rosales-Statkus, J Hoyos, J Pulido...	Are participants in a street-based HIV testing program able to perform their own rapid test and interpret the results?	2012	PloS one	dx.plos.org
10	A Mcroft, JD Lundgren, ML Sabin, AA Monforte...	Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological ...	2013	PLoS medicine	dx.plos.org
9	AC Thornton, M Rayment, G Elam, M Atkins...	Exploring staff attitudes to routine HIV testing in non-traditional settings: a qualitative study in four healthcare facilities	2012	Sexually transmitted ...	sti.bmj.com
8	D Alvarez-del Arco, S Monge, A Azcoaga...	HIV testing and counselling for migrant populations living in high-income countries: a systematic review	2012	... European Journal of ...	Oxford Univ Press
5	I Bozicevic, SZ Lepej, OD Rode, I Grgic...	Prevalence of HIV and sexually transmitted infections and patterns of recent HIV testing among men who have sex with men in Zagreb, Croatia	2012	Sexually transmitted ...	sti.bmj.com
5	M Desai, S Desai, AK Sullivan, M Mohabeer...	Audit of HIV testing frequency and behavioural interventions for men who have sex with men: policy and practice in sexual health clinics in England	2013	Sexually transmitted ...	sti.bmj.com
4	European Centre for Disease Prevention and Control	HIV testing: increasing uptake and effectiveness in the European Union	2010	Stockholm: ECDC	n.d.
4	L Ti, K Hayashi, K Kaplan, P Suwannawong...	Willingness to access peer-delivered HIV testing and counseling among people who inject drugs in Bangkok, Thailand	2013	Journal of community ...	Springer
4	S Moreno, M Ordobás, JC Sanz, B Ramos...	Prevalence of undiagnosed HIV infection in the general population having blood tests within primary care in Madrid, Spain	2012	Sexually transmitted ...	sti.bmj.com
4	I Jarrin, N Pantazis, MJ Gill, R Geskus...	Uptake of combination antiretroviral therapy (cART) and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia	2011	Clinical infectious ...	cid.oxfordjournals.org
3	M Sprenger	Know, treat, prevent-HIV testing, a key strategy in the prevention and control of the HIV/AIDS epidemic	2010	Eur Surveill	eurosurveillance.eu
3	MM Kall, RD Smith, VC Delpech	Late HIV diagnosis in Europe: A call for increased testing and awareness among general practitioners	2012	European Journal of ...	informahealthcare.com
3	D Alvarez-del Arco, S Monge...	HIV testing policies for migrants and ethnic minorities in EU/EFTA Member States	2013	... European Journal of ...	Oxford Univ Press
3	N Vives, D Carnicer-Pont, PG de Olalla...	Factors associated with late presentation of HIV infection in Catalonia, Spain	2012	... journal of STD & ...	std.sagepub.com
3	J Hoyos, S Fernández-Balbuena...	Never tested for HIV in Latin-American migrants and Spaniards: prevalence and perceived barriers	2013	Journal of the ...	ncbi.nlm.nih.gov
2	C Agustí, L Fernández-López, J Mascort, R Carrillo...	Acceptability of rapid HIV diagnosis technology among primary healthcare practitioners in Spain	2013	AIDS care	Taylor & Francis
2	TD Pillay, J Mullineux, CJ Smith...	Unlocking the potential: longitudinal audit finds multifaceted education for general practice increases HIV testing and diagnosis	2012	Sexually transmitted ...	sti.bmj.com
2	S Fernández-Balbuena, L de la Fuente...	Highly visible street-based HIV rapid testing: is it an attractive option for a previously untested population? A cross-sectional study	2013	Sexually transmitted ...	sti.bmj.com
1	E Guidance	HIV testing: increasing uptake and effectiveness in the European Union	2010	... : European Centre for Disease Prevention and ...	old.drugsandalcohol.ie

1	D Raben, V Delphech, J Wit, A Sullivan...	Conclusions from the HIV in Europe Copenhagen 2012 Conference and ways forward: working together for optimal HIV testing and earlier care	2013	HIV ...	Wiley Online Library
1	C Agustí, L Fernández-López, J Mascort...	Attitudes to rapid HIV testing among Spanish General Practitioners	2013	HIV ...	Wiley Online Library
1	T Qvist, SA Cowan, C Graugaard...	High linkage to care in a community-based rapid HIV testing and counseling project among men who have sex with men in Copenhagen	2014	Sexually transmitted ...	journals.lww.com
1	J Campo, J Cano, J del Romero...	Role of the dental surgeon in the early detection of adults with underlying HIV infection/AIDS	2012	... oral, patologia oral y ...	ncbi.nlm.nih.gov
1	J Janiec, K Haar, G Spiteri, G Likatavicius...	Surveillance of human immunodeficiency virus suggests that younger men who have sex with men are at higher risk of infection, European Union, 2003 to 2012	2013	Euro ...	eurosurveillance.org
1	P Mujyambere	Barriers to HIV voluntary counselling and testing among refugees and asylum seekers from African Great Lakes region living in Durban	2012	n.d.	scholar.sun.ac.za
1	K Wouters, K Fransen, G Beelaert...	Use of rapid HIV test in low threshold center in Antwerp, Belgium, 2007–2012	2014	... journal of STD & ...	std.sagepub.com
1	F Villaamil	Shared Embarrassment:(Not) Talking about Sex in HIV-Related Doctor–Patient Encounters	2013	Medical Anthropology	Taylor & Francis
0	MSM Lanarkshire	5.6. Implications for Service Provision in Lanarkshire	2013	Social Media, Men who have Sex ...	sexualhealthnetwork.org.uk
0	C Carvalho, R Fuertes, R Lucas, A Martins...	HIV testing among Portuguese men who have sex with men—results from the European MSM Internet Survey (EMIS)	2013	HIV ...	Wiley Online Library
0	D Gökengin, AM Geretti, J Begovac...	2014 European Guideline on HIV testing	2014	... journal of STD & ...	std.sagepub.com
0	I Montesinos, J Eykmans, ML Delforge	Evaluation of the Bio-Rad Geenius HIV-1/2 test as a confirmatory assay	2014	Journal of Clinical Virology	Elsevier
0	F Nakagawa, AN Phillips, JD Lundgren	Update on HIV in Western Europe	2014	Current HIV/AIDS Reports	Springer
0	S Session	AIDS/HIV in view of the XVIII International AIDS Conference (Vienna July 18)	2009	n.d.	west-info.eu
0	J Oliva, M Díez, S Galindo, C Cevallos, A Izquierdo...	Predictors of advanced disease and late presentation in new HIV diagnoses reported to the surveillance system in Spain	2014	Gaceta Sanitaria	Elsevier
0	K Storm	The HIV epidemic in Eastern Europe is out of control	2012	n.d.	isim.ku.dk
0	K Rützel, A Leffers, B Kucharova, B Milgrave, G Musat...	BORDERNETwork project	0	bordernet.eu	n.d.
0	J Hoyos Miller, S Fernández-Balbuena...	Time devoted to pre-and post-HIV test counselling in different health services according to participants of a rapid testing program in Madrid, Spain	2014	... y microbiologia clinica	Elsevier
0	A Pedrana, M Stooze	The future of HIV testing: Exploring new strategies to improve access to testing through community-based testing	2011	HIV Australia	search.informit.com.au
0	J Wilton	New PHAC testing guide includes recommendations to promote routine HIV testing	2013	Prevention	catie.ca
0	S Dias, A Gama, MO Martins	HIV/AIDS Among Immigrants in Portugal: Socio-Demographic and Behavioural Correlates of Preventive Practices	0	cdn.intechopen.com	n.d.

0	J Deblonde, FF Hamers, S Callens, R Lucas, H Barros...	HIV testing practices as reported by HIV-infected patients in four European countries	2014	AIDS care	Taylor & Francis
0	RE Golden, CB Collins, SD Cunningham...	Overview of Structural Interventions to Increase Voluntary Counseling and Testing (VCT) and Antiretroviral Therapy (ART)	2013	Best Evidence Structural ...	Springer
0	L Tooley, L Broeckerkaert	Routine and Targeted Testing	2013	Prevention	catie.ca
0	K Middelkoop, J Smit, R Wood, LG Bekker, L Myer	Case Study 18: A Drama-Based HIV Intervention in South Africa: Effect on Voluntary Counseling and Testing Original Program Developers and Evaluators	0	Best Evidence Structural ...	Springer
0	VM Puljić, MLK Ličina, M Kavić, TN Blažić	Repeat HIV Testing at Voluntary Testing and Counseling Centers in Croatia: Successful HIV Prevention or Failure to Modify Risk Behaviors?	2014	PloS one	dx.plos.org
0	TD Pillay, J Mullineux, CJ Smith...	Republished: Unlocking the potential: longitudinal audit finds multifaceted education for general practice increases HIV testing and diagnosis	2014	Postgraduate medical ...	pmj.bmj.com
0	I Menacho, E Sequeira, M Muns, O Barba, L Leal...	Comparison of two HIV testing strategies in primary care centres: indicator-condition-guided testing vs. testing of those with non-indicator conditions	2013	HIV ...	Wiley Online Library
0	S di Sanità	Evaluation of Rapid Progressors in HIV Infection as an Extreme Phenotype	2014	n.d.	pdfs.journals.lww.com
0	JM Reyes-Uruena, T Noori, A Pharris...	Nuevos tiempos para la salud de emigrantes en Europa	2014	Revista Española de ...	sanipe.es
0	A Wnuk, B Szetela, D Bander	3 ZASADY TESTOWANIA W KIERUNKU ZAKAŻENIA HIV-ZALECENIA	0	ZALECENIAPT AIDS	nipip.pl
0	PDDC Wild, J Dellinger	HIV-Testung an der Allgemeinbevölkerung	2013	Wiener Medizinische Wochenschrift	Springer
0	据腊红, 吕繁	两种常用 HIV 筛查方法的应用及成本效果的比较	2012	中华疾病控制杂志	journal.9med.net
0	C Agustí, L Fernández, J Mascort, R Carrillo...	Barreras para el diagnóstico de las infecciones de transmisión sexual y virus de la inmunodeficiencia humana en Atención Primaria en España	2013	... y Microbiología Clínica	Elsevier
0	J Wilton	L'Agence de la santé publique du Canada recommande le dépistage systématique du VIH	0	catie.ca	n.d.
0	L Tooley, L Broeckerkaert	Dépistage systématique et ciblé	0	catie.ca	n.d.
0	I Brosius, M Huisartgeneeskunde	De rol van de huisarts in de preventie van seksueel overdraagbare aandoeningen	0	icho-info.be	n.d.
0	P Huston	DES AMÉLIORATIONS SONT APPORTÉES AU RMTC	2013	RMTC	phac-aspc.gc.ca
0	J Dellinger, C Wild	HASH (0xb4c24b8)	2012	n.d.	eprints.hta.lbg.ac.at
0	F Villaamil	Cuerpos, virus y economías morales: la prueba del VIH	2013	Política y Sociedad	revistas.ucm.es
0	E Smjernice	Prevenција i nadzor zaraznih bolesti među intravenskim korisnicima droga	0	Citeseer	n.d.
0	W Iberoamericana-CIMF	XXXIII Congreso semFYC	2013	n.d.	osalde.org

13. Sprenger M. Know, treat, prevent – HIV testing, a key strategy in the prevention and control of the HIV/AIDS epidemic. Euro Surveill. 2010;15(48):pii=19736. Available online: <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19736>

Total nr. of papers: 4

H-index: 1

Cites	Authors	Title	Year	Source	Publisher
3	I Gorostiza, I Elizondo López de Landache...	HIV/AIDS screening program in community pharmacies in the Basque Country (Spain)	2013	Gaceta ...	SciELO Public Health
1	I Gorostiza, IE López de Landache, L Braceras Izagirre	Programa de cribado de VIH/sida en las oficinas de farmacia en la Comunidad Autónoma del País Vasco	2013	Gaceta Sanitaria	Elsevier
0	RM Chalmers, B Campbell, N Crouch, AP Davies	Value of syndromic surveillance in monitoring a focal waterborne outbreak due to an unusual Cryptosporidium genotype in Northamptonshire, United ...	0	eurosurveillance.org	n.d.
0	R Sekar, M Amudhan, M Sivashankar...	Recent trends in HIV prevalence in a remote setting of southern India: Insights into arranging HIV control policies	2013	The Journal of Infection in ...	jidc.org

14. European Centre for Disease Prevention and Control. Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals. Stockholm: ECDC; 2013

Total nr. of papers: 40

H-index: 4

Cites	Authors	Title	Year	Source	Publisher
26	P Zarb, B Coignard, J Griskeviciene, A Muller...	The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use	2012	Euro Surveill	researchgate.net
6	HFL Wertheim, A Chandna, PD Vu, C Van Pham...	Providing impetus, tools, and guidance to strengthen national capacity for antimicrobial stewardship in Viet Nam	2013	PLoS medicine	dx.plos.org
5	W Malcolm, D Nathwani, P Davey...	From intermittent antibiotic point prevalence surveys to quality improvement: experience in Scottish hospitals	2013	... Resist Infect Control	biomedcentral.com
4	A Sprowson, T Symes, SK Khan, T Oswald, MR Reed	Changing antibiotic prophylaxis for primary joint arthroplasty affects postoperative complication rates and bacterial spectrum	2013	The Surgeon	Elsevier
4	DL Monnet, M Sprenger	Hand hygiene practices in healthcare: measure and improve	2012	Euro. Surveill	eurosurveillance.eu
2	S Hansen, D Sohr, B Piening...	Antibiotic usage in German hospitals: results of the second national prevalence study	2013	Journal of ...	Br Soc Antimicrob Chemo

2	MA Borg	Cultural determinants of infection control behaviour: understanding drivers and implementing effective change	2014	Journal of Hospital Infection	Elsevier
2	CP Thomas, LSP Moore, N Elamin, M Doumith...	Early (2008–2010) hospital outbreak of <i>Klebsiella pneumoniae</i> producing OXA-48 carbapenemase in the UK	2013	International journal of ...	Elsevier
1	E Zabkova, L Murajda, H Hudeckova	POInt PREVALEnCE SURVEY OF nOSOCOMIAL InFEctIOnS In UnIVERSItY HOSPITAL In MARTIn	2011	Acta Medica Martiniana	degruyter.com
1	MA Borg	Prolonged perioperative surgical prophylaxis within European hospitals: an exercise in uncertainty avoidance?	2013	Journal of Antimicrobial Chemotherapy	Br Soc Antimicrob Chemo
0	MP Smiddy, OM Murphy	The use of point prevalence surveys of healthcare-associated infection to identify risk factors and facilitate infection prevention and control planning	2013	Healthcare Infection	CSIRO
0	T Welte	Nosocomial Infections—a Present and Future Challenge	2013	Deutsches Ärzteblatt International	ncbi.nlm.nih.gov
0	D Pittet	European Antibiotic Awareness Day	2013	Journal of Infection Prevention	bjj.sagepub.com
0	I Sviestina, J Aston, D Mozgis	Comparison of antimicrobial prescribing between two specialist paediatric centres in the UK and Latvia	2013	European Journal of Hospital ...	ejhp.bmj.com
0	WG Mackay, K Smith, C Williams, C Chalmers...	A review of infection control in community healthcare: new challenges but old foes	2014	European Journal of ...	Springer
0	E Malobicka, D Roskova, V Svihrova...	Point Prevalence Survey of Nosocomial Infections in University Hospital in Martin	2013	Acta Medica ...	degruyter.com
0	S Haller, T Eckmanns, J Benzler, K Tolksdorf, H Claus...	Results from the First 12 Months of the National Surveillance of Healthcare Associated Outbreaks in Germany, 2011/2012	2014	PloS one	dx.plos.org
0	IJ Abbott, AY Peleg	Acinetobacter baumannii and hospital infections	2014	Microbiology Australia	microbiology.publish.csiro.au
0	TZAH BOGOVIĆ, ANA BUDIMIR, Z BOŠNJAK...	Inhalation plus intravenous colistin versus intravenous colistin alone for treatment of ventilator associated pneumonia	2014	SIGNA VITAE	signavitae.com
0	YT Chen, M Rabilloud, JM Thiolet, B Coignard...	Benchmarking French regions according to their prevalence of healthcare-associated infections	2013	International journal for ...	ISQHC
0	T Gouliouris, SJ Peacock	The rise and fall of mandatory surveillance for glycopeptide-resistant enterococcal bacteraemia in England	2014	Journal of Infection	yadda.icm.edu.pl
0	A Voss, J Hopman, SS Magill...	Survey of health care-associated infections.	2014	The New England ...	Mass Medical Soc
0	N de Jong, A Eikelenboom-Boskamp, A Voss...	User-Centered and Persuasive Design of a Web-Based Registration and Monitoring System for Healthcare-Associated Infections in Nursing Homes	2014	eTELEMED 2014, The ...	thinkmind.org
0	F Agnoletti, E Mazzolini, C Bacchin, L Bano...	First reporting of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) ST398 in an industrial rabbit holding and in farm-related people	2014	Veterinary ...	Elsevier
0	J Davis, MT Molina, CP Leach...	Plasma-Polyplumbagin-Modified Microfiber Probes: A Functional Material Approach to Monitoring Vascular Access Line Contamination	2013	ACS applied materials & ...	ACS Publications
0	SJ Knowles, NP O'Sullivan, AM Meenan...	Maternal sepsis incidence, aetiology and outcome for mother and fetus: a prospective study	2014	... Journal of Obstetrics ...	Wiley Online Library

0	ML Lambert, N Hammami, B Catry, R Bruyndonckx...	Antimicrobial consumption in Belgian hospitals for selected diagnoses	0	nsih.be	n.d.
0	V Liebens, V Defraigne, A Van der Leyden...	A putative de-N-acetylase of the PIG-L superfamily affects fluoroquinolone tolerance in <i>Pseudomonas aeruginosa</i>	2014	Pathogens and ...	Wiley Online Library
0	RJ Wytzman	Résultats de la 5 ème campagne nationale pour la promotion de l'hygiène des mains	0	nsih.be	n.d.
0	RJ Wytzman	Septicémies à l'hôpital (SEP) Protocole de surveillance	2012	n.d.	nsih.be
0	B Bogdanić	Analiza uporabe antimikrobnih lijekova i mikrobioloških nalaza kao metoda praćenja prevalencije bolničkih infekcija u kliničkoj bolnici [Analysis use of antimicrobial ...	2013	n.d.	medlib.mef.hr
0	EA Smid, TEM Hopmans, SC de Greeff, MBG Koek	Daling van de prevalentie van zorginfecties in ziekenhuizen	0	Infectieziekten Bulletin	doc.utwente.nl
0	M PROSEN	ODSTRANJEVANJE DLAK KOT POMEMBEN DEJAVNIK PREPREČEVANJA OKUŽB KIRURŠKE RANE	0	Izdala in založila	soms.si
0	UBA El Mohammadi	Grado en Enfermería	0	zagan.unizar.es	n.d.
0	Á Asensio	Infección de la localización quirúrgica. Profilaxis antimicrobiana en cirugía	2014	Enfermedades Infecciosas y Microbiología Clínica	Elsevier
0	ICDS Goulão	Infeções associadas aos cuidados de saúde	2014	n.d.	recil.grupulusofona.pt
0	R Cantón, P Ruiz-Garbajosa	Infecciones causadas por bacterias grampositivas multiresistentes<i>(Staphylococcus aureus</i> y<i> Enterococcus</i> spp.)	2013	Enfermedades Infecciosas y Microbiología ...	Elsevier
0	PAC d'Azur	Enquête nationale de prévalence des infections nosocomiales et des traitements anti-infectieux en établissement de santé, France, juin 2012	2012	n.d.	cclin-sudest.chu-lyon.fr
0	N Hammami	Surveillance des septicémies à l'hôpital en Belgique	0	nsih.be	n.d.
0	N Hammami, ML Lambert	Surveillanceprogramma van septicemieën in ziekenhuizen in België Gegevens 2000-2011	2013	n.d.	nsih.be

15. Zarb P, Coignard B, Griskeviciene J, Muller A, Vankerckhoven V, Weist K, Goossens MM, Vaerenberg S, Hopkins S, Catry B, Monnet DL, Goossens H, Suetens C, National Contact Points for the ECDC pilot point prevalence survey, Hospital Contact Points for the ECDC pilot point prevalence survey. The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use. Euro Surveill. 2012;17(46):pii=20316.

Available online: <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20316>

Total nr. of papers: 26

H-index: 4

Cites	Authors	Title	Year	Source	Publisher
9	M Behnke, S Hansen, R Leistner, LAP Diaz...	Nosocomial infection and antibiotic use: a second national prevalence study in Germany	2013	Deutsches Ärzteblatt ...	ncbi.nlm.nih.gov
7	J Reilly, S Cairns, S Fleming, D Hewitt...	Results from the second Scottish national prevalence survey: the changing epidemiology of healthcare-associated infection in Scotland	2012	Journal of Hospital ...	Elsevier
6	E Ott, S Saathoff, K Graf, F Schwab...	The prevalence of nosocomial and community acquired infections in a university hospital: an observational study	2013	Deutsches Ärzteblatt ...	ncbi.nlm.nih.gov
6	M Pujol, E Limón	Epidemiología general de las infecciones nosocomiales. Sistemas y programas de vigilancia	2013	Enfermedades Infecciosas y Microbiología Clínica	Elsevier
4	P Zarb, B Coignard, J Griskeviciene, A Muller... The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use	2012	Euro Surveill	n.d.
4	T Bruun, HL Loewer	Prevalence surveillance system of nosocomial infections in Norway	2007	Euro Surveill	eurosurveillance.org
2	S Hansen, D Sohr, B Piening...	Antibiotic usage in German hospitals: results of the second national prevalence study	2013	Journal of ...	Br Soc Antimicrob Chemo
2	S Grau, G Bou, E Fondevilla, J Nicolás...	How to measure and monitor antimicrobial consumption and resistance	2013	... y microbiologia clinica	Elsevier
1	G Messina, E Ceriale, S Burgassi, C Russo...	Impact of a disinfecting technique on microbial contamination of computer keyboards and telephone handsets	2013	Journal of Hospital ...	sciedu.ca
1	SN Ladhani, ME Ramsay, JS Flood, H Campbell...	Vaccination catch-up campaign in response to recent increase in invasive Hib infection in the United Kingdom—implications for the rest of Europe?	2003	n.d.	eurosurveillance.org
0	R Plowman	Citation style for this article: Plowman R. The socioeconomic burden of hospital acquired infection. Euro Surveill. 2000; 5 (4): pii= 4. Available online: http://...	0	eurosurveillance.org	n.d.
0	M Cizman, B Beovic	Antibiotic hospital consumption expressed in defined daily doses (DDD)/100 bed-days	2014	Infection	Springer
0	C Suetens	Retrospective screening of serum and cerebrospinal fluid samples from patients with acute meningo-encephalitis does not reveal past Japanese encephalitis ...	0	eurosurveillance.org	n.d.
0	M Gregor, P Paterová, V Buchta, J Keřánek...	Healthcare-associated infections in gynecology and obstetrics at a university hospital in the Czech Republic	2014	International Journal of ...	Elsevier
0	R López-Gigosos, A Mariscal...	Persistence of nosocomial bacteria on 2 biocidal fabrics based on silver under conditions of high relative humidity	2014	American journal of ...	Elsevier

0	GSA Abis, HBAC Stockmann, M van Egmond...	Selective Decontamination of the Digestive Tract in Gastrointestinal Surgery: Useful in Infection Prevention? A Systematic Review	2013	Journal of ...	Springer
0	D Xie, X Fu, H Wang, L Wang, R Li, Q Luo...	Annual point-prevalence of healthcare-associated infection surveys in a university hospital in China, 2007–2011	2013	Journal of infection and ...	Elsevier
0	J Struwe	Citation style for this article: Struwe J, Dumpis U, Gulbinovic J, Lagergren Å, Bergman U. Healthcare associated infections in university hospitals in Latvia, ...	0	eurosurveillance.org	n.d.
0	K Kaier, ML Lambert, UK Frank, W Vach...	Impact of availability of guidelines and active surveillance in reducing the incidence of ventilator-associated pneumonia in Europe and worldwide	2014	BMC infectious ...	biomedcentral.com
0	M Christensen	Citation style for this article: Christensen M, Meyer M, Jepsen OB. Reuse of single-use sterile medical devices decreased in Danish hospitals after report ...	0	Endoscopy	eurosurveillance.org
0	C Rothe, C Schlaich, S Thompson	Healthcare-associated infections in sub-Saharan Africa	2013	Journal of Hospital Infection	Elsevier
0	G Sanclemente, M Bodro, C Cervera...	Protocolo de tratamiento antibiótico empírico de un paciente ingresado febril sin evidencia clínica de focalidad	2014	Medicine-Programa de ...	Elsevier
0	E Ott, S Saathoff, K Graf, F Schwab, IF Chaberny	Prävalenz von nosokomialen und mitgebrachten Infektionen in einer Universitätsklinik	0	data.aerzteblatt.de	n.d.
0	U Dumpis	Citation style for this article: Dumpis U, Balode A, Vīgante D, Narbutė I, Valinteliene R, Pirags V, Martinsons A, Vingre I. Prévalence des infections ...	0	eurosurveillance.org	n.d.
0	B Bogdanić	Analiza uporabe antimikrobnih lijekova i mikrobioloških nalaza kao metoda praćenja prevalencije bolničkih infekcija u kliničkoj bolnici [Analysis use of antimicrobial ...	2013	n.d.	medlib.mef.hr
0	AA Cuza, RC Gutiérrez...	Incidencia de infección relacionada con el cuidado sanitario en unidades de cuidados intensivos en Cuba. Año 2012	2013	Investigaciones ...	revcimeq.sld.cu
0	R Plowman	Citation style for this article: Plowman R. Il carico socioeconomico delle infezioni ospedaliere. Euro Surveill. 2000; 5 (4): pii= 4. Available online: http://www. ...	0	eurosurveillance.org	n.d.

16. European Centre for Disease Prevention and Control. Methodology protocol for estimating burden of communicable diseases. Stockholm: ECDC;2010.

Total nr. of papers: 6

H-index: 2

Cites	Authors	Title	Year	Source	Publisher
21	M Braks, J van der Giessen, M Kretzschmar...	Towards an integrated approach in surveillance of vector-borne diseases in Europe	2011	Parasit ...	biomedcentral.com

13	M Kretzschmar, MJJ Mangan, P Pinheiro, B Jahn...	New methodology for estimating the burden of infectious diseases in Europe	2012	PLoS medicine	dx.plos.org
0	D Plass, P Pinheiro, MJ Mangan	Health Adjusted Life Years (HALY)–A Promising Measure to Estimate the Burden of Zoonotic Diseases on Human Health?	0	cdn.intechopen.com	n.d.
0	CL Gibbons, MJJ Mangan, D Plass...	Measuring underreporting and under-ascertainment in infectious disease datasets: a comparison of methods	2014	BMC public ...	biomedcentral.com
0	PE DEFINIZIONI	SORVEGLIANZA DELLE MALATTIE GASTROENTERICHE ACUTE TRASMESSE DA ALIMENTI (MTA) IN SANITÀ PUBBLICA	0	ISTITUTO SUPERIORE DI SANITÀ	usl3.toscana.it
0	T Hald, DL Baggesen	EFSA Panel on Biological Hazards (BIOHAZ); Scientific Opinion on VTEC-seropathotype and scientific criteria regarding pathogenicity assessment	2013	n.d.	orbit.dtu.dk

17. Infanti J, Sixsmith J, Barry M M, Núñez-Córdoba J, Oroviogicochea-Ortega C, Guillén-Grima F. A literature review on effective risk communication for the prevention and control of communicable diseases in Europe. Stockholm: ECDC; 2013.

Total nr. of papers: 6

H-index: 1

Cites	Authors	Title	Year	Source	Publisher
1	G Cairns, M de Andrade...	Reputation, Relationships, Risk Communication, and the Role of Trust in the Prevention and Control of Communicable Disease: A Review	2013	Journal of health ...	Taylor & Francis
0	A Würz, ÜK Nurm, K Ekdahl	Enhancing the Role of Health Communication in the Prevention of Infectious Diseases	2013	Journal of health communication	Taylor & Francis
0	M Walker, G Elliott, P Fairbrother	Briefing Note: Identifying effective risk communication procedures and products	0	mams.rmit.edu.au	n.d.
0	G Bohlin, GE Höst	Is it my responsibility or theirs? Risk communication about antibiotic resistance in the Swedish daily press	0	jcom.sissa.it	n.d.
0	G Elliott, M Walker, V Cooper, P Fairbrother, K Toh	The RMIT 'Communications Grid': A Formative Knowledge Management Tool	0	mams.rmit.edu.au	n.d.
0	GM Mubyazi, VK Barongo, ML Kamugisha...	Public Knowledge, Perceptions and Practices in Relation to Infectious and other Communicable Diseases in Tanzania: Lessons Learnt from Babati District	2013	Rwanda Journal of ...	ajol.info

18. O'Flanagan D, Cormican M, McKeown P, Nicolay N, Cowden J, Mason B, Morgan D, Lane C, Irvine N, Browning L. A multi-country outbreak of Salmonella Agona, February - August 2008. Euro Surveill. 2008;13(33):pii=18956.

Available online: <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18956>

Total nr. of papers: 13

H-index: 6

Cites	Authors	Title	Year	Source	Publisher
85	JT Larsson, M Torpdahl, RF Petersen...	Development of a new nomenclature for Salmonella Typhimurium multilocus variable number of tandem repeats analysis (MLVA)	2009	Eurosurveillance	eurosurveillance.org
14	NM Keklik, A Demirci, VM Puri	Decontamination of unpackaged and vacuum-packaged boneless chicken breast with pulsed ultraviolet light	2010	Poultry science	ps.oxfordjournals.org
12	N Nicolay, L Thornton, S Cotter...	Salmonella enterica serovar Agona European outbreak associated with a food company	2011	Epidemiology and ...	Cambridge Univ Press
12	FJ Cooke, S Ginwalla, MD Hampton...	Report of neonatal meningitis due to Salmonella enterica serotype Agona and review of breast milk-associated neonatal Salmonella infections	2009	Journal of clinical ...	Am Soc Microbiol
9	A Baumann-Popczyk...	Incidence of self-reported acute gastrointestinal infections in the community in Poland: a population-based study	2012	Epidemiology and ...	Cambridge Univ Press
6	CA Gómez-Aldapa...	The role of foods in Salmonella infections	2012	... : Intech Publisher. p	cdn.intechopen.com
1	NM Keklik	Decontamination of poultry products by pulsed UV-light	2009	n.d.	etda.libraries.psu.edu
1	G Perdoncini	Salmonella spp. em granjas de postura em processo de certificação para a produção orgânica no Rio Grande do Sul	2011	n.d.	lume.ufrgs.br
0	T Westrell	european outbreaks	2007	SURVEILLANCE AND OUTBREAK REPORTS	Citeseer
0	T Westrell	Mapping the future dynamics of disease transmission: risk analysis in the United Kingdom Foresight Programme on the detection and identification of ...	0	eurosurveillance.org	n.d.
0	P Wall	One Health and the food chain: maintaining safety in a globalised industry	2014	Veterinary Record	veterinaryrecord.bmj.com
0	M Heck	Multilocus variable nuMber of tandeM repeats analysis (Mlva)-investigation of salMonella typhiMuriuM outbreaks	0	eurosurveillance.org	n.d.
0	T Westrell	Salmonella Typ himurium: experiencesf ro mrece nT eu ro p ean o uTb r eaks	0	eurosurveillance.org	n.d.

19. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), European Centre for Disease Prevention and Control (ECDC). Joint EMCDDA and ECDC rapid risk assessment: HIV in Injecting Drug Users in the EU/EEA, following a reported increase of cases in Greece and Romania. Lisbon: EMCDDA; 2012.

Total nr. of papers: 6

H-index: 1

Cites	Authors	Title	Year	Source	Publisher
2	E van Ginneken, J Habicht, L Murauskienė...	The Baltic states: building on 20 years of health reforms	2012	BMJ: British Medical ...	bmj.com
1	J Janiec, K Haar, G Spiteri, G LikataVICIUS...	Surveillance of human immunodeficiency virus suggests that younger men who have sex with men are at higher risk of infection, European Union, 2003 to 2012	2013	Euro ...	eurosurveillance.org
0	D Hedrich, E Kalamara, O Sfetcu, A Pharris, A Noor...	Surveillance of human immunodeficiency virus suggests that younger men who have sex with men are at higher risk of infection, European Union, 2003 to ...	0	eurosurveillance.org	n.d.
0	F Nakagawa, AN Phillips, JD Lundgren	Update on HIV in Western Europe	2014	Current HIV/AIDS Reports	Springer
0	D Hedrich, E Kalamara, O Sfetcu...	Human immunodeficiency virus among people who inject drugs: Is risk increasing in Europe?	2013	... Européen sur les ...	eurosurveillance.org
0	W Kaplan	Background Paper 6.7 Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndromes (AIDS)	2013	n.d.	who.int

20. European Centre for Disease Prevention and Control. Operational guidance on rapid risk assessment methodology. Stockholm: ECDC; 2011

Total nr. of papers: 10

H-index: 1

Cites	Authors	Title	Year	Source	Publisher
6	J Fonager, S Barzinci, TK Fischer	Emergence of a new recombinant Sydney 2012 norovirus variant in Denmark, 26 December 2012 to 22 March 2013	2013	Euro Surveill	eurosurveillance.eu
1	S Palmer, A Jansen, K Leitmeyer...	Evidence-Based Medicine applied to the control of communicable disease incidents when evidence is scarce and the time is limited	2013	... Européen sur les ...	eurosurveillance.org
0	S Palmer, A Jansen, K Leitmeyer, H Murdoch...	Emergence of a new recombinant Sydney 2012 norovirus variant in Denmark, 26 December 2012 to 22 March 2013 High prevalence of antibodies against ...	0	eurosurveillance.org	n.d.
0	R ASSESSMENT	Wild-type poliovirus 1 transmission in Israel—what is the risk to Europe?	0	Citeseer	n.d.
0	K Pak, L Genik	Risk Assessment References: Documented Literature Search	2012	n.d.	DTIC Document

0	A Economopoulou, P Kinross, D Domanovic...	International infectious disease surveillance during the London Olympic and Paralympic Games 2012: process and outcomes Ongoing multi-strain food-borne ...	0	eurosurveillance.org	n.d.
0	A Economopoulou, P Kinross, D Domanovic...	Infectious diseases prioritisation for event-based surveillance at the European Union level for the 2012 Olympic and Paralympic Games	2014	n.d.	eurosurveillance.org
0	T Hald	EFSA Panel on Biological Hazards (BIOHAZ); Scientific Opinion on on the development of a risk ranking framework on biological hazards	2012	n.d.	orbit.dtu.dk
0	B Guzman-Herrador, L Jensvoll...	Ongoing hepatitis A outbreak in Europe 2013 to 2014: imported berry mix cake suspected to be the source of infection in Norway	2014	... Europeen sur les ...	eurosurveillance.org
0	S Santos-Sanz, MJ Sierra- Moros...	POSIBILIDAD DE INTRODUCCIÓN Y CIRCULACIÓN DEL VIRUS DEL DENGUE EN ESPAÑA (*)	2014	Rev Esp Salud ...	msssi.gob.es

ANNEX E - UPDATED BIBLIOGRAPHY

- Amato-Gauci, A., Ammon, A.. "The surveillance of communicable diseases in the European Union - a long term strategy (2008-2013)". *Eurosurveillance*, Vol. 13, Issues 4-6. April-June 2008. Web. <http://www.eurosurveillance.org/images/dynamic/EE/V13N26/art18912.pdf>
- Bayer, C., Bernard, H., Prager, R., Rabsch, W., Hiller, P., Malorny, B., Pfefferkorn, B., Frank, C., de Jong, A., Friesema, I., Stark, K., Rosner, B.M.. "An outbreak of Salmonella Newport associated with mung bean sprouts in Germany and the Netherlands, October to November 2011". *Eurosurveillance*, vol 19(1):pii=20665 (2014).
- Bernard, E. J.. "The negative impact on public health" in *HIV & the Criminal Law*. London: NAM, 2010. *aidsmap.com*. Web. <http://www.aidsmap.com/The-negative-impact-on-public-health/page/1444157/>
- Dieleman, J., Romio, S., Johansen, K., Weibel, D., Bonhoeffer, J., Sturkenboom, M., VAESCO-GBS Case-Control Study Group. "Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe". *Pubmed* (2011). Jul 12;343:d3908. Web. <http://www.ncbi.nlm.nih.gov/pubmed/21750072>
- ECORYS Nederland BV. *External Evaluation of the ECDC*. Rotterdam, 15 August 2008. *ecdc.europa.eu*. Web. http://www.ecdc.europa.eu/en/aboutus/key%20documents/0808_kd_external_evaluation.pdf
- European Centre for Disease Prevention and Control, European Food Safety Authority. *Joint ECDC-EFSA rapid risk assessment on Multi-country outbreak of Salmonella Stanley infections. Third update*. Stockholm: ECDC; 2014. *ecdc.europa.eu*. Web. <http://www.ecdc.europa.eu/en/publications/Publications/salmonella-stanley-multi-country-outbreak-assessment-8-May-2014.pdf>
- European Centre for Disease Prevention and Control, European Food Safety Authority. *Joint ECDC-EFSA rapid risk assessment on Multi-country outbreak of Salmonella Stanley infections. Update*. Stockholm: ECDC; 2012. *ecdc.europa.eu*. Web. http://www.ecdc.europa.eu/en/publications/Publications/20120921_RRA_Stanley_Salmonella.pdf
- European Centre for Disease Prevention and Control, European Monitoring Centre for Drugs and Drug Addiction. *Prevention and control of infectious diseases among people who inject drugs*. Stockholm: ECDC; 2011. *ecdc.europa.eu*. Web. http://ecdc.europa.eu/en/publications/publications/111012_guidance_ecdc-emcdda.pdf
- European Centre for Disease Prevention and Control, WHO Regional Office for Europe. *First Memorandum of Understanding between the World Health Organisation, Regional Office for Europe ("WHO/EURO") and the European Centre for Disease Prevention and Control ("The Centre")*. 13 Sept 2005. *ecdc.europa.eu*. Web. http://www.ecdc.europa.eu/en/press/news/Documents/050919_MoU_ECDC_WHO_Euro.pdf
- European Centre for Disease Prevention and Control, European Food Safety Authority. *Memorandum of Understanding between the European Food Safety Authority and the European Centre for Disease Prevention and Control*. Brussels, 3 April 2008. *efsa.europa.eu*. Web. <http://www.efsa.europa.eu/en/cooperationagreements/docs/mouecdc.pdf>
- European Centre for Disease Prevention and Control, WHO Regional Office for Europe. *HIV/AIDS surveillance in Europe 2012*. Stockholm: ECDC; 2013. *ecdc.europa.eu*. Web. <http://www.ecdc.europa.eu/en/publications/Publications/hiv-aids-surveillance-report-2012-20131127.pdf>

European Centre for Disease Prevention and Control. *Strategies for disease-specific programmes 2010-2013*. Stockholm: ECDC; 2010. *ecdc.europa.eu*. Web.

http://www.ecdc.europa.eu/en/publications/publications/100714_cor_strategies_for_disease_specific_programmes_2010-2013.pdf

European Centre for Disease Prevention and Control. *Evidence-based methodologies for public health - How to assess the best available evidence when time is limited and there is lack of sound evidence*. Stockholm: ECDC; 2011. *ecdc.europa.eu*. Web.

http://ecdc.europa.eu/en/publications/Publications/1109_TER_evidence_based_methods_for_public_health.pdf

European Centre for Disease Prevention and Control. "Association of childhood narcolepsy and cataplexy and receipt of a pandemic influenza vaccine in Finland in 2009-10 – First papers in a peer review journal". *ecdc.europa.eu*. 30 Mar 2012. Web.

http://www.ecdc.europa.eu/en/activities/sciadvise/_layouts/forms/Review_DispatchForm.aspx?List=a3216f4c-f040-4f51-9f77-a96046dbfd72&ID=691

European Centre for Disease Prevention and Control. "Narcolepsy and Pandemrix Vaccine – an association in adults as well as children". *ecdc.europa.eu*. 24 Sept 2012. Web.

http://www.ecdc.europa.eu/en/activities/sciadvise/_layouts/forms/Review_DispatchForm.aspx?ID=716&List=a3216f4c-f040-4f51-9f77-a96046dbfd72

European Centre for Disease Prevention and Control. *2013 Learning and Development Catalogue*. 8 April 2013. Internal ECDC material. Unpublished.

European Centre for Disease Prevention and Control. *2013 Learning and Development Report*. January 2014. Internal ECDC Report. Unpublished.

European Centre for Disease Prevention and Control. *Administrative Arrangement between the World Health Organisation, Regional Office for Europe ("WHO/EURO") and The European Centre for Disease Prevention and Control ("ECDC")*. 25 Mar 2011. Internal WHO/EURO and ECDC Document. Unpublished.

European Centre for Disease Prevention and Control. *Analysis of the Indicators for the Strategic Multi-annual Programme 2007-2013 (Update 2012)*. MB27/9. Twenty-seventh Meeting of the ECDC Management Board. 20-21 Mar 2013. Internal ECDC Document. Unpublished.

European Centre for Disease Prevention and Control. *Annual Communication Plan 2011, 2012, 2013*. n.d. Internal ECDC Document. Unpublished.

European Centre for Disease Prevention and Control. *Annual epidemiological report 2011 - Reporting on 2009 surveillance data and 2010 epidemic intelligence data*. Stockholm: ECDC; 2011. *ecdc.europa.eu*. Web. http://www.ecdc.europa.eu/en/publications/Publications/1111_SUR_Annual_Epidemiological_Report_on_Communicable_Diseases_in_Europe.pdf

European Centre for Disease Prevention and Control. *Annual Epidemiological Report 2012. Reporting on 2010 surveillance data and 2011 epidemic intelligence data*. Stockholm: ECDC; 2013. *ecdc.europa.eu*. Web. <http://www.ecdc.europa.eu/en/publications/Publications/Annual-Epidemiological-Report-2012.pdf>

European Centre for Disease Prevention and Control. *Annual Epidemiological Report 2013. Reporting on 2011 surveillance data and 2012 epidemic intelligence data*. Stockholm: ECDC; 2013. *ecdc.europa.eu*. Web. <http://www.ecdc.europa.eu/en/publications/Publications/annual-epidemiological-report-2013.pdf>

European Centre for Disease Prevention and Control. *Annual Epidemiological Report on Communicable Diseases in Europe 2008*. Stockholm: ECDC; 2008. *ecdc.europa.eu*. Web. http://www.ecdc.europa.eu/en/publications/Publications/0812_SUR_Annual_Epidemiological_Report_2008.pdf

European Centre for Disease Prevention and Control. *Annual Epidemiological Report on Communicable Diseases in Europe 2009*. Stockholm: ECDC; 2009. *ecdc.europa.eu*. Web. http://www.ecdc.europa.eu/en/publications/Publications/0910_SUR_Annual_Epidemiological_Report_on_Communicable_Diseases_in_Europe.pdf

European Centre for Disease Prevention and Control. *Annual Epidemiological Report on Communicable Diseases in Europe 2010*. Stockholm: ECDC; 2010. *ecdc.europa.eu*. Web. http://www.ecdc.europa.eu/en/publications/Publications/1011_SUR_Annual_Epidemiological_Report_on_Communicable_Diseases_in_Europe.pdf

European Centre for Disease Prevention and Control. *Annual Report of the Director, 2009*. Stockholm: ECDC, 2010. *ecdc.europa.eu*. Web.

European Centre for Disease Prevention and Control. *Annual Report of the Director, 2010*. Stockholm: ECDC, 2011. *ecdc.europa.eu*. Web.

European Centre for Disease Prevention and Control. *Annual Report of the Director, 2012*. Stockholm: ECDC, 2013. *ecdc.europa.eu*. Web. <http://www.ecdc.europa.eu/en/aboutus/key%20documents/cor-annual-report-director-2012.pdf>

European Centre for Disease Prevention and Control. *ESCAIDE Abstract Book 2008*. Stockholm: ECDC, 2008.

European Centre for Disease Prevention and Control. *ESCAIDE Abstract Book 2009*. Stockholm: ECDC, 2009.

European Centre for Disease Prevention and Control. *ESCAIDE Abstract Book 2010*. Stockholm: ECDC, 2010.

European Centre for Disease Prevention and Control. *ESCAIDE Abstract Book 2012*. Stockholm: ECDC, 2012.

European Centre for Disease Prevention and Control. *ESCAIDE Abstract Book 2013*. Stockholm: ECDC, 2013.

European Centre for Disease Prevention and Control. *Assessing the potential impacts of climate change on food-and waterborne diseases in Europe*. Stockholm: ECDC; 2012. *ecdc.europa.eu*. Web. <http://www.ecdc.europa.eu/en/publications/Publications/1203-TER-Potential-impacts-climate-change-food-water-borne-diseases.pdf>

European Centre for Disease Prevention and Control. *Conclusion and Recommendation of the MB based on the External Evaluation of ECDC*. MB Extraordinary 1/5. 23 Sept 2008. Internal ECDC Document. Unpublished.

European Centre for Disease Prevention and Control. *Coordinating Competent Bodies: structures, interactions and terms of reference*. Main text and annexes. 7 Dec 2012. Internal ECDC Document. Unpublished.

European Centre for Disease Prevention and Control. *Developing a Microbiology Capability Monitoring System for the European Union – Revised Version 2.1*. NMFP11/6. Eleventh Meeting of the ECDC National Microbiology Focal Points. 7-8 Nov 2013. Internal ECDC Document. Unpublished.

European Centre for Disease Prevention and Control. *General Strategy and Framework of Actions (2007-2013) for ECDC Cooperations with Microbiology Laboratories and Research Institutes in the EU*. Eleventh Meeting of the ECDC Management Board. 13-14 Dec. 2007.

European Centre for Disease Prevention and Control. *Ensuring quality in public health microbiology laboratories in the EU: Quality control and areas in need of strengthening*. Meeting Report. 9-10 Sept. 2009. [ecdc.europa.eu](http://www.ecdc.europa.eu). Web.

http://www.ecdc.europa.eu/en/publications/Publications/0912_MER_Ensuring_Quality_in_Public_Health_Microbiology_Laboratories_in_the_EU.pdf

European Centre for Disease Prevention and Control. *Disease specific surveillance report production*. 21 Aug 2012. Internal ECDC Report. Unpublished.

European Centre for Disease Prevention and Control. *ECDC Compendium for Management of Laboratory External Quality Assessment schemes*. 18 Mar 2013. Internal ECDC Document. Unpublished.

European Centre for Disease Prevention and Control. *ECDC Microbiology Activities Report 2012. Overview of activities, suggestions for next steps and Considerations for further strategic planning*. n.d. Internal ECDC Report. Unpublished.

European Centre for Disease Prevention and Control. *ECDC Project Office governance. Project management methodology implementation planning*. SMT91. Ninety-first Meeting of the ECDC Senior Management Team. 16 Apr 2013. Internal ECDC Document. Unpublished.

European Centre for Disease Prevention and Control. *ECDC Public Health Microbiology Programme and Microbiology Coordination Section. Revised Terms of Reference*. Oct 2012. Internal ECDC Document. Unpublished.

European Centre for Disease Prevention and Control. *ECDC Rapid Risk Assessment. A(H5N1) Highly Pathogenic Avian Influenza in Egypt – Implications for human health in Europe*. Stockholm: ECDC; 2011. [ecdc.europa.eu](http://www.ecdc.europa.eu). Web.

http://www.ecdc.europa.eu/en/publications/Publications/110915_TER_Rapid_risk_assessment_AH5N1_Egypt.pdf

European Centre for Disease Prevention and Control. *ECDC Risk Assessment. 2009 Influenza A(H1N1) pandemic*. Stockholm: ECDC; 2009. [ecdc.europa.eu](http://www.ecdc.europa.eu). Web.

http://www.ecdc.europa.eu/en/healthtopics/documents/0908_influenza_ah1n1_risk_assessment.pdf

European Centre for Disease Prevention and Control. *ECDC scientific advice on seasonal influenza vaccination of children and pregnant women*. Stockholm: ECDC; 2012. [ecdc.europa.eu](http://www.ecdc.europa.eu). Web.

<http://www.ecdc.europa.eu/en/publications/publications/seasonal%20influenza%20vaccination%20of%20children%20and%20pregnant%20women.pdf>

European Centre for Disease Prevention and Control. *ECDC Stakeholders Analysis Final report*. n.d. Internal ECDC Report. Unpublished.

European Centre for Disease Prevention and Control. *ECDC Strategic Multi-annual Programme 2007-2013: Public Health Activities, Disease-specific Programmes and Multilateral Partnerships*. Stockholm: ECDC, 2008. [ecdc.europa.eu](http://www.ecdc.europa.eu). Web.

European Centre for Disease Prevention and Control. *ECDC strategic multi-annual programme 2014–2020*. Stockholm: ECDC; 2014. [ecdc.europa.eu](http://www.ecdc.europa.eu). Web.

<http://www.ecdc.europa.eu/en/aboutus/Key%20Documents/Strategic-multiannual-programme-2014-2020.pdf>

European Centre for Disease Prevention and Control. *ECDC Threat Assessment. Public health issue. Implication for Europe of the identification in North America of human cases of influenza A/H1N1, with a unique gene segment combination*. Stockholm: ECDC; 2009. [ecdc.europa.eu](http://www.ecdc.europa.eu). Web.

http://ecdc.europa.eu/en/healthtopics/h1n1/documents/1001_ra_090430.pdf

European Centre for Disease Prevention and Control. *Surveillance and early detection and response systems in Latvia*. Stockholm: ECDC; 2013. *ecdc.europa.eu*. Web.

<http://www.ecdc.europa.eu/en/publications/Publications/surveillance-latvia-country-mission.pdf>

European Centre for Disease Prevention and Control. *EPIET fellowships in Field Epidemiology and Public Health Microbiology: An option paper to prepare a consultation of stakeholders*. 17 Sept 2012. Internal ECDC Report. Unpublished.

European Centre for Disease Prevention and Control. *External quality assurance scheme for Salmonella typing*. Stockholm: ECDC, 2010. *ecdc.europa.eu*. Web.

http://www.ecdc.europa.eu/en/publications/Publications/1011_TER_External_quality_assurance_scheme_for_salmonella_typing.pdf

European Centre for Disease Prevention and Control. *Fostering collaboration in public health microbiology in the European Union*. Stockholm: ECDC; 2010. *ecdc.europa.eu*. Web.

http://www.ecdc.europa.eu/en/publications/Publications/1012_TER_Fostering_collaboration.pdf

European Centre for Disease Prevention and Control. *Fourth external quality assurance scheme for Salmonella typing*. Stockholm: ECDC; 2013. *ecdc.europa.eu*. Web.

<http://www.ecdc.europa.eu/en/publications/Publications/salmonella-external-quality-assessment-EQA-scheme-for-typing-2013.pdf>

European Centre for Disease Prevention and Control. *Framework for the monitoring of agreements signed between ECDC and other organisations (Draft)*. Sept 2012. Internal ECDC Document. Unpublished.

European Centre for Disease Prevention and Control. *FWD Molecular Surveillance Pilot. Standard Operating Procedures*. (10 Items). n.d. Internal ECDC Documents. Unpublished.

European Centre for Disease Prevention and Control. *Guiding Principles for Disease-Specific Work in ECDC*. 30 Mar 2011. Internal ECDC Document. Unpublished.

European Centre for Disease Prevention and Control. *HIV testing: increasing uptake and effectiveness in the European Union*. Stockholm: ECDC;2010. *ecdc.europa.eu*. Web.

http://ecdc.europa.eu/en/publications/publications/101129_gui_hiv_testing.pdf

European Centre for Disease Prevention and Control. *Joint technical mission: HIV in Greece 28–29 May 2012*. Stockholm: ECDC; 2013. *ecdc.europa.eu*. Web.

<http://ecdc.europa.eu/en/publications/publications/hiv-joint-technical%20mission-hiv-in-greece.pdf>

European Centre for Disease Prevention and Control. *Improving performance: ECDC initiatives on quality management*. MB29/14. Twenty-ninth Meeting of the ECDC Management Board. 14-15 Nov 2013. Internal ECDC Document. Unpublished.

European Centre for Disease Prevention and Control. *Independence policy and implementing rules on Declarations of Interests*. MB26/11 Rev. 1. Twenty-sixth Meeting of the ECDC Management Board. 14-15 Nov 2012. Internal ECDC Document. Unpublished.

European Centre for Disease Prevention and Control. *Long-term Surveillance Strategy 2014-2020*. Stockholm: ECDC; 2013. *ecdc.europa.eu*. Web. <http://www.ecdc.europa.eu/en/publications/publications/long-term-surveillance-strategy-2014-2020.pdf>

European Centre for Disease Prevention and Control. *Manual for monitoring data quality and evaluation of surveillance systems. Working group surveillance systems quality*. Nov 2013. Internal ECDC Document. Unpublished.

European Centre for Disease Prevention and Control. *Media Coverage Report Q1-Q4 2011. January – December 2011*. n.d. Internal ECDC Document. Unpublished.

European Centre for Disease Prevention and Control. *Media Coverage Report Q1-Q4 2012. January – December 2012*. n.d. Internal ECDC Document. Unpublished.

European Centre for Disease Prevention and Control. *Media Coverage Report Q2-Q4 2010. April-December 2010*. n.d. Internal ECDC Document. Unpublished.

European Centre for Disease Prevention and Control. *Methodology protocol for estimating burden of communicable diseases*. Stockholm: ECDC; 2010. [ecdc.europa.eu](http://www.ecdc.europa.eu/en/publications/publications/1106_ter_burden_of_disease.pdf). Web. http://www.ecdc.europa.eu/en/publications/publications/1106_ter_burden_of_disease.pdf

European Centre for Disease Prevention and Control. *memor in association with pandemic influenza vaccination (a multi-country European epidemiological investigation)*. Stockholm: ECDC; 2012. [ecdc.europa.eu](http://www.ecdc.europa.eu/en/publications/publications/vaesco%20report%20final%20with%20cover.pdf). Web. <http://www.ecdc.europa.eu/en/publications/publications/vaesco%20report%20final%20with%20cover.pdf>

European Centre for Disease Prevention and Control. *Organisation of procurement and finance at ECDC – review 2013*. SMT97. Ninety-seventh Meeting of the ECDC Senior Management Team. 11 Jun 2013. Internal ECDC Document. Unpublished.

European Centre for Disease Prevention and Control. *Organisational Development of ECDC*. MB16/8. Sixteenth Meeting of the ECDC Management Board. 24-25 June 2009. Internal ECDC Document. Unpublished.

European Centre for Disease Prevention and Control. *Metadata Implementation Procedure*. Internal ECDC Document. Unpublished.

European Centre for Disease Prevention and Control. *Technical Analysis Plan. Surveillance Report HIV/AIDS 2011*. Internal ECDC Document. Unpublished.

European Centre for Disease Prevention and Control. *Technical Analysis Plan. Surveillance Report Zoonosis 2012*. Internal ECDC Document. Unpublished.

European Centre for Disease Prevention and Control. *Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals*. Stockholm: ECDC; 2013. [ecdc.europa.eu](http://www.ecdc.europa.eu/en/publications/publications/healthcare-associated-infections-antimicrobial-use-pps.pdf). Web. <http://www.ecdc.europa.eu/en/publications/publications/healthcare-associated-infections-antimicrobial-use-pps.pdf>

European Centre for Disease Prevention and Control. *Policy on data submission, access, and use of data within TESSy – 2011 revision*. MB23/17. n.d. Internal ECDC Document. Unpublished.

European Centre for Disease Prevention and Control. *Proposal for the future of EPIET, based on the recent EPIET Consultation*. Twenty-sixth Meeting of the ECDC Management Board. 14-15 Nov 2012. Internal ECDC Document. Unpublished.

European Centre for Disease Prevention and Control. *Rapid Risk Assessment. Multi-country outbreak of Salmonella Stanley infections*. Stockholm: ECDC; 2012. [ecdc.europa.eu](http://www.ecdc.europa.eu). Web.

<http://www.ecdc.europa.eu/en/publications/publications/1207-ter-rapid-risk-assessment-salmonella-stanley-outbreak.pdf>

European Centre for Disease Prevention and Control. *Report of the First Evaluation of EUPHEM 2012*. 29 Jan 2013. Internal ECDC Report. Unpublished.

European Centre for Disease Prevention and Control. *Revised Internal Control Standards*. MB18/13. Eighteenth Meeting of the ECDC Management Board. 17-19 Mar 2010. Internal ECDC Document. Unpublished.

European Centre for Disease Prevention and Control. *Second external quality assurance scheme for Salmonella typing*. Stockholm: ECDC; 2011. [ecdc.europa.eu](http://www.ecdc.europa.eu). Web.

http://www.ecdc.europa.eu/en/publications/Publications/1107_TER_EQA_Salmonella_2.pdf

European Centre for Disease Prevention and Control. *Surveillance and early detection and response system assessment. Questionnaire for completion by country prior to review team visit*. 2012. Internal ECDC Document. Unpublished.

European Centre for Disease Prevention and Control. *Surveillance of Communicable Diseases in the European Union. A long term strategy: 2008-2013*. Stockholm: ECDC; 2008. [ecdc.europa.eu](http://www.ecdc.europa.eu). Web. http://www.ecdc.europa.eu/en/aboutus/Key%20Documents/08-13_KD_Surveillance_of_CD.pdf

European Centre for Disease Prevention and Control. *Sustainable development and implementation of the EPIET: Multi-annual Strategic vision*. Twenty-third Meeting of the ECDC Management Board. 26 Oct 2011. Internal ECDC Document. Unpublished.

European Centre for Disease Prevention and Control. *TESSy - The European Surveillance System. A complete user guide for (i) submitters uploading data to the TESSy database and gaining approval; (ii) consumers retrieving data and printing preformatted reports. User Guide Draft Version 0.9*. Nov 2012. Internal ECDC Document. Unpublished.

European Centre for Disease Prevention and Control. *The 2009 A(H1N1) pandemic in Europe*. Stockholm: ECDC; 2010. [influenzasources.org](http://www.influenzasources.org). Web.

http://www.influenzasources.org/files/ECDC_H1N1_Review_101108_SPR_pandemic_experience.pdf

European Centre for Disease Prevention and Control. *The ECDC strategy and roadmap for integration of molecular typing into European level surveillance and epidemic preparedness*. AF33/revised. Thirty-third Meeting of the ECDC Advisory Forum. 20-21 Feb 2013. Internal ECDC Document. Unpublished.

European Centre for Disease Prevention and Control. *Surveillance of communicable diseases in Europe - a concept to integrate molecular typing data into EU-level surveillance*. Stockholm: ECDC; 2013. [ecdc.europa.eu](http://www.ecdc.europa.eu). Web. <http://www.ecdc.europa.eu/en/publications/Publications/surveillance-concept-molecular%20typing-sept2011.pdf>

European Centre for Disease Prevention and Control. *Third external quality assurance scheme for Salmonella typing*. Stockholm: ECDC; 2012. [ecdc.europa.eu](http://www.ecdc.europa.eu). Web.

<http://www.ecdc.europa.eu/en/publications/Publications/1204-TER-EQA-Salmonella-typing.pdf>

European Centre for Disease Prevention and Control. *Update of the position statement of the Commission and ECDC on human pathogen laboratories: A joint vision and strategy for the future*. Twenty-third Meeting of the ECDC Management Board. 9-10 Nov 2011. Stockholm: ECDC, 2011. [ecdc.europa.eu](http://www.ecdc.europa.eu). Web. http://ecdc.europa.eu/en/activities/microbiology/Documents/111214_microbiology_laboratory.pdf

European Centre for Disease Prevention and Control. *Updated. Public Health Microbiology Strategy & Work Plan 2012-2016*. Stockholm: ECDC, 2014. *ecdc.europa.eu*. Web.

http://ecdc.europa.eu/en/activities/microbiology/Documents/1203_updated-ECDC-public-health-microbiology-strategy-work-plan-2012-2016.pdf

European Centre for Disease Prevention and Control. *Weekly Influenza Surveillance Overview (WISO) - WISO Archive*. Stockholm: ECDC. *ecdc.europa.eu*. Web.

http://ecdc.europa.eu/en/healthtopics/seasonal_influenza/epidemiological_data/pages/weekly_influenza_surveillance_overview.aspx

European Commission. "Commission Decision of 28 April 2008 amending Decision 2002/253/EC laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119/98/EC of the European Parliament and of the Council". *Official Journal of the European Union*, L159/46. 18 Jun 2008. Web. http://ec.europa.eu/health/ph_threats/com/docs/1589_2008_en.pdf

European Commission. "Fact sheet: EU Health Security Committee". Brussels: EC, 2011. *ec.europa.eu*. Web.

European Food Safety Authority, European Centre for Disease Prevention and Control. "The European Union Summary Report on Trends and Sources of Zoonoses, Zoonotic Agents and Food-borne Outbreaks in 2011". *EFSA Journal*. (2013). 11(4):3129 [250 pp.].

European Food Safety Authority, European Centre for Disease Prevention and Control. "The European Union Summary Report on Trends and Sources of Zoonoses, Zoonotic Agents and Food-borne Outbreaks in 2012". *EFSA Journal*. (2014). 12(2):3547

European Monitoring Centre for Drugs and Drug Addiction, European Centre for Disease Prevention and Control. *Joint EMCDDA and ECDC Rapid Risk Assessment. HIV in injecting drug users in the EU/EEA, following a reported increase of cases in Greece and Romania*. Lisbon: EMCDDA; 2012. *emcdda.europa.eu*. Web. <http://www.emcdda.europa.eu/publications/joint-publications/hiv-in-injecting-drug-users-2011>

European Monitoring Centre for Drugs and Drug Addiction. "EMCDDA and ECDC facilitate sub-regional exchange of knowledge and best practice in monitoring and preventing drug-related infections". *emcdda.europa.eu*. 7 April 2014. Web.

European Parliament. "Decision No 1082/2013/EU of the European Parliament and of the Council of 22 October 2013 on serious cross-border threats to health and repealing Decision No 2119/98/EC". *Official Journal of the European Union*, L 293/1. 5 November 2013. *eur-lex.europa.eu* Web. <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2013:293:0001:0015:EN:PDF>

European Parliament. "Regulation (EC) No 851/2004 of the European Parliament and of the Council of 21 April 2004 establishing a European centre for disease prevention and control, *Official Journal of the European Union*, L 142/1. 30 April 2004. *ecdc.europa.eu*. Web. http://www.ecdc.europa.eu/en/aboutus/key%20documents/0404_kd_regulation_establishing_ecdc.pdf

Health Protection surveillance Centre. *Report of an International Outbreak Investigation into a Multi-country Outbreak of Salmonella Agona, Europe, 2008*. Dublin: HPSC, 2011. *hpsc.ie*. Web. <http://www.hpsc.ie/A-Z/Gastroenteric/Salmonellosis/Outbreaks/File,12549,en.pdf>

Hellenic Center for Disease Control and Prevention, *Global AIDS Response Progress Report 2013, Greece*. Athens: Keelpno, 2013. *Keelpno.gr*. Web. <http://www.keelpno.gr/Portals/0/%CE%91%CF%81%CF%87%CE%B5%CE%AF%CE%B1/HIV/GARP%202013.pdf>

Mackenbach, J. P., and McKee, M., eds. *Successes and failures of health policy in Europe. Four decades of divergent trends and converging challenges*. Open University Press, 2013. *euro.who.int*. Web. <http://www.euro.who.int/en/about-us/partners/observatory/studies/successes-and-failures-of-health-policy-in-europe.-four-decades-of-divergent-trends-and-converging-challenges>

Mereckiene, J., Cotter, S., Weber, J.T., Nicoll, A., D'Ancona, F., Lopalco, P.L., Johansen, K., Wasley, A.M., Jorgensen, P., Lévy-Bruhl, D., Giambi, C., Stefanoff, P., Dematte, L., O'Flanagan, D., the VENICE project gatekeepers group. "Influenza A(H1N1)pdm09 vaccination policies and coverage in Europe". *Eurosurveillance* (2012). 17(4):pii=20064. Web. <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20064>

COWI Consortium (Milieu Ltd.). *Evaluation of the European Scientific Conference on Applied Infectious Disease Epidemiology (ESCAIDE)*. March 2012. *Unpublished*.

O'Flanagan, D., Cormican, M., McKeown, P., Nicolay, N., Cowden, J., Mason, B., Morgan, D., Lane, C., Irvine, N., Browning, L.. "A multi-country outbreak of Salmonella Agona, February - August 2008". *Eurosurveillance* (2008). 13(33):pii=18956. Web. <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18956>

O'Flanagan, D., Cotter, S., Mereckiene, J., for VENICE II Consortium. *Pandemic A(H1N1) 2009 Influenza Vaccination Survey, Influenza season 2009/2010*. August 2010-April 2011. *Venice.cineca.org*. Web. http://venice.cineca.org/Final_Report_VENICE_Pandemic_Influenza_2009.pdf

Pages, N., et al. *Scientific review on mosquitoes and mosquito-borne diseases*. Parma: EFSA, 2009. *efsa.europa.eu*. Web.

Palm, D., Pereyaslov, D., Vaz, J., Broberg, E., Zeller, H., Gross, D., Brown, C.S., Struelens, M.J., on behalf of the Joint ECDC-WHO Regional Office for Europe Novel Coronavirus Laboratory Survey participants; ECDC National Microbiology Focal Points, WHO European Region EuroFlu Network and European Network for Diagnostics of "Imported" Viral Diseases (ENIVD). "Laboratory capability for molecular detection and confirmation of novel coronavirus in Europe, November 2012". *Eurosurveillance* (2012). 17(49):pii=20335. Web. <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20335>

Príkazský V. "The field epidemiology manual (FEM) wiki: a collaborative eLearning online portal to be launched at ESCAIDE. *Euro Surveill.* 2010;15(44):pii=19701. Available online: <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=1970>

Reading Room Ltd. *ECDC Digital Strategy*. 17 July 2012. Internal ECDC Document. *Unpublished*.

Rosin, P., Niskanen, T., Palm, D., Struelens, M., Takkinen, J., Shiga toxin-producing Escherichia coli Experts of the European Union Food- and Waterborne Diseases and Zoonoses Network. "Laboratory preparedness for detection and monitoring of Shiga toxin 2-producing Escherichia coli O104:H4 in Europe and response to the 2011 outbreak". *Eurosurveillance* (2013). 18(25):pii=20508. Web. <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20508>

Royal Tropical Institute. *External Review of the European Programme for Intervention Epidemiology Training (EPIET)*. Sept. 30, 2010. Web. <http://ecdc.europa.eu/en/epiet/about/documents/epiet%20evaluation%202010.pdf>

Struelens, M.J., Brisse, S.. "From molecular to genomic epidemiology: transforming surveillance and control of infectious diseases". *Eurosurveillance* (2013) 18(4):pii=20386. Web. <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20386>

Valenciano, M., Ciancio, B.C., on behalf of the I-MOVE study team. "I-MOVE: a European network to measure the effectiveness of influenza vaccines". *Eurosurveillance*. 2012;17(39):pii=20281. Web. <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20281>

World Health Organisation. *Communication for behavioural Impact (COMBI) A toolkit for behavioural and social communication in outbreak response*. Geneva: WHO, 2012. *who.int*. Web. http://www.who.int/ihr/publications/combi_toolkit_outbreaks/en/

World Health Organisation. *Implementation of the International Health Regulations (2005) Report of the Review Committee on the Functioning of the International Health Regulations (2005) in relation to Pandemic (H1N1) 2009*. Geneva: WHO, 2011. *who.int*. Web. http://apps.who.int/gb/ebwha/pdf_files/WHA64/A64_10-en.pdf

Economisti Associati
Via Rialto 9
40124 Bologna
ITALY

Phone **+39 051 6569606**

Fax **+39 051 6486838**

E-mail **main@economistiassociati.com**